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 Summary  
BEACH (Bettering the Evaluation and Care of Health) is a continuous national study of general 
practice activity in which ever-changing random samples of about 1,000 individual general 
practitioners (GPs) participate each year. Each GP records details of 100 consecutive encounters with 
consenting patients. BEACH began in April 1998 and is now in its 18th year.  
From June 2005 to June 2014 the population of Australia rose by 16%, from 20.2 million to 
23.5 million, and from June 2005 to June 2014 the proportion aged 65 years and over rose by 35% 
(from 2.6 to 3.5 million). About 85% of the Australian population claimed at least one GP consultation 
from Medicare in both 2005–06 and 2014–15. The number of Medicare-claimed GP consultation items 
(excluding practice nurse items) grew by 36% from 101.1 million to 137.3 million. The average number 
of GP visits per head of population rose from 5.0 to 5.8, and the average for those who visited at least 
once rose from 5.9 visits to 6.8.  
Administrative statistics provide information about the frequencies and costs of visits claimed for GP 
services and some prescribed pharmaceuticals. BEACH gives us an understanding of changes in the 
content of encounters and the services and treatments GPs provide.  
This book presents results of each of 10 years of BEACH data to identify changes over the decade 
2005–06 to 2014–15. The report is based on details of almost one million GP–patient encounters from 
9,773 participating GPs. Estimates are given of the national effect of change in GP activity through 
extrapolation of the BEACH results to the total Medicare GP consultations claimed in the first and last 
year of the decade. Released in parallel with this report is a more detailed report of results for  
2014–15 in the BEACH program, General practice activity in Australia 2014–15.1 This companion 
report contains a feature chapter investigating changes in the care of older people in general practice 
over 15 years, 2000–01 to 2014–15 (see Chapter 14).  
The GP participants and their practices (Chapter 4) 
Reflecting changes in the recognised GP workforce, females made up an increasing proportion of GP 
participants (37% in 2005–06 to 43% in 2014–15), as did the proportion aged 55 years and over (from 
39% to 45%). Average hours in patient care decreased from 39 to 37 hours per week, with a decrease 
from 42% to 30% of GPs working more than 40 hours. 
The proportion of GP participants who graduated from their primary medical degree in Australia 
decreased from 72% to 67%. GP participants holding Fellowship of the Royal Australian College of 
General Practitioners increased from 41% to 64%. 
The move toward larger practices continued, with decreased proportions of participants working in 
solo practice (13% to 9%), and in practices of 2–4 individual GPs (35% to 21%), while the proportion 
in practices of 10 or more GPs more than doubled, from 13% to 29%. The proportion using deputising 
services for some or all of their after-hours patient care increased from 51% to 57%. 
The encounters (Chapter 5) 
As a proportion of all MBS/DVA-claimable recorded consultations, short surgery consultations, chronic 
disease management items, health assessments, and GP mental health care, all increased 
significantly while standard surgery consultations decreased significantly. 
Over the decade, the mean length of consultations for MBS/DVA-claimable encounters significantly 
increased from 13.9 minutes to 14.7 minutes, and in the last 2 years the median length increased from 
12 to 13 minutes.  
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The patients at encounters (Chapter 6) 
Patients aged 65+ years accounted for an increasing proportion of GPs’ workload (from 27% to 31% 
of encounters). This change affected all aspects of general practice as older patients are more likely to 
have more problems (particularly chronic conditions) managed at encounters and are more likely to 
have multimorbidity. 
Encounters with patients new to the practice decreased from 9% to 6% perhaps reflecting the 
increased proportion of workload spent with older patients. The proportion with Repatriation Health 
Cards decreased from 3% to 2%, probably due to the decline in numbers of World War 2 veterans and 
their partners. 
There was no significant change in the number of patient reasons for encounter (RFEs) recorded per 
100 encounters, but RFEs describing processes of care increased, particularly requests for 
‘medications, treatments and therapeutics’ and test results. There was a large increase in requests for 
administrative procedures such as sickness certificates. 
Problems managed at encounters (Chapter 7) 
In 2014–15, GPs managed 155 problems per 100 encounters, significantly more than a decade earlier 
(146 per 100). The combination of the increased number of problems managed at encounters and the 
increased number of GP visits, suggests 65 million more problems were managed at GP–patient 
encounters in Australia in 2014–15 than in 2005–06. 
Across the decade, the most frequently managed problems were hypertension, check-up and upper 
respiratory tract infection. Significant increases occurred in management rates of general check-up, 
depression, back complaints, prescriptions, gastro-oesophageal reflux disease, anxiety, test results, 
administrative procedure, vitamin/nutritional deficiency, atrial fibrillation/flutter, and abnormal test 
results. The last of these is likely to be due to the increasing number of tests per order which 
increases the chance of an abnormal result being reported, and consequently managed. 
There were significant decreases in management rates of hypertension and immunisation/vaccination. 
The latter is probably due to delayed supply of the influenza vaccination prior to the 2015 flu season, 
which meant that the vaccination period began after the conclusion of the 2014–15 BEACH year. 
The management rate of chronic conditions in 2014–15 did not differ from the rate in 2005–06. The 
most commonly managed were non-gestational hypertension, depressive disorder, non-gestational 
diabetes, chronic arthritis and lipid disorders. There were increased management rates of depressive 
disorder, oesophageal disease, atrial fibrillation/flutter, chronic back pain and unspecified chronic pain. 
Extrapolation of these findings to all MBS-claimed GP consultation items suggests that compared with 
a decade earlier, in 2014–15 there were: 
• 23 million more chronic problem management occasions in general practice in 2014–15 than a 
decade earlier, even without an change in their management rate by GPs 
• 2.4 million more GP management occasions of depressive disorder, 1.4 million more of 
oesophageal disease, 880,000 more of atrial fibrillation/flutter, 520,000 more of chronic back pain, 
and 480,000 more of unspecified chronic pain. 
Overview of changes in management of problems (Chapters 8–12) 
All management actions are reported as both rates per 100 encounters and per 100 problems 
managed. The former is used to extrapolate the national effect of an increase while the latter is used 
to describe changes in how GPs actually manage the problems they treat. Readers should be aware 
that even without a change in rates of clinical actions the total number of these actions undertaken 
nationally will still increase due to the increased number of problems managed combined with the 
increased visit rate. 
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The changes in management actions from 2005–06 to 2014–15 (described as rates per 100 problems 
managed) are summarised below.  
• Medications prescribed/supplied/advised decreased, from 71 to 67 per 100 problems, largely due 
to a significant decrease in the rate of prescribed medications and GP-supplied medications. 
– Prescribed medications decreased significantly from 59 to 55. However, due to the increased 
attendance rate, we estimated there were 31 million more prescriptions being given nationally 
in 2014–15 than a decade earlier. 
– GP-supplied medications significantly decreased from 6.0 to 5.2 but this rate varied widely 
over the decade.  
– The rate of advised over-the-counter (OTC) medications did not change over the decade. 
• Clinical treatments were provided at similar rates in 2005–06 (20 per 100 problems managed) 
and 2014–15 (22 per 100). However, due to the increased number of problems managed, clinical 
treatments per 100 encounters increased from 29 to 34, suggesting about 17 million more were 
provided nationally in 2014–15 than in 2005–06. 
• Procedures undertaken significantly increased, from 10 to 11, and combined with the increased 
number of problems managed, rose from 14 to 17 per 100 encounters. The extrapolated effect 
was about 9 million more procedures undertaken nationally in 2014–15. 
• Referrals to medical specialists rose from 5.6 to 6.2, and those referred to allied health services 
increased from 2.0 to 3.3. This increase, combined with more problems managed and more visits, 
suggests about 10 million more GP referrals were made nationally in 2014–15 than in 2005–06, 
which included about 5 million more to medical specialists and 4 million more to allied health 
services. 
• Pathology tests/batteries orders increased by 15%, from 26 tests/batteries to 30. Tests ordered 
per 100 encounters increased from 39 to 47, which suggests about 26 million more tests/test 
batteries were ordered nationally in 2014–15. 
• Imaging tests ordered increased from 6 to 7 per 100 problems. Total imaging orders per 100 
encounters increased significantly from 9 to 12, suggesting nationally there were 7 million more 
tests ordered in 2014–15 than in 2005–06. 
Medications (Chapter 9) 
• Drug types prescribed less often in 2014–15 compared with 2005–06 included antibacterials for 
systemic use, systemic anti-inflammatory medications and sex hormones. Those prescribed more 
often included psychoanaleptics, digestive drugs for acid-related disorders and antiepileptic drugs. 
– Individual drugs prescribed more often included esomeprazole, oxycodone, rosuvastatin, 
pantoprazole, and pregabalin. In contrast, some decreased, including amoxycillin, plain 
paracetamol and paracetamol/codeine combination products. 
– Five repeats were recorded for a greater proportion of prescriptions, and one repeat for a 
smaller proportion of prescriptions. 
• Eight of the top 10 GP-supplied medications were vaccines, and rates of most childhood vaccines 
increased. However, the GP supply rate of influenza virus vaccine significantly decreased after 
peaks in previous years. There was a significant increase in GP supply of vitamin B12. 
• The rate of advice for OTC medications did not change but there was a significant rise in advised 
purchase of vitamin D3 (cholecalciferol). The increase started in 2008–09, about the same time as 
a doubling of the management rate of nutritional/vitamin deficiency. 
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Other (non-pharmacological) treatments (Chapter 10) 
Clinical treatments  
• General advice and education was the most frequently recorded clinical treatment throughout the 
decade, provided at a rate of 3.9 per 100 problems managed in 2014–15. There was no significant 
change in the rate between 2005–06 and 2014–15. 
• There were significant increases in the rate GPs provided advice/education about medication, 
counselling/advice about lifestyle, and in other administrative procedures/documentation.  
• There was a marginal decrease in the rate of counselling/advice about nutrition/weight and 
exercise over the decade.  
• There was increased use of clinical treatments in management of general check-ups.  
Procedures 
The increased rate of procedures undertaken in general practice was particularly reflected in a five-
fold increase in international normalised ratio (INR) tests, a small but significant increase in electrical 
tracings, and a marginal increase in dressings. There was an increase in the likelihood that a 
procedure would be used in the management of general check-ups and atrial fibrillation/flutter. 
Practice nurse/Aboriginal health worker activity 
Practice nurse/Aboriginal health worker (PN/AHW) involvement in GP-patient encounters increased 
over the decade. They were involved in 4% of encounters in 2005–06, their involvement peaked at 9% 
in 2009–10, then decreased to 7% by 2014–15.The proportion of problems managed with their 
assistance increased from 3% in 2005–06 to 6% in 2009–10, then gradually decreased to 5% by 
2014–15. Their assistance was usually in procedural work, while their provision of clinical treatments 
(such as advice and health education) remained infrequent. There were significant increases in 
frequency of their involvement in management of check-ups, diabetes, atrial fibrillation/flutter, and 
vitamin/nutritional deficiency.  
Referrals (Chapter 11)  
The likelihood that a problem managed would be referred increased from 8% to 10%. The rate of 
referral to medical specialists rose from 5.6 per 100 problems managed in 2005–06 to 6.2 per 100 in 
2014–15. The rate of referral to allied health services increased from 2.0 per 100 problems managed 
in 2005–06 to 3.3 in 2014–15. Referrals to psychologists rose four-fold and those to podiatrists/ 
chiropodists doubled. 
Tests and investigations (Chapter 12) 
Pathology test orders  
• There was no change in the proportion of problems involving at least one pathology test (13% in 
2005–06 and 2014–15). However, there was a 15% increase in the number of tests/batteries 
ordered, due to GPs ordering more tests per problem once the decision to order had been made. 
The largest increase was in orders for chemical pathology, which increased from 15 to 18 per 100 
problems managed. 
• The proportion of encounters involving at least one pathology test increased from 16% to 18%, 
and the rate of ordering increased from 39 to 47 tests per 100 encounters. This suggests that 
pathology was ordered at about 8 million more encounters nationally in 2014–15 than 10 years 
earlier, and there were 26 million more tests ordered nationally. These increases were driven by 
the rise in the number of problems managed at encounter and the increased GP attendance rate.  
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Imaging orders 
• The likelihood of GPs ordering imaging at an encounter rose from 8% to 10%, suggesting such 
orders were placed at 6 million more encounters nationally in 2014–15 than a decade earlier.  
• There was a move away from ordering diagnostic radiology toward ultrasound imaging. 
Ultrasounds were the most commonly ordered, and ordering increased from 3 to 5 orders per  
100 encounters, a national increase of about 4 million ultrasound orders. The rates of 
computerised tomography and magnetic resonance imaging, while accounting for a lower 
proportion of orders, also increased over the decade. 
Substudies of patient risk factors (Chapter 13)  
Body mass index 
• Adults (n = 30,000–32,000 per year): Prevalence of obesity in sampled adult patients (aged 18+ 
years) increased significantly from 22% in 2005–06 to 28% in 2014–15. The prevalence of 
overweight (34–35%) and of underweight (2–3%) did not change. Prevalence of normal weight 
decreased from 41% to 36%. 
• Children (n = 3,000–4,000 per year): There was a marginally significant decrease in the 
prevalence of obesity among sampled children (aged 2–17 years) from 11% to 9%, but no change 
in prevalence of overweight or underweight.  
Smoking (n = 31,000–34,000 per year): Among sampled adults (aged 18+ years), there was a 
significant decrease in prevalence of current daily smoking and occasional smoking from 17% and 4% 
respectively in 2005–06, to 14% and 2% in 2014–15.  
Alcohol consumption (n = 30,000–34,000 per year): Among sampled adults (aged 18+ years), 
prevalence of at-risk levels of alcohol consumption declined from 26% in 2005–06 to 23% in 2014–15, 
and there was an increase in non-drinkers from about 29% to 34%.  
Risk profile in adults (n = 29,000–32,000 per year): There was a significant increase in the 
proportion of sampled adults with one risk factor, from 49% to 52%. Throughout the decade, about 
one-fifth of patients had two risk factors. There was a significant decrease in the proportion of sampled 
patients with three risk factors from 4% to 3%.  
Attending population prevalence estimates: We estimate the prevalence of risk factors for patients 
who attend a GP at least once in the surveyed year by applying statistical adjustment for adult 
population attendance rates by age–sex. This adjustment is available for data collected from 2007–08 
to 2014–15. Over this time the prevalence in the population attending at least once, of: 
• obesity increased from 23% to 27% 
• daily smoking decreased from 19% to 17% 
• at-risk alcohol consumption decreased from 29% to 26%. 
The proportion of patients with only one risk factor increased from 48% to 50%, and there was a 
corresponding decrease in the prevalence of patients with three risk factors (overweight/obesity and 
daily smoking and at-risk alcohol consumption) from 5% to 4%. 
  
 
  
 1 Introduction 
This report is the 39th book in the General practice series from the Bettering the Evaluation of Care 
and Health (BEACH) program. It includes summary results from the most recent 10 years of the 
program, from 2005–06 to 2014–15 inclusive. 
Released in parallel with this report is a more detailed report of results for 2014–15 in the BEACH 
program, General practice activity in Australia 2014–15,1 available at 
<purl.library.usyd.edu.au/sup/9781743324523>. 
BEACH is a continuous national study of general practice activity in which ever-changing random 
samples of about 1,000 general practitioners (GPs) participate each year. Each participating GP 
records details of 100 consecutive GP–patient encounters with consenting patients. 
The BEACH program began in April 1998 and was the culmination of about 20 years research and 
development work at the University of Sydney. Initially the program was conducted by the Family 
Medicine Research Centre (FMRC), University of Sydney, in collaboration with the Australian Institute 
of Health and Welfare (AIHW), under the AIHW Act, but from April 2011, it has been conducted by the 
FMRC alone. BEACH is currently supported financially by government and private industry (see 
Acknowledgments). 
At the end of its 17th year (March 2015), the BEACH database included records for almost 1.7 million 
GP–patient encounters from 16,747 GP participants, representing 10,340 individual GPs. This book 
investigates results of each of the 10 years of data to identify changes that occurred over the decade 
2005–06 to 2014–15. This report is based on information about 1 million GP–patient encounters 
provided by 9,773 participating GPs. 
The structure of this report follows the usual approach of the annual BEACH reports. Ten years of 
results are provided about the GPs, the patients and the problems managed, followed by an overview 
of management, and specific chapters for each type of management action. Changes in prevalence of 
some patient risk factors are also presented. 
Each chapter contains an overview of the section (including definitions where relevant) and a brief 
description of the major findings, followed by the results tables. In the tables, statistically significant 
changes between 2005–06 and 2014–15 are marked. The national effect of significant change can be 
estimated by extrapolating the BEACH results to all GP Medicare-claimed encounters. The method 
adopted for extrapolation of the effect of a change is described in Section 2.9. Examples of 
extrapolation of a measured change are also provided in each of Chapters 5 to 12 inclusive. The 
reader can apply this method to any significant change in the BEACH data presented in terms of rate 
per 100 encounters, to gain an estimate of the size of the national effect of this change. 
In this report, changes over time in, for example, GP management actions for a specific problem, or 
changes in the problems managed for a selected group of patients, are not generally investigated. 
However, such analyses can be requested from the FMRC. Details are provided on the FMRC website 
<sydney.edu.au/medicine/fmrc/>. 
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1.1 Background 
GPs are usually the first port of call in the Australian healthcare system. Payment for GP visits is 
largely on a fee-for-service system, there being no compulsory patient lists or registration. People are 
free to see multiple practitioners and visit multiple practices of their choice. There is a universal 
medical insurance scheme (managed by Medicare Australia), which covers all or most of an 
individual’s costs for a GP visit.  
Changes in demographics, health expenditure and provision of general practice services over the 
decade are outlined below. 
Population changes 
The Australian population increased by 16% between June 2005 (20.2 million) and June 2014 
(23.5 million).2 Over the same period: 
• the proportion of the population aged 65 years and over increased by 35%, from 2.6 million people 
to 3.5 million2 
• the number of Australians aged 85 years and over increased by 51% from 302,000 people to 
457,000.2  
Australia’s population is projected to change significantly over the coming decades. The number of 
Australians aged 65 and over is projected to more than double, from 3.6 million in 2014–15 to 
8.9 million by 2054–55. A greater proportion of the population will be aged 65 and over, increasing 
from 15% of the total population today, to about 23% over the next 40 years.3 Readers interested the 
changes in the care of older people in general practice should see the feature (Chapter 14) in the 
companion report General practice activity in Australia 2014–15.1  
Population ageing is projected to have significant implications for health and aged care service 
demand.3 As life expectancy continues to improve, people are living longer with disease, so a greater 
part of the GP workload will involve management of older patients with multiple chronic conditions. 
Health expenditure 
• In 2013–14, Australia’s health expenditure was $154.6 billion,4 $60.5 billion (78%) more than in 
2005–06 ($86.9 billion).5 
• The average amount spent per head of population was $6,639 in 2013–14, increasing from $4,268 
in 2005–06.4,5 
• Health expenditure as a proportion of gross domestic product (GDP) increased, from 8.7% in 
2005–06 to 9.8% in 2013–14.4,5  
• In 2005–06, governments funded more than two-thirds (67.8%) of health costs, compared with 
60.8% in 2013–14.4,5  
General practice services 
• The amount spent on general practice services (total non-referred attendances including 
GP/vocationally recognised GP, Enhanced Primary Care, other, and practice nurse items) 
increased from $3.8 billion in the 2005–06 financial year to $6.8 billion in the 2014–15 financial 
year.6 
• Changes in the number of practising GPs in Australia over the last decade are difficult to calculate 
due to the varying methods used to count GPs. According to reports from the AIHW, in 2005 there 
were 22,589 primary care practitioners in Australia (including but not limited to GPs),7 while in 
2012 there were 25,958 medical practitioners self-identifying as GPs, making up 25,063 full-time 
equivalents (FTE, based on a 40-hour week).8 More recent general practice workforce statistics 
from the Australian Government Department of Health (DoH) indicated that in 2013–14, there 
were 32,401 GPs (defined as GPs or Other Medical Practitioners who provided at least one 
Medicare claimed GP service during that year), making up 19,365 FTE.9 
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• In the April 2014 to March 2015 year, 85.8% of the Australian population claimed at least one GP 
service from Medicare (personal communication, DoH, June 2015). In the same period, Medicare 
paid rebates for about 137.3 million claimed general practice service items (total non-referred 
attendances excluding practice nurse items),10 at an average of about 5.8 GP visits per head of 
population or 6.8 visits per person who visited at least once. This equates to about 2.6 million  
GP–patient encounters per week. 
• A decade earlier, in the 2005–06 financial year, total Medicare claims for GP–patient encounters 
numbered 101.1 million,6 an average attendance rate of 5.0 per head of population. 
Medicare statistics provide information about the frequencies and costs of visits claimed from 
Medicare for GP services. BEACH gives us an understanding of the content of GP–patient encounters 
and the services and treatments that GPs provide. The BEACH program aims to: 
• provide a reliable and valid data collection process for general practice that is responsive to the 
ever-changing needs of information users 
• establish an ongoing database of GP–patient encounter information 
• assess patient risk factors and health states, and their relationship with service activity. 
Users of BEACH data might wish to consolidate information from multiple sources. Integration can 
provide a more comprehensive picture of the health and health care of the Australian community. 
Readers need to be aware of how the BEACH data differ from those drawn from other sources. A 
summary of differences between the BEACH data sets and those in national administrative data sets 
and studies is available in General practice activity in Australia 2014–15 (Sections 1.2 and 1.3).1  
1.2 Access to BEACH data 
Different bundles of BEACH data are available to the general public, to BEACH-participating 
organisations, and to other organisations and researchers. 
Public domain 
This annual publication provides a comprehensive view of general practice activity in Australia. The 
BEACH program has generated many papers on a wide variety of topics in journals and professional 
magazines. All published material from BEACH is available at 
<sydney.edu.au/medicine/fmrc/publications>. 
Since April 1998, a section at the bottom of each encounter form has been used to investigate aspects 
of patient health or healthcare delivery not covered by general practice consultation-based 
information. These additional substudies are referred to as SAND (Supplementary Analysis of 
Nominated Data). The SAND methods are described in Section 2.6. Abstracts of results and the 
research tools used in all SAND substudies from April 1998 to March 2015 have been published. 
Those from: 
• April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia11 
• April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts and 
research tools 1999–200612 
• August 2006 to March 2014 were published in each of the BEACH annual reports13-20 
• April 2014 to March 2015 are included in Chapter 15 of General practice activity in Australia  
2014–15.1 
Abstracts of results for all SAND substudies are also available on the FMRC website 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts> where you can search by topic. 
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Participating organisations 
Organisations providing funding for the BEACH program receive summary reports of the encounter 
data quarterly, and standard reports or specifically designed analyses about their subjects of interest. 
Participating organisations also have direct access to straightforward analyses on any selected 
problem, medication, pathology or imaging test through an interactive web server. All data made 
available to participating organisations have been further ‘de-identified’. Patients are not identifiable 
even from the original encounter data forms, but are further stripped of date of birth (replaced with age 
in years and months) and postcode of residence (replaced with state and area type). GP 
characteristics data are provided only in the form of grouped output (for example, GPs aged less than 
35 years) to any organisation. 
External purchasers of reports 
Non-contributing organisations may purchase standard reports or other ad hoc analyses. Charges are 
outlined at <sydney.edu.au/medicine/fmrc/beach/data-reports/for-purchase>. The FMRC should be 
contacted for specific quotations. Contact details are provided at the front of this publication. 
Analysis of the BEACH data is a complex task. The FMRC has designed standard reports that cover 
most aspects of a subject under investigation. Examples of a problem-based standard report (subject: 
ischaemic heart disease in patients aged 45 years and over), a group report (subject: female patients 
aged 15–24 years) and a pharmacological-based standard report (subject: allopurinol) for a 
single year’s data, are available at <sydney.edu.au/medicine/fmrc/beach/data-reports/for-purchase>. 
Customised data analyses can be done where the specific research question is not adequately 
answered through standard reports.  
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 2 Methods 
In summary: 
• each year, BEACH involves a new random sample of about 1,000 GPs 
• each GP records details of about 100 doctor–patient encounters of all types  
• the GP sample is a rolling (ever-changing) sample, with about 20 GPs participating in any one 
week, 50 weeks a year (with two weeks break over Christmas) 
• each GP can be selected only once per Quality Improvement & Continuing Professional 
Development (QI & CPD) Program triennium (that is, once in each 3-year period) 
• the encounter information is recorded by the GPs on structured paper encounter forms 
(Appendix 1) 
• GP participants also complete a questionnaire about themselves and their practice (Appendix 2). 
2.1 Sampling methods 
The source population includes all vocationally registered GPs and all general practice registrars who 
claimed a minimum of 375 Medicare general practice items of service in the most recently available  
3-month Medicare data period (which equates to 1,500 such claims in a year). This ensures inclusion 
of the majority of part-time GPs, while excluding those who are not in private practice but claim for a 
few consultations a year. 
The Medicare statistics section of the Department of Health (DoH) updates the sample frame quarterly 
from the Medicare claims data. They then remove from the sample frame any GPs already randomly 
sampled in the current triennium, and draw a new sample from those remaining in the sample frame. 
This ensures the timely addition of new entries to the profession, and timely exclusion of those GPs 
who have stopped practising, have already participated or been approached in the current triennium. 
2.2 Recruitment methods 
The randomly selected GPs are approached by letter, posted to the address provided by DoH. 
• Over the following 10 days, the telephone numbers generated from the Medicare data are 
checked using the electronic white and yellow pages. This is necessary because many of the 
telephone numbers provided from the Medicare data are incorrect. 
• The GPs are then telephoned in the order they were approached and, referring to the approach 
letter, asked whether they will participate. 
• This initial telephone contact with the practice often indicates that the selected GP has moved 
elsewhere, but is still in practice. Where a new address and/or telephone number can be obtained, 
these GPs are followed up at their new address. 
• GPs who agree to participate are set an agreed recording date several weeks ahead. 
• A research pack is sent to each participant before the planned start date. 
• Each GP receives a telephone reminder early in the agreed recording period – this also provides 
the GP with an opportunity to ask questions about the recording process. 
• GPs can use a ‘freecall’ (1800) number to ring the research team with any questions during their 
recording period. 
• Non-returns are followed up by regular telephone calls for 3 months. 
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• Participating GPs earn clinical audit points towards their QI & CPD requirements through the 
Royal Australian College of General Practitioners (RACGP) and/or the Australian College of Rural 
and Remote Medicine (ACRRM). As part of this QI process, each GP receives an analysis of his 
or her results compared with those of nine other de-identified GPs who recorded at about the 
same time. Comparisons with the national average and with targets relating to the National Health 
Priority Areas are also provided. In addition, GPs receive some educational material related to the 
identification and management of patients who smoke or consume alcohol at hazardous levels. 
Additional points can be earned if the participant chooses to do a follow-up audit of smoking and 
alcohol consumption among a sample of patients about 6 months later. 
2.3 Ethics approval and informed patient consent 
Ethics approval for this study in 2014–15 was obtained from the Human Ethics Committee of the 
University of Sydney.  
Although the data collected by the GPs are not sufficient to identify an individual patient, informed 
consent for GP recording of the encounter details is required from each patient. GPs are instructed to 
ensure that all patients presenting during their recording period are provided with a Patient Information 
Card (Appendix 3), and to ask the patient if they are happy for their data to be included in the study. If 
the patient refuses, details of the encounter are not recorded. This is in accordance with the ethics 
requirements for the BEACH program. 
2.4 Data elements 
BEACH includes three interrelated data collections: GP characteristics, encounter data and patient 
health status. An example of the form used to collect the encounter data and the data on patient 
health status is included in Appendix 1. The GP characteristics questionnaire is provided in 
Appendix 2. The GP characteristics and encounter data collected are summarised below. Patient 
health status data are described in Section 2.6. 
GP profile form (Appendix 2) 
• GP characteristics: age and sex, years in general practice, number of direct patient care hours 
worked per week, intended changes in hours of direct patient care in 5 years, country of 
graduation, general practice registrar status, Fellow of the RACGP status, Fellow of the ACRRM 
status, use of computers at work for clinical purposes, work undertaken in other clinical settings, 
number of practice locations worked in a regular week. 
• Practice characteristics: postcode of major practice, number of individual and number of full-
time equivalent (FTE) GPs working in the practice, number of individual and number of FTE 
practice nurses working in the practice, usual after-hours care arrangements, other health services 
located at the major practice. 
Encounter recording form (Appendix 1) 
• Encounter data: date of consultation, type of consultation (direct/indirect) (tick box options), up to 
three Medicare Benefits Schedule (MBS)/Department of Veterans’ Affairs (DVA) item numbers 
(where applicable), and other payment source (where applicable) (tick box options). 
• Patient data: date of birth, sex and postcode of residence. Tick boxes (yes/no options) are 
provided for Commonwealth concession card holders, holders of a Repatriation Health Card (from 
DVA), non-English-speaking background (patient self-reported that a language other than English 
is the primary language at home), Aboriginal person (self-identification), and Torres Strait Islander 
person (self-identification). Space is provided for up to three patient reasons for encounter (RFEs). 
(See Glossary). 
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• The problems managed at encounter (at least one and up to four). Tick boxes are provided to 
denote the status of each problem as new or continuing for the patient and whether the problem is 
considered by the GP to be work-related. 
• Management of each problem, including: 
– medications prescribed, supplied by the GP and advised for over-the-counter (OTC) purchase 
including brand name, form (where required), strength, regimen, status (new or continuing 
medication for this problem), number of repeats 
– other treatments provided for each problem, including counselling, advice and education, and 
procedures undertaken, and whether the recorded other treatment was provided by a practice 
nurse (tick box) 
– new referrals to medical specialists, allied health services, emergency departments, and 
hospital admissions 
– investigations, including pathology tests, imaging and other investigations ordered.  
2.5 The BEACH relational database 
The BEACH relational database is described diagrammatically in Figure 2.1. Note that:  
• all variables can be directly related to the encounter, the GP and the patient characteristics 
• all types of management are directly related to the problem being managed  
• RFEs have only an indirect relationship with problems managed, as a patient may describe  
one RFE (such as ‘repeat prescriptions’) that is related to multiple problems managed, or  
several RFEs (such as ‘runny nose’ and ‘cough’) that relate to a single problem managed  
(such as upper respiratory tract infection) (see Section 6.3). 
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The encounter 
 date 
 direct (face to face) 
— Medicare/DVA item 
number(s) claimable 
— workers compensation 
— other paid 
— no charge 
 indirect (e.g. telephone) 
Patient substudies (SAND) 
 risk factors 
— body mass 
— smoking status 
— alcohol consumption  
 other topics 
Management of each problem 
Medications (up to four per problem) 
 prescribed 
 over-the-counter advised 
 provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
 procedural treatments 
 clinical treatments (e.g. advice, 
counselling) 
 practice nurse involvement 
 
Other management 
 referrals (up to two) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
 pathology tests ordered (up to five) 
 imaging ordered (up to three) 
GP characteristics 
 age and sex 
 years in general practice 
 country of graduation 
 direct patient care hours/week 
 FRACGP status (yes/no) 
 FACRRM status (yes/no) 
 currently a registrar (yes/no) 
 clinical use of computers  
 
Practice characteristics 
 practice size (no. & FTE GPs) 
 practice nurse(s) (no. & FTE) 
 after-hours arrangements 
 postcode  
 presence of other health services 
Problems managed 
 diagnosis/problem label 
 problem status (new/old) 
 work-related problem status 
The patient 
 age and sex 
 practice status (new/old) 
 Commonwealth concession 
card status 
 Repatriation Health Card 
status 
 postcode of residence 
 NESB/Indigenous status 
 reasons for encounter 
Note: FRACGP – Fellow of the Royal Australian College of General 
Practitioners; FACRRM – Fellow of the Australian College of 
Rural and Remote Medicine; FTE – full-time equivalent;  
DVA – Department of Veterans’ Affairs; NESB – non-English-
speaking background; SAND – Supplementary Analysis of 
Nominated Data. 
Figure 2.1: The BEACH relational database 
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2.6 Supplementary Analysis of Nominated Data 
A section at the bottom of each recording form investigates aspects of patient health or health care 
delivery in general practice not covered by the consultation-based data. These substudies are referred 
to as SAND (Supplementary Analysis of Nominated Data). 
• Each year, the 12-month data period is divided into 10 blocks, each of 5 weeks, with three 
substudies per block. The research team aims to include data from about 100 GPs in each block.  
• Each GP’s pack of 100 forms is made up of 40 forms that ask for the start and finish times of the 
encounter, and include questions about patient risk factors: patient height and weight (used to 
calculate body mass index, BMI), alcohol intake and smoking status (patient self-report). The 
methods and results of topics in the SAND substudies for alcohol consumption, smoking status 
and BMI are reported in Chapter 13. The start and finish times collected on these encounters are 
used to calculate the length of consultation. The length of consultation for Medicare-claimable 
encounters is reported in Section 5.3. 
• The remaining 60 forms in each pack are divided into two blocks of 30, so each SAND block 
includes about 3,000 records. Some topics are repeated to increase sample size. Different 
questions are asked of the patient in each block and these vary throughout the year. 
• The order of SAND sections is rotated in the GP recording pack, so that 40 patient risk factor 
forms may appear first, second or third in the pad. Rotation of ordering ensures there was no 
order effect on the quality of the information collected. 
Abstracts of results and the research tools used in all SAND substudies from April 1998 to March 2014 
have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia11 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts 
and research tools 1999–200612 
• conducted between August 2006 and March 2014 have been published in each of the general 
practice activity annual reports13-20 
• conducted in the 2014–15 BEACH year are provided in Chapter 15 of the companion report, 
General practice activity in Australia 2014–15.1 
Abstracts of results for all SAND substudies are also available on the FMRC’s website 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
2.7 Statistical methods 
The analysis of the 2014–15 BEACH data was conducted with Statistical Analysis System (SAS) 
version 9.3.21  
BEACH has a single stage cluster sample study design, each 100 encounters forming a cluster 
around each GP participant. In cluster samples, variance needs to be adjusted to account for 
correlation between observations within clusters. Procedures in SAS version 9.3 were used to 
calculate the intracluster correlation, and adjust the confidence intervals accordingly.21  
Post-stratification weighting of encounter data adjusts for: any difference in the age–sex distribution of 
the participating GPs and those in the sample frame from which the samples were drawn; and for the 
varying activity level of each GP (measured by number of claims each has made in the previous 
12 months from Medicare Australia). Each year, the age–sex distribution of patients at the sampled 
encounters has excellent precision when compared with the age–sex distribution of patients at all 
Medicare-claimed services of this type.  
9
  
The encounter is the primary unit of inference. Proportions are used only when describing the 
distribution of an event that can arise only once at a consultation (for example, patient or GP age and 
sex), or to describe the distribution of events within a class of events (for example, problem A as a 
percentage of total problems). Due to rounding, proportions may not always add to exactly 100%. 
Rates per 100 encounters are used when an event can occur more than once at the consultation (for 
example, RFEs, problems managed or medications). Rates per 100 problems are also used when a 
management event can occur more than once per problem managed.  
Statistical significance is tested by chi-square statistic for GP characteristics, but significance of 
differences in/for rates is judged by non-overlapping confidence intervals of the results being 
compared. The magnitude of this difference can be described as at least p < 0.05. Assessment using 
non-overlapping confidence intervals (CIs) is a conservative measure of significance,22-24 particularly 
when differences are assessed by comparing results from independent random samples, as is the 
case when changes over time are investigated using BEACH data. Due to the number of comparisons 
made in this and the companion publication, we believe this more conservative approach is warranted. 
• Changes over time in the frequency of events are judged significant (that is, a real change has 
occurred) if the two sets of CIs do not overlap. For example, Result A: 11.5 per 100 encounters 
(95% CI: 11.3–11.7) is significantly less than Result B: 11.9 per 100 encounters  
(95% CI: 11.8–12.0). 
• If the two sets of CIs butt together, the difference is regarded as marginal. For example,  
Result A: 11.5 per 100 encounters (95% CI: 11.3–11.7) is marginally lower than Result B:  
11.9 (95% CI: 11.7–12.1). 
• If the two sets of 95% confidence intervals overlap, then no change was measured. 
• Differences discussed in this report are statistically significant unless otherwise stated. 
2.8 Changes over time 
For each of the 10 years from 2005–06 to 2014–15, patient RFEs and problems managed are 
reported as rates per 100 encounters. In earlier years, rates per 100 encounters were used when 
measuring changes in each of the management actions (prescriptions, other treatments, referrals, 
pathology and imaging). However, there has been a significant increase in the number of problems 
managed per encounter (see Chapter 7). This means that at each encounter, there is an increased 
chance of a management action occurring, without any change in the management practise of GPs. 
All management actions are therefore reported in two ways — as rates per 100 problems managed 
(used as the primary measure of change in GP behaviour) and as rates per 100 encounters (used as 
the basis of extrapolation).  
Data presented in this report are comparable for each result across all data years wherever possible. 
However, as in any long-term research program, changes occur over the years. Where methodological 
changes have occurred, the data have either: 
• been recalculated across all years using the new method (for example, body mass index was 
recalculated due to a change in the World Health Organization’s [WHO] body mass index 
groupings) 
• been regrouped for comparability. Where this occurs, it is noted in the footnotes of the table. An 
example is the combined presentation of home visits and institutional visits in Chapter 5 because 
the MBS now has only one item number for both. In previously published data it was possible to 
differentiate the two 
• been omitted from this report (if recalculation or grouping was not possible). Where data are 
omitted, this is noted as not applicable (N/A) or not available (NAv), as appropriate. 
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Each table includes the most frequent events occurring in 2014–15, and the comparative results for 
each of the earlier years. In addition, each table includes data for events that were more frequent in 
past year(s), but were no longer the most frequent in 2014–15. In general, results are presented in 
decreasing 2014–15 order of frequency. 
The direction and type of change between 2005–06 and 2014–15 is indicated for each result in the far 
right column of the tables: 
• / indicates a statistically significant change (increase or decrease) in 2014–15 when compared 
with the first year of data reported 
• / indicates a marginally significant change in 2014–15 when compared with the first year of 
data reported 
• — indicates there was no significant change in 2014–15 when compared with the first year of data 
reported 
• § indicates a noteworthy change during the decade. 
2.9 Extrapolated national estimates 
Extrapolations can be used to estimate the number of occurrences of a selected event at GP–patient 
encounters in Australia at a single time point, or to estimate the total national effect of a measured 
change. 
Where the results demonstrate a significant change over time, the estimated national change across 
total GP Medicare services from 2005–06 to 2014–15 can be calculated using the method detailed 
below. Note that extrapolations are always based on rate per 100 encounters rather than rate per 100 
problems, because there is no independent measure of the number of problems managed in 
Australian general practice. In contrast, the number of national encounters can be drawn from 
Medicare claims data.  
Examples of extrapolated national change are given in each chapter in the report from Chapter 5 to 
Chapter 12 inclusive. 
When extrapolating measured change over the decade to national estimates, we: 
• divide the ‘rate per 100 encounters’ of the selected event for 2005–06 by 100, and then multiply by 
the total number of general practitioner service items claimed through Medicare in 2005–06 
(rounded to the nearest 100,000). As shown in Table 2.1, this was 98.2 million. This provides the 
estimated national number of events in 2005–06 
• repeat the process using data from 2014–15. 
The difference between the two estimates gives the estimated national change in the frequency of that 
event between 2005–06 and 2014–15. Estimated national number of events is rounded to the nearest 
100,000 if more than one million, and to the nearest 10,000 if below one million. It is possible to use 
this method to calculate the national effect of any significant change in a single result over any two 
time points.  
• Change is expressed as the estimated increase or decrease over the study period in the number 
of general practice contacts for that event (for example, an increase or decrease in the number of 
GP management contacts with problem X); or an increase or decrease in the number of times a 
particular management action (for example, a selected medication type) was prescribed in 
Australia in 2014–15, when compared with (usually) 2005–06. 
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Extrapolations can also be made using data from a single time point to estimate the number of 
occasions that an event occurs in general practice encounters nationally in a specific year. When 
extrapolating from a single time point we: 
• divide the ‘rate per 100 encounters’ of the selected event by 100, and multiply by the total number 
of general practitioner consultations claimed through Medicare that year (rounded to nearest 
100,000) to give the estimated national number of events in that year. 
Table 2.1 provides the total (rounded) number of general practice professional service items claimed 
from Medicare in each financial year from 2005–06 to 2014–15.  
Table 2.1: Rounded number of general practice professional services claimed from Medicare Australia 
each financial year, 2005–06 to 2014–15 (millions) 
 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 2013–14 2014–15(a) 
Rounded number of 
Medicare GP items 
of service claimed 
101.1 103.4 109.5 113.0 116.6 119.2 123.9 126.8 134.2 137.3 
(a) Medicare data for the 2014–15 year included data from the April 2014 to March 2015 quarters because the 2014–15 financial year data 
were not available at the time of preparation of this report. 
Source: Medicare Statistics.10  
Examples of extrapolation 
Example 1: Change in the number of pathology tests/batteries ordered nationally (with 95% 
confidence intervals) 
Orders for chemistry tests increased by 25.8%, from 21.7 tests/batteries (95% CI: 20.5–22.9) per 
100 encounters in 2005–06 to 27.3 (95% CI: 26.1–28.6) in 2014–15. 
The calculation used to extrapolate the effect of this change across Australia is:  
• In 2005–06 (21.7/100) x 101.1 million = 21.9 million chemistry tests/batteries ordered nationally  
Lower confidence interval: 20.5/100 x 101.1 million = possibly as few as 20.7 million 
Upper confidence interval: 22.9/100 x 101.1 million = possibly as many as 23.2 million 
• In 2014–15, (27.3/100) x 137.3 million = 37.5 million chemistry tests/batteries ordered  
Lower confidence interval: 26.1/100 x 137.3 million = possibly as few as 35.8 million 
Upper confidence interval: 28.6/100 x 137.3 million = possibly as many as 39.3 million. 
This suggests there were 15.6 million (37.5 million minus 21.9 million) more GP ordered chemistry 
tests/batteries in Australia in 2014–15 than in 2005–06. This is our best estimate of the change, but 
we are 95% confident that the true result is between 15.1 and 16.1 million additional chemistry test/ 
batteries ordered in 2014–15. 
This is the result of the compound effect of the increase in the number of tests ordered by GPs at 
encounters plus the increased number of GP visits over the decade across Australia. 
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Example 2: National change in the number of GP–patient encounters at which upper 
respiratory tract infection (URTI) was managed (with 95% confidence intervals)  
The management rate of URTI (the common cold) did not change between 2005–06 (6.2 per 100 
encounters, 95% CI: 5.8–6.6) and 2014–15 (5.8 per 100, 95% CI: 5.4–6.2).  
For 2005–06, our best estimate for the total national encounters involving management of URTI is: 
6.27 million [(6.2/100) x 101.1 million], but we are 95% confident that the true number lies 
between 5.86 million [(5.8/100) x 101.1 million] and 6.67 million [(6.6/100) x 101.1 million]. 
For 2014–15, our best estimate for the total national encounters involving management of URTI is: 
7.96 million [(5.8/100) x 137.3 million], but we are 95% confident that the true number lies 
between 7.41 million [(5.4/100) x 137.3 million] and 8.51 million [(6.2/100) x 137.3 million]. 
Therefore, we estimate that even though the management rate of URTI did not change in an average 
100 encounters, the huge increase in the number of attendances nationally in 2014–15 (compared 
with 2005–06) led to an estimated additional 1.69 million (95% CI: 1.55 million–1.84 million) more  
GP–patient encounters across the country at which GPs managed URTI, when compared with a 
decade earlier.  
Considerations and limitations in extrapolations 
The extrapolations to the total number of events occurring nationally in any one year are only 
estimates. They may provide: 
• an underestimate of the true ‘GP workload’ of a condition/treatment because the extrapolations 
are made to Medicare-claimed GP consultations, not to the total number of GP–patient encounters 
per year – an additional 5% of BEACH encounters annually include encounters paid by sources 
other than Medicare, such as DVA, state governments, workers compensation insurance, and 
employers 
• an underestimate of activities of relatively low frequency with a skewed distribution across 
individual GPs.  
Further, the base numbers used in the extrapolations are rounded to the nearest 100,000, and 
extrapolation estimates are rounded to the nearest 100,000 if more than one million, and to the 
nearest 10,000 if below one million. However, the rounding has been applied to all years, so the effect 
on measures of change will be very small. Therefore, the extrapolation still provides an indication of 
the size of the effect of measured change nationally. 
Extrapolations are based on the unit of the encounter because the number of national encounters is 
quantifiable using Medicare claims data. However, the reader should be aware that where an event 
can occur more than once per encounter (for example, GPs can record up to two referrals per 
encounter), the extrapolation represents the number of occurrences of that event nationally (or 
example, number of referrals nationally), rather than the number of encounters nationally where at 
least one event (or example, referral) occurred. 
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2.10 Classification of data 
The following data elements are classified according to the International Classification of Primary Care 
– Version 2 (ICPC-2), a product of the World Organization of Family Doctors (Wonca):25 
• patient reasons for encounter (RFEs) 
• problems managed 
• clinical treatments (for example, counselling, advice) 
• procedural treatments 
• referrals 
• investigations ordered (including pathology, imaging and other investigations). 
The ICPC-2 is used in more than 45 countries as the standard for data classification in primary care. It 
is accepted by the World Health Organization in the WHO Family of International Classifications,26 and 
is the declared national standard in Australia for reporting of health data from general practice and 
patient self-reported health information.27 
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic code) and 
seven components on the other (numeric codes) (Figure 2.2). Chapters are based on body systems, 
with additional chapters for psychological and social problems. Component 1 includes symptoms and 
complaints. Component 7 covers diagnoses – it can also be expanded to provide data about 
infections, injuries, neoplasms, congenital anomalies and ‘other’ diagnoses. 
Component 2 (diagnostic, screening and prevention) is often applied in describing the problem 
managed (for example, check-up, immunisation). Components 3 to 6 cover other processes of care, 
including referrals, other (non-pharmacological) treatments and orders for pathology and imaging. The 
components are standard and independent throughout all chapters. The updated component 
groupings of ICPC-2 codes, released by the Wonca International Classification Committee in 200428 
have been used in this report. 
The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptom rubrics have been 
selected for inclusion on the basis of their relative frequency in primary care settings, or because of 
their relative importance in describing the health of the community. ICPC-2 has about 1,370 rubrics 
and these are sufficient for meaningful analyses. However, reliability of data entry, using ICPC-2 
alone, requires a thorough knowledge of the classification, for correct classification of a concept to be 
ensured. 
In 1995, recognising a need for a coding and classification system for general practice electronic 
health records, the Family Medicine Research Centre (FMRC) (then Unit) developed an extended 
clinical terminology classified according to the ICPC, now called ICPC-2 PLUS.29 This is an interface 
terminology, developed from all the terms used by GPs in studies such as The Australian Morbidity 
and Treatment Survey 1990–91 (113,468 encounters),30 A comparison of country and metropolitan 
general practice 1990–91 (51,277 encounters),31 The Morbidity and Therapeutic Index 1992–1998 
(a clinical audit tool that was available to GPs; approximately 400,000 encounters), and BEACH  
1998–2015 (about 1.7 million encounters). Together, these make up about 2.3 million encounter 
records, involving about 3.4 million free text descriptions of problems managed and a further 
3.4 million descriptions of patient reasons for encounter.  
These terms are classified according to ICPC-2 to ensure data can be compared internationally. 
Readers interested in seeing how coding works can download the ICPC-2 PLUS Demonstrator at 
<sydney.edu.au/medicine/fmrc/icpc-2-plus/demonstrator>. 
When the free-text data are received from the GPs, trained secondary coders (who are undergraduate 
students), code the data in specific terms using ICPC-2 PLUS. This ensures high coder reliability and 
automatic classification of the concept, and allows us to ‘ungroup’ such ICPC-2 rubrics as ‘other 
diseases of the circulatory system’ and select a specific disease from the terms within it. 
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 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening, prevention                   
 3. Treatment, procedures, medication                   
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General and unspecified L Musculoskeletal U Urinary 
 B Blood & blood-forming organs N Neurological W Pregnancy, family planning 
 D Digestive P Psychological X Female genital  
 F Eye R Respiratory Y Male genital  
 H Ear S Skin Z Social  
 K Circulatory T Endocrine, nutritional & metabolic   
 
Figure 2.2: The structure of the International Classification of Primary Care – Version 2 (ICPC-2) 
Presentation of data classified in ICPC-2 
Statistical reporting is usually at the level of the ICPC-2 classification (for example, acute otitis 
media/myringitis is ICPC-2 code H71). However, there are some exceptions where data are grouped 
either above the ICPC-2 level or across the ICPC-2 level. These grouped morbidity, pathology and 
imaging codes are defined in Appendix 4 available at: <hdl.handle.net/2123/13765>. 
Reporting morbidity with groups of ICPC-2 codes 
When recording problems managed, GPs may not always be very specific. For example, in recording 
the management of hypertension, they may simply record the problem as ‘hypertension’. In ICPC-2, 
‘unspecified hypertension’ is classified as ‘uncomplicated hypertension’ (code K86). There is another 
code for ‘complicated hypertension’ (K87). In some cases the GP may simply have failed to specify 
that the patient had hypertension with complications. The research team therefore feels that for 
national data reporting, it is more reliable to group the codes K86 and K87 and label this 
‘Hypertension*’ – the asterisk indicating that multiple ICPC-2 codes (as in this example), or ICPC-2 
PLUS codes (see below), are included. Appendix 4, Table A4.1 lists the codes included in these 
groups.  
Reporting morbidity with groups of ICPC-2 PLUS codes 
In other cases, a concept can be classified within (but be only part of) multiple ICPC-2 codes. For 
example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to site, such as L92 
– shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of shoulder, rotator cuff 
syndrome). When reporting osteoarthritis in this publication, all the more specific osteoarthritis ICPC-2 
PLUS terms classified within all the appropriate ICPC-2 codes are grouped. This group is labelled 
‘Osteoarthritis*’ – the asterisk again indicating multiple codes, but in this case they are PLUS codes 
rather than ICPC-2 codes. Appendix 4, Table A4.1 lists the codes included in these groups. 
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Reporting chronic morbidity 
Chronic conditions are medical conditions characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an 
individual’s quality of life.  
To identify chronic conditions, a chronic condition list32 classified according to ICPC-2 was applied to 
the BEACH data set. Chronic and non-chronic conditions (for example, diabetes and gestational 
diabetes) are often grouped together when reporting (for example, diabetes – all*). When reporting 
chronic morbidity, only problems regarded as chronic have been included in the analysis. Where the 
group used for the chronic analysis differs from that used in other analyses in this report, they are 
marked with a double asterisk. Codes included in the chronic groups are listed in Appendix 4, Table 
A4.2. 
Reporting pathology and imaging test orders 
All the pathology and imaging tests are coded very specifically in ICPC-2 PLUS, but ICPC-2 classifies 
pathology and imaging tests very broadly (for example, a test of cardiac enzymes is classified in K34 – 
Blood test associated with the circulatory system; a CT scan of the lumbar spine is classified as L41 – 
Diagnostic radiology/imaging of the musculoskeletal system). In Australia, the MBS classifies 
pathology and imaging tests in groups that are relatively well recognised. The team therefore 
regrouped all pathology and imaging ICPC-2 PLUS codes into MBS standard groups. This allows 
comparison of data between data sources. For groups marked with an asterisk, inclusions are listed in 
Appendix 4, Tables A4.8 and A4.9. 
Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP, or advised for over-the-counter purchase, 
are coded and classified according to an in-house classification, the Coding Atlas for Pharmaceutical 
Substances (CAPS). 
This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as medication 
class, medication group, generic name/composition, and brand name. 
The generic name of a medication is its non-proprietary name, which describes the pharmaceutical 
substance(s) or active pharmaceutical ingredient(s). 
When strength and regimen are combined with the CAPS code, we can derive the prescribed daily 
dose for any prescribed medication or group of medications. 
CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)33 classification, which is the 
Australian standard for classifying medications at the generic level.27 The ATC has a hierarchical 
structure with five levels. For example: 
• Level 1: C – Cardiovascular system 
• Level 2: C10 – Serum lipid reducing agents 
• Level 3: C10A – Cholesterol and triglyceride reducers 
• Level 4: C10AA – HMG CoA reductase inhibitors 
• Level 5: C10AA01 – Simvastatin (the generic drug). 
Use of the pharmaceutical classifications in reporting 
For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme or the 
ATC. They each have advantages in different circumstances. 
In the CAPS system, a new drug enters at the product and generic level, and is immediately allocated 
a generic code. Therefore, the CAPS classification uses a bottom-up approach. 
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In the ATC, a new generic may initially enter the classification at any level (1 to 5), not always at the 
generic level. Reclassification to lower ATC levels may occur later. Therefore, the ATC uses a top-
down approach. 
When analysing medications across time, a generic medication that is initially classified to a higher 
ATC level will not be identifiable in that data period and may result in under-enumeration of that drug 
during earlier data collection periods. 
There are some differences in the labels applied to generic medications in the two classifications. For 
example, the medication combination of paracetamol and codeine is labelled as ‘Paracetamol/codeine’ 
in CAPS and as ‘Codeine combinations excluding psycholeptics’ in the ATC. 
2.11 Quality assurance 
All morbidity and therapeutic data elements were secondarily coded by staff entering key words or 
word fragments, and selecting the required term or label from a pick list. This was then automatically 
coded and classified by the computer. To ensure reliability of data entry we use computer-aided error 
checks (‘locks’) at the data entry stage, and a physical check of samples of data entered versus those 
on the original recording form. Further logical data checks are conducted through SAS regularly. 
2.12 Validity and reliability 
A discussion of the reliability and validity of the BEACH program has been published elsewhere.34 This 
section summarises some aspects of reliability and validity of active data collection from general 
practice that should be considered by the reader.  
In the development of a database such as BEACH, data gathering moves through specific stages: GP 
sample selection, cluster sampling around each GP, GP data recording, secondary coding and data entry. 
At each stage the data can be invalidated by the application of inappropriate methods. The methods 
adopted to ensure maximum reliability of coding and data entry have been described above. The 
statistical techniques adopted to ensure valid analysis and reporting of recorded data are described in 
Section 2.7. Previous work has demonstrated the extent to which a random sample of GPs recording 
information about a cluster of patients represents all GPs and all patients attending GPs,35 the degree to 
which GP-reported patient RFEs and problems managed accurately reflect those recalled by the patient,36 
and reliability of secondary coding of RFEs37 and problems managed.30 The validity of ICPC as a tool with 
which to classify the data has also been investigated in earlier work.38 
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 3 The samples 
For annual response rates and measures of representativeness of individual annual GP samples, 
please see the annual report for each year in question (available at: 
<sydney.edu.au/medicine/fmrc/publications/books/GP-series>). 
More detailed descriptive analyses of the final sample in 2014–15 can be found in Chapter 3 of 
General practice activity in Australia 2014–15.1  
Table 3.1 shows the number of encounter records contained in each year of the BEACH program 
since April 2005, and the size of the database for those 10 years for each variable (weighted), upon 
which all comparisons over time described in this report are based. 
Table 3.1: Annual summary of data sets, 2005–06 to 2014–15 (final weighted data) 
Variable 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 2013–14 2014–15 
Total 10 
years 
General 
practitioners 1,017 930 953 1,011 988 958 984 978 959 995 9,773 
Encounters 101,993 91,805 95,898 96,688 101,349 95,839 99,030 98,564 95,879 98,728 975,773 
Reasons for 
encounter 153,309 138,434 146,696 151,282 157,071 149,005 153,218 152,278 148,880 151,636 1,501,809 
Problems 
managed 149,088 136,333 145,078 149,462 155,373 146,141 152,286 152,517 151,675 153,133 1,491,086 
Medications 106,493 93,193 98,439 102,737 108,001 100,817 106,007 101,065 98,394 101,776 1,016,922 
Other 
treatments 44,504 41,011 49,130 49,048 53,243 50,235 53,395 53,163 54,104 50,204 498,037 
Referrals & 
admissions 12,242 11,230 12,017 13,251 13,481 13,526 14,382 14,561 15,012 15,697 135,399 
Pathology 39,358 38,963 41,375 44,066 45,594 43,313 46,544 46,398 47,035 46,435 439,081 
Imaging 9,003 8,229 9,143 9,469 9,877 9,370 9,978 10,163 10,460 11,314 97,006 
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 4 The participating GPs 
4.1 Characteristics of the participating GPs 
In BEACH, each GP participant completes a profile questionnaire about themselves and the major 
practice at which they work (see Appendix 2). Over the 10 years, the questions have occasionally 
been altered to improve the quality and clarity of the data collected, or to investigate topics not 
previously surveyed as they became relevant. Therefore, for some characteristics we have data over 
the full 10-year period, and for others, over shorter periods. 
In this chapter, statistical significance of change is tested with the 2 (chi-square) statistic, with a 
decision level of α < 0.05. More detailed analyses of the participating GPs in 2014–15 can be found in 
Chapter 4 in General practice activity in Australia 2014–15.1  
Over the period 2005–06 to 2014–15, some trends emerged in the characteristics of GP BEACH 
participants (Table 4.1). The most noticeable changes are listed below and some are presented in 
Figure 4.1. 
• The feminisation of the general practice workforce is reflected in the growing proportion of GP 
participants who are female. The proportion of female participants increased from 37.2% in  
2005–06 to 42.7% in 2014–15. This change reflects change in the sex distribution of all 
recognised GPs claiming more than 375 general practice Medicare items of service in the 
previous quarter (34.8% in 2005–0639 and 42.0% in 2014–15), as provided each year by DoH from 
Medicare claims data. In Table 4.1, there was a ‘spike’ in the proportion of female GPs among the 
participating sample in 2009–10. As previously reported, this was the result of female GPs being 
over-represented in the sample provided by (then) DoHA when compared with the national sample 
frame (as may occasionally happen in the random sampling process).16  
• From 2005–06 to 2014–15, there was a significant change in the age distribution of participants, 
with a decrease in the proportion aged 35–44 years (from 22.2% to 19.0%), and an increase in the 
proportion aged 55 years and over (from 38.7% to 45.3%). Again, these changes reflect the 
changes in the practising GP population (as defined for BEACH from Medicare claims data), in 
which the proportion aged 35–44 years decreased from 24.1%39 to 22.7%, and the proportion 
aged 55 years and over increased from 32.7%39 to 40.4%. In BEACH, the mean age of GP 
participants in 2005–06 was 51.5 years (median 51 years), while in 2014–15, it was 52.4 years 
(median 53 years). 
• There was a significant increase in the proportion of GPs working 21–40 hours per week in direct 
patient care (from 47.1% in 2005–06 to 58.0% in 2014–15), and a significant decrease in the 
proportion working 41–60 hours (39.0% in 2005–06 to 28.4% in 2014–15), the dramatic change 
occurring in 2009–10 (from 40.2% in 2008–09 to 30.8% in 2009–10). The proportion working more 
than 60 hours per week in direct patient care also steadily decreased (from 3.4% to 1.7% over the 
decade). When the last two results are combined, there was a decrease from 42.4% of 
participants working more than 40 hours per week in direct patient care in 2005–06 to 30.1% 
working these hours in 2014–15. There was a significant decrease in the mean number of hours 
spent in direct patient care, from 39.1 hours in 2005–06 to 36.6 hours in 2014–15. This has 
implications for workforce planning. 
• The proportion of GPs who had graduated from their primary medical degree in Australia 
significantly decreased, from 72.0% in 2005–06 to 67.0% in 2014–15. 
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• The proportion of GP participants holding Fellowship of the RACGP (FRACGP) significantly 
increased, from 40.7% in 2005–06 to 63.8% in 2014–15. Since 1995, FRACGP has been 
mandatory for new clinicians entering general practice, so this change would largely reflect the 
inclusion of new GPs into practice who hold FRACGP. 
• The proportion of GPs currently in training programs increased in recent years, peaking in  
2012–13 at 6.1%, but showing a significant increase over the decade from 2.6% in 2005–06 to 
3.8% in 2014–15. 
4.2 Characteristics of participants’ major practice 
From 2005–06 to 2014–15, some trends emerged in the characteristics of the GP participants’ major 
practices (Table 4.2). The most noticeable changes over the 10 years are listed below.  
• The proportion of participants in solo practice, and the proportion in smaller practices of 2–4 GPs 
decreased significantly. Whereas in 2005–06 about half (48.3%) of participating GPs worked 
either solo, or in these small practices, the proportion decreased to 30.8% by 2014–15. The 
proportion working in practices of 10 or more individual GPs more than doubled (from 13.3% in 
2005–06 to 29.1% in 2014–15). Data were not available for 2007–08 and 2008–09, as the 
question was altered to capture full-time equivalent GPs at the practice instead of number of 
individuals. However from 2009–10, both data elements were captured. 
• Changes noted in regard to after-hours care are described below (multiple responses were 
allowed for this question). 
– The proportion of GPs working in practices that provided their own after-hours services (with 
no reliance on other arrangements) did not change over the decade (21.9% in 2005–06 and 
21.4% in 2014–15, results not tabled). The proportion in practices that provided all or some of 
their own after-hours care (for example, provide their own and in co-operation with other 
practices) decreased from 34.6% to 31.6% (Table 4.2).  
– The proportion providing after-hours services in cooperation with other practices (as their sole 
arrangement) decreased over the time period, from 11.2% in 2005–06 to 8.6% in 2014–15 
(results not tabled), and decreased from 15.7% to 11.6% when this option was combined with 
others (for example, provided some of their own and some in co-operation with other practices; 
or co-operatively with other practices and also using a deputising service).  
– However, the proportion of GPs working in practices that solely used deputising services for 
the provision of their after-hours care significantly increased from 38.3% in 2005–06 to 48.2% 
in 2014–15 (results not tabled). When deputising services were used in combination with other 
arrangements the proportion increased from 50.8% to 56.9%. 
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* Multiple responses were allowed. 
Note:  FRACGP – Fellows of the Royal Australian College of General Practitioners; Own A.H. – the practice provides its own after-hours 
service for their patients; Co-op A.H. – the practice provides after-hours services in a cooperative arrangement with other practices; 
Deputising A.H. – the practice uses deputising services for the provision of their after-hours care. 
Figure 4.1: Selected characteristics of participating GPs and their practices, 2005–06 and 2014–15 
Female < 45 years 55+ years Solo GP 10+ GPs FRACGP Own A.H.* Co-opA.H.*
Deputising
A.H.*
2005–06 37.2 26.9 38.7 13.1 13.3 40.7 34.6 15.7 50.8
2014–15 42.7 26.4 45.3 9.6 29.1 63.8 31.6 11.6 56.9
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 5 The encounters 
This chapter includes details about the encounters in general practice from each of the most recent 10 
years of the BEACH study from 2005–06 to 2014–15. The direction and type of change from 2005–06 
to 2014–15 is indicated for each result in the far right column of the tables: / indicates a statistically 
significant change (increase or decrease) in 2014–15 compared with 2005–06; / indicates a 
marginally significant change in 2014–15 compared with 2005–06; — indicates there was no 
significant change in 2014–15 compared with 2005–06; and § indicates a noteworthy change during 
the decade. 
Significant changes in rates per 100 encounters can be extrapolated to estimate the national increase 
or decrease in the measured event between 2005–06 and 2014–15. Some examples of extrapolated 
change are provided. The method used to extrapolate to national change estimates is described in 
Section 2.9. More detailed analyses of the GP–patient encounters in 2014–15 can be found in 
Chapter 5 of General practice activity in Australia 2014–15.1  
5.1 Content of the encounters 
Table 5.1 provides an overview of the changes that occurred between 2005–06 and 2014–15. The 
number of patient reasons for encounter (RFEs) recorded by the GP fluctuated over the decade, 
starting from 150.3 RFEs per 100 encounters in 2005–06, rising to a peak of 156.5 in 2008–09 and 
then falling to 153.6 per 100 encounters in 2014–15. Changes in types of RFEs are reported in 
Chapter 6. 
The number of problems managed increased from 146.2 per 100 encounters in 2005–06 to 155.1 per 
100 encounters in 2014–15. This represents an additional 65.1 million problems managed in general 
practice in 2014–15 than a decade earlier. Further details about changes in the types of problems 
managed are presented in Chapter 7. 
From 2014–15 onwards, data regarding the work-related nature of the problem under management is 
no longer collected and is therefore reported as not available in Table 5.1. 
The changes in management actions described below are measured in terms of rates per 100 
encounters. As there was a significant increase in the number of problems managed at encounters, it 
may be more informative to consider changes in GP management actions in terms of rates per 100 
problems managed as described in Chapters 8 to 12, inclusive. 
There was no change in the rate of medications recorded per 100 encounters over the decade. 
Specific changes in the types of medications recorded are detailed in Chapter 9. 
Between 2005–06 and 2014–15, there was a significant increase in the rate of clinical treatments 
(such as advice and counselling) provided, from 29.3 per 100 encounters in 2005–06 to 33.9 per 100 
in 2014–15. This represents an additional 16.9 million clinical treatments provided nationally in general 
practice in 2014–15 than a decade earlier. This pattern was reflected in the increase in the total other 
treatments (of which clinical treatments are the major component). These changes are described in 
further detail in Chapter 10.  
There was a significant increase in the number of procedural treatments performed in general practice 
between 2005–06 and 2014–15, from 14.4 per 100 encounters to 17.0 per 100 encounters. This 
increase represents an additional 8.8 million procedures performed nationally in 2014–15 compared 
with a decade earlier. More detail is provided in Chapter 10.  
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Referrals increased over the decade 2005–06 to 2014–15, from 12.0 to 15.9 per 100 encounters. This 
represented 9.7 million more referrals nationally in 2014–15 than a decade earlier. The change was 
reflected in increased referrals to medical specialists and to allied health services and is described 
further in Chapter 11. 
Orders for pathology and imaging tests also increased significantly between 2005–06 and 2014–15. 
Orders for other investigations decreased significantly over the period. These changes are reported in 
greater detail in Chapter 12. 
5.2 Medicare/DVA-claimable encounters 
Table 5.2 provides a summary of encounters recorded in BEACH as claimable through the Medicare 
Benefits Schedule/Department of Veterans’ Affairs (MBS/DVA). These are expressed as a proportion 
of all MBS/DVA-claimable encounters. Before 2005–06, only one item number was recorded on the 
BEACH encounter form. In 2005–06, this increased to three items, to capture practice nurse item 
numbers and other additional information about the Medicare items used in general practice.  
Only one MBS/DVA-claimable item per encounter is counted in Table 5.2. The selection of one item 
number per encounter was based on priority, whereby consultation item numbers overrode Practice 
Incentives Program payment item numbers, which overrode procedural item numbers, which overrode 
other Medicare item numbers. Table 5.2 includes only items claimed by GPs (excluding items claimed 
for practice nurses etc.) and the major changes are summarised below. 
• Short surgery consultations increased significantly from 1.0% of MBS/DVA-claimable encounters 
in 2005–06 to 1.7% in 2014–15. Previous research suggests that part of this increase is related to 
increasing practice nurse involvement in GP encounters.40 
• Standard consultations decreased significantly from 83.7% of MBS/DVA-claimable encounters in 
2005–06 to 78.8% in 2014–15. 
• Long surgery consultations accounted for 9.8% of MBS/DVA-claimable encounters in 2005–06, 
and remained steady until 2007–08. The proportion dropped significantly in 2008–09, then slowly 
rose again and in 2014–15 was not significantly different to 10 years earlier. 
• The proportion of encounters claimable under chronic disease management items, GP mental 
healthcare items and health assessments all significantly increased. 
In May 2010, changes were made to the MBS that combined the existing Medicare items for home 
visits, consultations at hospitals and consultations at other institutions.41 Unfortunately, this change no 
longer allows a discrete measure of GP home visit frequency through MBS data. To allow the 
comparison of changes over time, we have applied this change to all previous years in the decade, 
and now report a single line for ‘home and institution visits’. There was no change in the proportion of 
home and institution visits (together) between 2005–06 and 2014–15. 
5.3 Consultation length 
In a subsample of consultations, start and finish times were recorded. There was a significant increase 
in the mean length of consultation from 13.8 minutes to 14.4 minutes between 2005–06 and 2014–15 
for A1 MBS/DVA-claimable encounters. The mean length of consultation for all MBS/DVA-claimable 
encounters also increased significantly from 13.9 minutes to 14.7 minutes between 2005–06 and 
2014–15. The median consultation length for both of these groups of items increased from 12 to 13 
minutes in the last 2 years (Table 5.3).  
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 6 The patients 
This chapter includes data about the patients who participated in the BEACH study, including their 
characteristics and their reasons for encounter (RFEs), from each of the most recent 10 years of the 
BEACH study. The direction and type of change from 2005–06 to 2014–15 is shown for each result in 
the column on the far right of the tables: / indicates a statistically significant change (increase or 
decrease) in 2014–15 compared with 2005–06; / indicates a marginally significant change in 
2014–15 compared with 2005–06; — indicates there was no significant change in 2014–15 compared 
with 2005–06; and § indicates a noteworthy change during the decade. 
Detailed analyses of the patients at encounters in 2014–15 can be found in Chapter 6 of General 
practice activity in Australia 2014–15.1 
Significant changes in rates per 100 encounters can be extrapolated to estimate the national increase 
or decrease in the measured event between 2005–06 and 2014–15. There were 36.2 million more 
encounters claimed through Medicare in 2014–15 than in 2005–06 (137.3 million versus 
101.1 million). It should be noted that because of this increase, a lower rate of events per 100 
encounters can result in an increase in the estimated total number of events nationally. Examples of 
extrapolated change are provided. The method used to extrapolate to national change estimates is 
described in Section 2.9. 
6.1 Age and sex of patients at encounter 
Figure 6.1 and Table 6.1 show the age and sex distribution of patients at BEACH encounters from 
2005–06 to 2014–15. Over this period, there was no significant change in the proportion of encounters 
with male and female patients. The proportion of encounters with patients aged less than 45 years 
decreased from 45.7% to 42.0%, while the proportion with patients aged 65 years and over increased 
from 26.7% to 30.7%. When extrapolated, considering the increased number of encounters nationally, 
the annual number of encounters with patients aged less than 45 years increased by about 
11.5 million over the decade, while the annual number of encounters with patients aged 65 years and 
over increased by about 15.2 million nationally.  
Readers interested the changes in the care of older people (aged 65 years or more) in general 
practice should see the feature (Chapter 14) in the companion report General practice activity in 
Australia 2014–15.1  
6.2 Other patient characteristics 
Over the decade, there was a significant decrease in the proportion of encounters that were with 
patients new to the practice (from 9.1% in 2005–06 to 6.3% in 2014–15). Between 2005–06 and 
2014–15, the proportion of encounters with patients holding a Commonwealth concession card did not 
significantly change (45.4% to 46.2%) while those patients with a Repatriation Health Card decreased 
by one-third (3.4% to 2.1%). There was no significant change in the proportion of encounters that were 
with patients from a non-English-speaking background. There was a significant increase in the 
proportion of patients identifying themselves as Indigenous, from 1.0% in 2005–06 to 1.7% in 2014–15 
(Table 6.1). 
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 Note: Missing data removed. 
Figure 6.1: Age and sex distribution of patients at encounters, 2005–06 and 2014–15 (95% confidence 
intervals) 
6.3 Patient reasons for encounter 
Patient RFEs reflect the patient’s demand for care and can provide an indication of service use 
patterns. Patient demand for care can be influenced by interventions aimed at the general population 
(for example, health awareness campaigns in popular media and print). 
Participating GPs were asked to record at least one, and up to three, patient RFEs in words as close 
as possible to those used by the patient, before the diagnostic or management process had begun. 
RFEs can be expressed in terms of one or more symptoms (for example, ‘itchy eyes’, ‘chest pain’), in 
diagnostic terms (for example, ‘about my diabetes’, ‘for my hypertension’), a request for a service  
(‘I need more scripts’, ‘I want a referral’), an expressed fear of disease, or a need for a check-up. 
The patient may describe a single RFE that relates to a single problem managed at the encounter, a 
single RFE that relates to multiple problems, multiple symptoms that relate to a single problem 
managed at the encounter, or multiple RFEs that relate to multiple problems managed at the 
encounter. GPs may also manage a problem that was unrelated to the patient’s RFE (for example, a 
patient presents about their diabetes but while they are there, the GP also provides a vaccination and 
manages their hypertension). 
  
Male Female <1 year 1–4 years
5–14 
years
15–24 
years
25–44 
years
45–64 
years
65–74 
years
75+
years
2005–06 44.0 56.0 2.1 4.3 6.0 9.4 23.9 27.6 12.2 14.6
2014–15 42.9 57.1 1.9 4.5 5.2 8.2 22.3 27.3 14.2 16.5
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Patient characteristics 
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Number of reasons for encounter 
Table 6.2 shows that between 2005–06 and 2014–15, there was a marginal decrease in the proportion 
of encounters involving a single RFE, from 60.9% to 58.5% in 2014–15. The proportion of encounters 
with two RFEs significantly increased from 27.8% in 2005–06 to 29.4% of all encounters in 2014–15. 
Extrapolation of this increase suggests there were about 12.3 million more encounters nationally 
where two RFEs were reported in 2014–15 than in 2005–06. The proportion with three RFEs did not 
significantly change over the decade.  
The overall rate of RFEs did not significantly change, with 150.3 reported per 100 encounters in  
2005–06 and 153.6 reported per 100 encounters in 2014–15 (Table 6.3).  
Reasons for encounter by ICPC-2 component 
The distribution of patient RFEs by ICPC-2 component is presented in Table 6.3. 
Symptoms and diagnoses 
• RFEs expressed in terms of a symptom or complaint (for example, ‘tired’, ‘feeling anxious’) were 
the most frequent in all years and their presentation rate did not significantly change across the 
decade. 
• With one exception, the rate of RFEs relating to specific diagnoses (including infections, injuries, 
neoplasms, congenital anomalies, and other diagnoses) did not significantly change across the 
decade. The exception was a significant decrease in the rate of RFEs related to infections, from 
8.3 to 7.0 per 100 encounters. 
Processes of care 
RFEs relating to three of the five processes of care groups significantly increased across the decade. 
• Patient requests for medications, treatments and therapeutics (such as repeat prescriptions) 
significantly increased from 14.4 to 16.1 per 100 encounters across the decade. 
• Presentations for test results increased by nearly 50%, from 6.5 to 9.5 per 100 encounters. When 
extrapolated, we estimate 6.5 million more encounters nationally with an RFE of this type in  
2014–15 than a decade earlier. This increase reflects that seen in orders by GPs for tests and 
investigations (see Chapter 12). 
• The rate of requests for an administrative procedure (such as a sickness certificate) nearly 
doubled from 1.7 to 3.3 per 100 encounters. This change equates to an estimated national 
increase of approximately 2.8 million more requests for an administrative procedure nationally in 
2014–15 than in 2005–06. 
Patient requests for ‘diagnostic and preventive procedures’ and ‘referrals and other RFEs’ did not 
significantly change across the decade. 
Reasons for encounter by ICPC-2 chapter 
• Table 6.4 shows that between 2005–06 and 2014–15 the rate at which patients described RFEs of 
a general and unspecified nature increased by nearly 25%. When extrapolated to national 
estimates, this equates to about 24.9 million more general and unspecified RFEs in 2014–15 than 
in 2005–06. 
• RFEs related to psychological problems increased by about 20% over the decade. This equates to 
approximately 5.2 million more RFEs related to psychological problems nationally in 2014–15 than 
in 2005–06. The increased role of GPs in the management of mental health was the focus of 
Chapter 14 in the book General practice activity in Australia, health priorities and policies 1998 to 
2008.42 
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• The rate at which patients presented RFEs relating to the blood and blood-forming organs 
increased marginally by 25%. This is probably linked to increased INR testing (as shown in 
Chapter 10). 
Table 6.4 also shows that between 2005–06 and 2014–15, there were significant decreases in: 
• the rate of RFEs relating to respiratory problems, which decreased by about 10% 
• the rate of RFEs relating to the circulatory system, which decreased by nearly 20%. This may be 
linked to the decrease in the management rate of hypertension (as discussed in Chapter 7)  
• the rate of RFEs relating to ear problems, which decreased by nearly 15%  
• the rate of eye problem RFEs, which decreased by one-quarter over the decade 
• the rate of RFEs relating to neurological problems (a marginal decrease). 
Proportion of encounters with at least one RFE by ICPC-2 chapter 
Table 6.5 shows that between 2005–06 and 2014–15 there were significant increases in the 
proportion of encounters: 
• where patients described at least one RFE of a general and unspecified nature (a 20% increase). 
When extrapolated to national estimates, this equates to about 20.5 million more encounters with 
at least one general and unspecified RFE in 2014–15 than in 2005–06 
• with at least one RFE of a psychological nature (an increase of almost 20%). This equates to 
approximately 4.4 million more encounters with at least one RFE of a psychological nature 
nationally in 2014–15 than in 2005–06 
• where patients presented at least one RFE relating to the blood and blood-forming organs 
increased marginally by about one-third. 
Table 6.5 also shows that between 2005–06 and 2014–15, there were significant decreases in the 
proportion of encounters with at least one: 
• RFE relating to respiratory problems (about 15%) 
• circulatory-related RFE (about 20%) 
• ear-related RFE (about 10%) 
• neurological RFE (a marginal decrease). 
Most frequent patient reasons for encounter 
The most frequent individual RFEs are shown in Table 6.6. Over the decade, there were significant 
increases in RFEs related to specific processes of care, as expected from results in Table 6.3. 
Specifically there were significant increases in: 
• requests for test results (by nearly 50%) 
• patient requests for administrative procedures (such as sickness certificates) (which nearly 
doubled). 
Interestingly, the rate of requests for blood tests increased significantly between 2005–06 and  
2012–13, but then significantly decreased, reverting to a rate similar in 2014–15 to that of 2005–06. 
The rate of presentations for immunisation/vaccination was significantly lower in 2014–15 than in any 
other year in the decade. This parallels the decrease in the management rate of 
immunisations/vaccinations (Chapter 7) and decreases in GP-supplied vaccines (Chapter 9), and is 
likely to be associated with the delay in influenza vaccine supplies in 2015. There was also a 
significant spike in 2009–10 coinciding with the H1N1 influenza pandemic. 
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In terms of symptoms and diagnoses, from 2005–06 to 2014–15 there were significant increases in 
patient presentations of depression (by 20%). This result, combined with the marginal increase in 
anxiety presentations (by 25%), explains some of the increase in the rate of psychological RFEs 
reported above, and may have resulted from the introduction of both the Better Outcomes and Better 
Access general practice mental health care initiatives during the decade.43 
From 2005–06 to 2014–15, there were marginal increases in patient presentations of: 
• skin symptoms or complaints (by about 15%) 
• weakness/tiredness (by about 15%) 
• shoulder symptom/complaint (by nearly 20%) 
• diabetes (by 30%), equating to an extrapolated estimated 770,000 more diabetes-related RFEs in 
2014–15 than a decade earlier. 
From 2005–06 to 2014–15, there were significant decreases in the RFE rates for ear pain/earache 
(25%) and chest pain (not otherwise specified) (nearly 20%), and a marginally significant decrease in 
presentations for vomiting (about 20%). 
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t c
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 c
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pa
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w
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6;
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te
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ig
ni
fic
an
t d
iff
er
en
ce
 b
et
w
ee
n 
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–0
6 
an
d 
20
14
–1
5.
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fid
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ce
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FE
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 re
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on
 fo
r e
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ou
nt
er
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 
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at
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r d
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 c
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re
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in
di
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e 
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 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
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00
5–
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. 
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en
ce
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te
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C
P
C
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rn
at
io
na
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ca
tio
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e 
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 2
; R
FE
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at
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9 
(0
.8
–1
.0
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
—
 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; a
nd
 —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; I
C
P
C
-2
 –
 In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 P
rim
ar
y 
C
ar
e 
- V
er
si
on
 2
; R
FE
 –
 re
as
on
 fo
r e
nc
ou
nt
er
. 
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t f
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en
t p
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nt
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R
at
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r 
10
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5%
 C
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P
at
ie
nt
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n
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en
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un
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7 
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07
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20
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9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
(n
 =
 1
01
,9
93
) 
 
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 (
n
 =
 9
6,
68
8)
 
 (n
 =
 1
01
,3
49
) 
 (
n
 =
 9
5,
83
9)
 
 (
n
 =
 9
9,
03
0)
 
 (
n
 =
 9
8,
56
4)
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n
 =
 9
5,
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 =
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.0
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.7
) 
 
11
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C
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-u
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) 
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.2
) 
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1 
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.0
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.3
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—
 
U
pp
er
 r
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n 
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4 
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) 
 
2.
4 
(2
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–2
.7
) 
 
2.
2 
(2
.0
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.5
) 
 
2.
3 
(2
.0
–2
.6
) 
 
2.
2 
(1
.9
–2
.5
) 
 
2.
0 
(1
.8
–2
.3
) 
 
1.
9 
(1
.7
–2
.1
) 
 
2.
3 
(2
.0
–2
.5
) 
 
1.
7 
(1
.5
–1
.9
) 
 
2.
1 
(1
.8
–2
.4
) 
—
 
Fe
ve
r 
2.
2 
(1
.9
–2
.5
) 
 
1.
8 
(1
.6
–2
.0
) 
 
2.
1 
(1
.8
–2
.5
) 
 
1.
9 
(1
.7
–2
.1
) 
 
2.
2 
(2
.0
–2
.5
) 
 
2.
0 
(1
.8
–2
.3
) 
 
1.
9 
(1
.7
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.1
) 
 
1.
9 
(1
.7
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.1
) 
 
1.
8 
(1
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) 
 
1.
8 
(1
.7
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.0
) 
—
 
(c
on
tin
ue
d)
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6 
(c
on
tin
ue
d)
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os
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re
qu
en
t p
at
ie
nt
 r
ea
so
ns
 fo
r 
en
co
un
te
r,
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5–
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4–
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R
at
e 
pe
r 
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0 
en
co
un
te
rs
 (9
5%
 C
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P
at
ie
nt
 r
ea
so
n
 
fo
r 
en
co
un
te
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05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
(n
 =
 1
01
,9
93
) 
 
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 (
n
 =
 9
6,
68
8)
 
 (n
 =
 1
01
,3
49
) 
 (
n
 =
 9
5,
83
9)
 
 (
n
 =
 9
9,
03
0)
 
 (
n
 =
 9
8,
56
4)
 
 (
n
 =
 9
5,
87
9)
 
 
(n
 =
 9
8,
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8)
 
H
ea
da
ch
e*
 
2.
0 
(1
.9
–2
.1
) 
 
1.
9 
(1
.7
–2
.0
) 
 
1.
9 
(1
.8
–2
.1
) 
 
1.
9 
(1
.8
–2
.1
) 
 
1.
8 
(1
.6
–1
.9
) 
 
1.
7 
(1
.6
–1
.9
) 
 
1.
8 
(1
.7
–2
.0
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
5 
(1
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–1
.6
) 
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7 
(1
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–1
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
 
S
ki
n 
sy
m
pt
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pl
ai
nt
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ot
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) 
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.5
) 
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.5
) 
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) 
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) 
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.7
) 
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–1
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(1
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O
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n/
ad
vi
ce
/d
ie
t –
 a
ll*
 
1.
4 
(1
.3
–1
.6
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
8 
(1
.6
–2
.0
) 
 
1.
6 
(1
.5
–1
.8
) 
 
1.
9 
(1
.7
–2
.1
) 
 
1.
8 
(1
.5
–2
.1
) 
 
1.
6 
(1
.5
–1
.8
) 
 
1.
6 
(1
.5
–1
.8
) 
 
1.
7 
(1
.6
–1
.9
) 
 
1.
5 
(1
.4
–1
.7
) 
—
 
H
yp
er
te
ns
io
n/
hi
gh
 b
lo
od
 
pr
es
su
re
* 
1.
9 
(1
.6
–2
.1
) 
 
2.
1 
(1
.8
–2
.5
) 
 
2.
1 
(1
.8
–2
.3
) 
 
2.
1 
(1
.9
–2
.4
) 
 
2.
0 
(1
.7
–2
.3
) 
 
1.
9 
(1
.7
–2
.2
) 
 
1.
8 
(1
.5
–2
.0
) 
 
1.
9 
(1
.7
–2
.2
) 
 
1.
9 
(1
.6
–2
.2
) 
 
1.
5 
(1
.3
–1
.7
) 
—
 
A
nx
ie
ty
* 
1.
2 
(1
.0
–1
.3
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
4 
(1
.3
–1
.6
) 
 
1.
5 
(1
.3
–1
.6
) 

 
W
ea
kn
es
s/
tir
ed
ne
ss
 
1.
3 
(1
.2
–1
.4
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
4 
(1
.3
–1
.5
) 
 
1.
3 
(1
.2
–1
.5
) 
 
1.
4 
(1
.3
–1
.5
) 
 
1.
4 
(1
.3
–1
.5
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
5 
(1
.4
–1
.6
) 

 
O
th
er
 re
fe
rr
al
s 
N
E
C
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.5
) 
 
1.
4 
(1
.3
–1
.5
) 
 
1.
5 
(1
.4
–1
.6
) 

 
S
ne
ez
in
g/
na
sa
l c
on
ge
st
io
n 
1.
3 
(1
.1
–1
.6
) 
 
1.
1 
(0
.9
–1
.2
) 
 
1.
4 
(1
.2
–1
.6
) 
 
1.
3 
(1
.1
–1
.5
) 
 
1.
6 
(1
.3
–1
.8
) 
 
1.
4 
(1
.2
–1
.7
) 
 
1.
5 
(1
.3
–1
.7
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
3 
(1
.1
–1
.5
) 
—
 
S
ho
ul
de
r s
ym
pt
om
/c
om
pl
ai
nt
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
4 
(1
.3
–1
.5
) 
 
1.
1 
(1
.0
–1
.3
) 
 
1.
2 
(1
.1
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 

 
D
ia
be
te
s 
– 
al
l* 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
3 
(1
.1
–1
.4
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
4 
(1
.3
–1
.6
) 
 
1.
3 
(1
.1
–1
.4
) 
 
1.
4 
(1
.3
–1
.6
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
3 
(1
.1
–1
.4
) 

 
D
ia
rr
ho
ea
 
1.
3 
(1
.2
–1
.4
) 
 
1.
3 
(1
.2
–1
.5
) 
 
1.
4 
(1
.3
–1
.6
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
—
 
E
ar
 p
ai
n/
ea
ra
ch
e 
1.
6 
(1
.5
–1
.7
) 
 
1.
4 
(1
.3
–1
.5
) 
 
1.
4 
(1
.3
–1
.5
) 
 
1.
4 
(1
.3
–1
.6
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
5 
(1
.3
–1
.6
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.1
–1
.3
) 

 
S
le
ep
 d
is
tu
rb
an
ce
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
2 
(1
.1
–1
.3
) 
—
 
(c
on
tin
ue
d)
 
46
  
Ta
bl
e 
6.
6 
(c
on
tin
ue
d)
: M
os
t f
re
qu
en
t p
at
ie
nt
 r
ea
so
ns
 fo
r 
en
co
un
te
r,
 2
00
5–
06
 to
 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 (
95
%
 C
I)
 
 
P
at
ie
nt
 r
ea
so
ns
 
fo
r 
en
co
un
te
r 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
(n
 =
 1
01
,9
93
) 
 
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 (
n
 =
 9
6,
68
8)
 
 (n
 =
 1
01
,3
49
) 
 (
n
 =
 9
5,
83
9)
 
 (
n
 =
 9
9,
03
0)
 
 (
n
 =
 9
8,
56
4)
 
 (
n
 =
 9
5,
87
9)
 
 (
n
 =
 9
8,
72
8)
 
V
er
tig
o/
di
zz
in
es
s 
1.
1 
(1
.1
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
0 
(0
.9
–1
.0
) 
 
1.
1 
(1
.1
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(1
.0
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
—
 
Fo
ot
/to
e 
co
m
pl
ai
nt
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.1
) 
 
1.
1 
(1
.0
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
—
 
S
w
el
lin
g 
(s
ki
n)
* 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(1
.0
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
—
 
Le
g/
th
ig
h 
co
m
pl
ai
nt
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(1
.0
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(1
.0
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.9
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.0
) 
 
1.
0 
(0
.9
–1
.0
) 
—
 
Fo
llo
w
-u
p 
en
co
un
te
r N
O
S
 
0.
6 
(0
.5
–0
.7
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.7
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.7
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 

 
C
he
st
 p
ai
n 
N
O
S
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
1 
(1
.0
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.9
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–0
.9
) 

 
V
om
iti
ng
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 

 
O
th
er
 re
as
on
 fo
r e
nc
ou
nt
er
 
N
E
C
 
1.
0 
(0
.8
–1
.1
) 
 
1.
0 
(0
.9
–1
.2
) 
 
0.
7 
(0
.6
–0
.9
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.8
–1
.1
) 
 
0.
9 
(0
.7
–1
.1
) 
 
1.
0 
(0
.7
–1
.3
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.9
) 
—
 
To
ta
l R
FE
s 
15
0.
3 
(1
48
.4
–1
52
.2
) 
 
15
0.
8 
(1
48
.9
–1
52
.7
) 
 
15
3.
0 
(1
51
.1
–1
54
.8
) 
 
15
6.
5 
(1
54
.7
–1
58
.2
) 
 
15
5.
0 
(1
53
.1
–1
56
.8
) 
 
15
5.
5 
(1
53
.5
–1
57
.5
) 
 
15
4.
7 
(1
52
.8
–1
56
.7
) 
 
15
4.
5 
(1
52
.7
–1
56
.3
) 
 
15
5.
3 
(1
53
.3
–1
57
.3
) 
 
15
3.
6 
(1
51
.8
–1
55
.4
) 
—
 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
1,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
). 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
O
S
 –
 n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
; R
FE
 –
 re
as
on
 fo
r e
nc
ou
nt
er
; N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
. T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 R
FE
s 
th
at
 w
er
e 
re
co
rd
ed
 a
t a
 ra
te
 o
f ≥
 1
.0
 p
er
 1
00
 e
nc
ou
nt
er
s 
in
 a
ny
 y
ea
r.
 
47
  
 7 Problems managed 
A ‘problem managed’ is a formal statement of the provider’s understanding of a health problem 
presented by the patient, family or community, and can be described in terms of a disease, symptom 
or complaint, social problem, or ill-defined condition. At each patient encounter, up to four problems 
could be recorded by the GP and a minimum of one problem was compulsory. GPs were instructed to 
record each problem at the most specific level possible from the information available. As such, the 
problem managed may be limited to the level of a presenting symptom rather than a diagnosis. 
The status of each problem to the patient – new (first presentation to a medical practitioner), or old 
(follow-up of previously managed problem) – was also indicated. The concept of a principal diagnosis, 
which is often used in hospital statistics, is not adopted in studies of general practice where multiple 
problem management is the norm rather than the exception. Further, the range of problems managed 
at the encounter often crosses multiple body systems and may include undiagnosed symptoms, 
psychosocial problems, chronic disease or preventive health, which makes the designation of a 
principal diagnosis difficult. Thus the order in which the problems were recorded by the GP is not 
significant. 
This chapter includes data about the problems managed in general practice from each of the most 
recent 10 years of the BEACH study: 2005–06 to 2014–15. The direction and type of change from 
2005–06 to 2014–15 is indicated for each result in the far right column of the tables: / indicates a 
statistically significant change (increase or decrease) in 2014–15 compared with 2005–06; / 
indicates a marginally significant change in 2014–15 compared with 2005–06; — indicates there was 
no significant change in 2014–15 compared with 2005–06; and § indicates a noteworthy change 
during the decade. 
Significant changes in the rate per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the measured event between 2005–06 and 2014–15. Examples of 
extrapolated change are given. The method used to extrapolate to national change estimates is 
described in Section 2.9. The number of GP–patient encounters claimed through the MBS nationally 
increased by 36.2 million (35.8%) between 2005–06 (101.1 million encounters) and 2014–15 (137.3 
million encounters). As a result, a decreased rate of a particular ‘measured event’ per 100 encounters 
may yield a national increase in the absolute number of those events. 
Detailed analyses of ‘problems managed’ by participating GPs in the 2014–15 BEACH year can be 
found in the companion report, General practice activity in Australia 2014–15.1 
There are two ways to describe the relative frequency of problems managed: as a percentage of all 
problems managed in the study, or as a rate of problems managed per 100 encounters. Where groups 
of problems are reported (for example, circulatory problems), it must be remembered that more than 
one of that type of problem (such as hypertension and heart failure) may have been managed at a 
single encounter.  
The reader must be mindful that a rate per 100 encounters for a single ungrouped problem, for 
example ‘asthma, 2.1 per 100 encounters,’ can be regarded as equivalent to ‘asthma is managed at 
2.1% of encounters’, and can be extrapolated (with the methods described in Section 2.9) to 
accurately estimate the number of national encounters involving management of the selected problem. 
This is not the case for grouped concepts (ICPC-2 chapters and those marked with asterisks in the 
tables) for which extrapolations represent the number of problem contacts involving the management 
of any of the problems within the group at general practice encounters nationally. In these cases, an 
extrapolated result may be an overestimate of the number of encounters involving management of 
these problems. This is because multiple problems (within the selected group) can be recorded within 
a single encounter. To estimate more precisely the number of encounters nationally that involve 
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management of the grouped concept, the extrapolation has to be based on the proportion of 
encounters involving at least one of the concepts within the group.  
 
 
  
 
Note: Data are drawn from Tables 7.2, 7.5 and 7.6. 
Figure 7.1: Changes in the management rates of all problems, new problems and chronic 
problems, 2005–06 to 2014–15 (95% confidence intervals) 
 
Table 7.3b describes the proportion of encounters during which at least one problem has been 
managed within an ICPC-2 chapter, for each of the 10 years from 2005–06 to 2014–15. The table 
allows users to make the following kinds of statements: “in 2014–15 at least one respiratory problem 
was managed at 17.8% of encounters”, and then extrapolate this result (see Section 2.9). Such 
extrapolation suggests that at least one respiratory problem was managed at 24.4 million encounters 
nationally in 2014–15. 
Figure 7.1 shows a statistically significant increase in the rate at which all problems were managed per 
100 encounters over the 10 years to 2014–15. However, there was no change in the rate at which 
chronic problems were managed. This suggests that non-chronic problems were the major contributor 
to the increase in the number of problems managed. There was also no change over the decade in 
the rate at which new problems were managed. 
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7.1 Number of problems managed 
GPs are asked to record up to four problems at each encounter. Table 7.1 shows the number of 
problems managed at encounters over the decade. There were increases in the proportion of 
encounters at which two, three and four problems were managed, and a decrease in encounters 
where only one problem was managed. When extrapolated to all GP–patient encounters in Australia, 
this suggests there were there were about 12.3 million more occasions on which two problems were 
managed, 5.2 million more occasions where three problems were managed, and 2.1 million more 
occasions where four problems were managed by GPs in Australia in 2014–15 than in 2005–06. 
Despite the decrease in encounters where only one problem was managed, due to the overall 
increase in the number of encounters nationally, there were 16.6 million more occasions on which one 
problem was managed in 2014–15 than in 2005–06.  
These results led to a significant increase in the average number of problems managed at encounter, 
from 146.2 per 100 encounters in 2005–06 to 155.1 in 2014–15 (Table 7.2). This suggests there were 
an additional 65.1 million problems managed at GP–patient encounters in Australia in 2014–15 than in 
2005–06. 
7.2 Problems managed by ICPC-2 component 
To provide a better understanding of the types of problems managed during general practice 
encounters, problems managed in general practice may be examined using the components of the 
ICPC-2 classification. The component structure of ICPC-2 is described in detail in Section 2.8.  
Table 7.2 shows there were significant increases in the management rate of problems at encounters 
across a number of ICPC-2 components. Extrapolated to national general practice encounters, these 
increases represent about: 
• 16.0 million more contacts with problems described by GPs in terms of ‘symptoms and complaints’ 
in 2014–15 than in 2005–06 
• 2.7 million more contacts described as ‘medications, treatments and therapeutics’ in 2014–15 than 
in 2005–06 
• 1.6 million more contacts described as ‘test results’ in 2014–15 than in 2005–06 
• 1.4 million more contacts with problems classified as ‘administrative’. 
There was no change over the decade in the management of problems described as ‘diagnosis, 
diseases’. This component can be broken down into various subtypes (described in Section 2.8), 
some of which do show change over the decade. There were marginal increases in the management 
of ‘other diagnoses’ (representing 28.0 million more contacts for the management of ‘other diagnoses’ 
in 2014–15 than in 2005–06), and neoplasms (representing 2.3 million more contacts for the 
management of neoplasms in 2014–15 than in 2005–06). 
The management rate of ‘infections’ decreased over the 10-year period. However, due to an overall 
increase in the number of encounters in Australian general practice (as described in the introduction to 
this chapter), there were actually 5.7 million more contacts with problems classified as infections in 
2014–15 than in 2005–06. 
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7.3 Problems managed by ICPC-2 chapter and 
 individual problems managed 
Problems managed at general practice encounters classified by ICPC-2 chapter are described in 
Table 7.3a for all years from 2005–06 to 2014–15.  
General and unspecified problems were the most frequently managed in 2014–15, with their 
management rate significantly increasing from 15.1 per 100 encounters in 2005–06 to 19.9 per 100 in 
2014–15, an increase of 31.8% over the decade. 
There were significant increases in the management rates of some problem types at general practice 
encounters:  
• musculoskeletal problems, from 17.2 to 18.5 per 100 encounters 
• psychological problems, from 11.1 to 13.6 per 100 encounters 
• endocrine and metabolic problems, from 11.6 to 13.0 per 100 encounters 
• digestive problems, from 10.1 to 11.3 per 100 encounters 
• neurological problems, from 3.6 to 4.1 per 100 encounters 
• urological problems, from 3.1 to 3.5 per 100 encounters 
• social problems, from 0.6 to 0.9 per 100 encounters (Table 7.3a). 
Over the decade, there was a statistically significant decrease in the management rate of respiratory 
problems, from 20.6 to 18.5 per 100 encounters. There are many possible reasons for this decline, 
including education campaigns discouraging the use of antibiotics for URTI and a shift to practice 
nurses and pharmacists providing influenza vaccinations rather than GPs. Contradicting this trend, a 
statistically significant spike in the rate of respiratory problems in 2009–10 was likely due to concern 
regarding H1N1 influenza. 
• There was a significant decrease in the management rate of problems classified to the ‘eye’ 
chapter, from 2.8 to 2.3 per 100 encounters, and a marginal decrease in the management rate of 
ear problems over the decade, from 4.0 to 3.6 per 100 encounters. 
• Table 7.3b shows changes over time in the proportion of encounters during which at least one 
problem was managed per ICPC-2 chapter. The table shows that there were significant increases 
in the proportion of encounters at which at least one problem was managed in some ICPC-2 
chapters. Examples include: 
– general and unspecified problems (from 14.4% of encounters in 2005–06 to 18.4% in  
2014–15), representing an additional 10.7 million encounters during which at least one general 
and unspecified problem was managed in 2014–15 than in 2005–06 
– musculoskeletal problems (from 16.4% to 17.5%), representing an additional 7.5 million 
encounters during which at least one musculoskeletal problem was managed in 2014–15 than 
in 2005–06 
– psychological problems (from 10.5% to 12.7%), representing an additional 6.8 million 
encounters during which at least one psychological problem was managed in 2014–15 than in 
2005–06 
– endocrine and metabolic problems (from 10.7% to 11.8%), representing an additional 5.4 
million encounters in 2014–15 where at least one endocrine and metabolic problem was 
managed than in 2005–06. 
In contrast, the proportion of encounters during which at least one respiratory problem was managed 
decreased from 19.8% to 17.8%. However, due to the overall increase in general practice encounters 
nationally, this equated to an increase of 4.4 million encounters during which at least one respiratory 
problem was managed in 2014–15 than in 2005–06. Similarly, there was a decrease in the proportion 
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of encounters during which at least one ear problem was managed, but there were an additional 
900,000 encounters during which at least one ear problem was managed in 2014–15 than in 2005–06. 
Similarly, the proportion of encounters during which at least one eye problem was managed 
decreased, but there were an additional 430,000 encounters during which at least one eye problem 
was managed in 2014–15 than in 2005–06 due to the increase in the number of encounters nationally. 
The individual problems managed most frequently are described in Table 7.4. This demonstrates that 
in all years from 2005–06 to 2014–15, the most frequently managed problems were hypertension, 
check-up, upper respiratory tract infection (URTI) and depression.  
Though the most frequently managed problem across the decade, the management rate of 
hypertension decreased from 2005–06 to 2014–15, from 9.4 per 100 encounters to 7.9 per 100. 
However, due to the overall increase in the number of general practice encounters, this equated to an 
additional 1.3 million encounters at which hypertension was managed in 2014–15 than in 2005–06. Of 
the most frequently managed problems, hypertension was the only chronic problem with a decreased 
management rate over the decade. This is worthy of further investigation and will be monitored over 
the next year. 
There was no overall change in the management rate of URTI between 2005–06 and 2014–15. 
However, as reported in last year’s report, General practice activity in Australia 2013–14,20 a 
significant decrease was observed in the management rate of URTI between 2012–13 (5.8 per 100 
encounters) and 2013–14 (4.9 per 100 encounters). In this year’s data (2014–15) the management 
rate has bounced back to the rate seen in 2012–13 (5.8 per 100 encounters). Reasons for this are 
unclear, and we will continue to monitor any changes over the coming years. 
Over the decade 2005–06 to 2014–15, the management rate of immunisation/vaccination decreased 
significantly. However, there were numerous fluctuations in the management rate over the decade, 
with a significant spike in 2009–10 (7.3 per 100) that coincided with the H1N1 influenza pandemic, and 
a significant decrease in 2014–15 which may be explained by a delay in supply of the influenza 
vaccine in 2014–15, from early March to late April 2015.44 The BEACH data year runs from 1 April to 
30 March, meaning that fewer influenza vaccinations were given in the 2014–15 BEACH year than 
usual. This is supported by other results in Table 7.3 of General practice activity in Australia 2014–15.1 
While the management rate of immunisation/vaccination for general problems (for example, childhood 
immunisations) did not significantly differ in 2014–15 (2.0 per 100 encounters) from that of 2013–14 
(1.9 per 100 encounters),20 the management rate of respiratory immunisation/vaccination in 2014–15 
was less than half (1.4 per 100 encounters) that seen in 2013–14 (3.6 per 100 encounters).20 If the 
2016 release of influenza vaccine is not delayed, we would expect to see a spike in next year’s 
results. 
There were statistically significant increases in the management rates of a number of problem types, 
including general check-up, depression, back complaints, prescriptions, gastro-oesophageal reflux 
disease, anxiety, test results, administrative procedure, vitamin/nutritional deficiency, atrial 
fibrillation/flutter and abnormal test results. When extrapolated to all GP–patient encounters across 
Australia, these changes represent: 
• 2.5 million more occasions of depression management 
• 2.0 million more general check-ups in 2014–15 than in 2005–06. It is likely that the introduction  
of MBS items for health assessments contributed to this increase. These health assessments  
are targeted towards particular groups of patients, including those aged 75 years and over, the 
‘Healthy Kids Check’ for children of pre-school age (scheduled to be discontinued from  
1 November 2015), and those aged 45–49 at risk of developing chronic disease45  
• 1.9 million more occasions of management of back complaints 
• 1.6 million more contacts for test results and 1.1 million more contacts for abnormal test results. 
These increases may be explained by an increased rate of pathology test ordering over the 
decade, as described in Chapter 12 
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• 1.5 million more occasions where gastro-oesophageal reflux disease was managed 
• 1.2 million more occasions of anxiety management 
• 1.4 million more contacts for problems regarded as administrative procedures 
• 1.4 million more occasions where vitamin/nutritional deficiency was managed 
• 880,000 more occasions where atrial fibrillation/flutter was managed. 
In contrast, over the decade there was a significant decrease in the management rate of sprain/strains 
which, when extrapolated to general practice encounters across Australia, represented 170,000 fewer 
occasions where sprains/strains were managed in 2014–15 than in 2005–06. Whether this represents 
a decrease in the incidence of sprains/strains in the community or a move to present for 
sprains/strains to other health services (for example, physiotherapists, emergency departments) rather 
than general practice is worthy of investigation. 
7.4 Most common new problems 
There was no change in the management rate of all new problems combined over the decade. URTI 
was the most frequently managed new problem. Although there was no overall change in its 
management rate between 2005–06 and 2014–15, there was a marginal decrease in its management 
rate in 2013–14, from 4.5 per 100 encounters in 2012–13 to 3.8 per 100 encounters in 2013–14, then 
an increase to 4.4 per 100 in 2014–15. There was also a decrease in new presentations of acute 
bronchitis/bronchiolitis from 2012–13 (1.7 per 100 encounters) to 2013–14 (1.3 per 100), increasing to 
1.6 per 100 in 2014–15 (Table 7.5).  
Though there was no overall change over the decade for new presentations for immunisation/ 
vaccination, significant changes occurred during the decade that reflect the management of all 
immunisation/vaccinations problems, discussed in Section 7.3.  
The management rate of new check-ups increased significantly (from 2.2 to 3.1 per 100 encounters). 
This is likely to be due to the ageing population and MBS items specifically for check-ups (as 
discussed above). When extrapolated, this increase represents 2.0 million additional occasions where 
a check-up was managed as a new problem in Australia in 2014–15 compared with 2005–06.  
7.5 Most frequently managed chronic problems 
To identify chronic conditions, a list classified according to ICPC-2, based on work undertaken by 
O’Halloran et al. in 200432 and regularly updated by O’Halloran (see ‘Chronic conditions’ grouper G84 
<sydney.edu.au/medicine/fmrc/icpc-2-plus/demonstrator>), was applied to the BEACH data set. In 
other parts of this chapter, both chronic and non-chronic conditions (for example, diabetes and 
gestational diabetes) may have been grouped together when reporting (for example, diabetes – all*, 
Table 7.4). In this section, only problems regarded as chronic have been included in the analysis. For 
this reason, the condition labels in Table 7.6 may differ from those in Table 7.4. Where the group used 
for the chronic analysis differs from that used in other analyses in this report, they are marked with a 
double asterisk (for example, Diabetes [non-gestational]**). Codes included in asterisked concepts are 
presented in Appendix 4, Table A4.2. 
Table 7.6 shows the most frequently managed chronic problems between 2005–06 and 2014–15. The 
management rate of chronic conditions did not change overall between 2005–06 (52.1 per 100 
encounters) and 2014–15 (55.0 per 100 encounters), however there were significant changes 
throughout the decade, notably in 2008–09, when the rate increased to 56.9 per 100 encounters. 
However, due to the increase in the number of GP visits nationally, we estimate that GPs managed 
23 million more chronic problems in 2014–15 than they did a decade earlier. 
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The most common chronic problems managed were non-gestational hypertension, depressive 
disorder, non-gestational diabetes, chronic arthritis and lipid disorder.  
From 2005–06 to 2014–15, there were significant increases in the management rates of: 
• depressive disorder (representing 2.4 million more occasions of management in 2014–15 than in 
2005–06) 
• oesophageal disease (representing 1.4 million more occasions of management) 
• atrial fibrillation/flutter (representing 880,000 million more occasions of management) 
• chronic back pain (520,000 more contacts for this problem) and unspecified chronic pain 
(representing 480,000 more contacts for this problem in 2014–15 than in 2005–06). 
There were marginally significant increases in the management rates of the following: 
• non-gestational diabetes (representing 2.0 million more occasions of management in 2014–15 
than in 2005–06) 
• malignant neoplasms of the skin (640,000 more contacts for this problem) 
• chronic obstructive pulmonary disease (representing 530,000 more occasions of management) 
• hypothyroidism/myxoedema (representing 390,000 more occasions of management) 
• shoulder syndrome (460,000 more contacts for this problem) 
• obesity (350,000 more contacts for this problem in 2014–15 than in 2005–06). 
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7.
8–
19
.1
) 

 
S
ki
n 
16
.7
 
(1
6.
1–
17
.2
) 
 
17
.6
 
(1
6.
9–
18
.2
) 
 
17
.2
 
(1
6.
5–
17
.9
) 
 
17
.0
 
(1
6.
5–
17
.5
) 
 
16
.5
 
(1
5.
9–
17
.1
) 
 
16
.8
 
(1
6.
3–
17
.3
) 
 
16
.7
 
(1
6.
1–
17
.2
) 
 
16
.9
 
(1
6.
3–
17
.5
) 
 
17
.9
 
(1
7.
2–
18
.6
) 
 
17
.1
 
(1
6.
6–
17
.7
) 
—
 
C
irc
ul
at
or
y 
16
.9
 
(1
6.
1–
17
.7
) 
 
17
.4
 
(1
6.
7–
18
.1
) 
 
17
.6
 
(1
6.
8–
18
.3
) 
 
18
.5
 
(1
7.
8–
19
.3
) 
 
16
.7
 
(1
6.
0–
17
.4
) 
 
16
.7
 
(1
5.
9–
17
.4
) 
 
17
.2
 
(1
6.
4–
18
.0
) 
 
16
.5
 
(1
5.
8–
17
.3
) 
 
17
.3
 
(1
6.
5–
18
.1
) 
 
15
.9
 
(1
5.
1–
16
.6
) 
§ 
P
sy
ch
ol
og
ic
al
 
11
.1
 
(1
0.
5–
11
.7
) 
 
10
.9
 
(1
0.
5–
11
.4
) 
 
11
.5
 
(1
0.
9–
12
.0
) 
 
12
.4
 
(1
1.
9–
12
.9
) 
 
12
.1
 
(1
1.
6–
12
.7
) 
 
12
.3
 
(1
1.
8–
12
.9
) 
 
13
.0
 
(1
2.
3–
13
.6
) 
 
13
.1
 
(1
2.
4–
13
.7
) 
 
13
.7
 
(1
3.
0–
14
.3
) 
 
13
.6
 
(1
2.
9–
14
.3
) 

 
E
nd
oc
rin
e 
an
d 
m
et
ab
ol
ic
 
11
.6
 
(1
1.
0–
12
.2
) 
 
12
.1
 
(1
1.
6–
12
.6
) 
 
12
.9
 
(1
2.
4–
13
.5
) 
 
13
.5
 
(1
3.
0–
14
.1
) 
 
12
.7
 
(1
2.
1–
13
.2
) 
 
12
.8
 
(1
2.
2–
13
.4
) 
 
13
.5
 
(1
3.
0–
14
.1
) 
 
13
.8
 
(1
3.
1–
14
.4
) 
 
13
.6
 
(1
3.
0–
14
.1
) 
 
13
.0
 
(1
2.
5–
13
.6
) 

 
D
ig
es
tiv
e 
10
.1
 
(9
.8
–1
0.
4)
 
 
10
.4
 
(1
0.
1–
10
.7
) 
 
10
.7
 
(1
0.
4–
11
.1
) 
 
10
.5
 
(1
0.
2–
10
.8
) 
 
10
.7
 
(1
0.
3–
11
.0
) 
 
10
.6
 
(1
0.
3–
10
.9
) 
 
11
.1
 
(1
0.
8–
11
.4
) 
 
10
.9
 
(1
0.
6–
11
.3
) 
 
11
.2
 
(1
0.
8–
11
.5
) 
 
11
.3
 
(1
1.
0–
11
.7
) 

 
Fe
m
al
e 
ge
ni
ta
l s
ys
te
m
 
5.
8 
(5
.4
–6
.2
) 
 
5.
7 
(5
.3
–6
.1
) 
 
5.
8 
(5
.4
–6
.2
) 
 
6.
1 
(5
.7
–6
.6
) 
 
5.
5 
(5
.1
–5
.8
) 
 
5.
5 
(5
.2
–5
.9
) 
 
5.
5 
(5
.1
–5
.8
) 
 
5.
3 
(4
.9
–5
.6
) 
 
5.
6 
(5
.2
–5
.9
) 
 
5.
4 
(5
.0
–5
.7
) 
—
 
N
eu
ro
lo
gi
ca
l 
3.
6 
(3
.4
–3
.8
) 
 
3.
7 
(3
.6
–3
.9
) 
 
3.
6 
(3
.4
–3
.7
) 
 
3.
8 
(3
.6
–3
.9
) 
 
3.
5 
(3
.3
–3
.6
) 
 
3.
7 
(3
.6
–3
.9
) 
 
3.
6 
(3
.4
–3
.8
) 
 
3.
6 
(3
.5
–3
.8
) 
 
4.
0 
(3
.8
–4
.2
) 
 
4.
1 
(3
.9
–4
.3
) 

 
P
re
gn
an
cy
 a
nd
 fa
m
ily
 
pl
an
ni
ng
  
3.
8 
(3
.6
–4
.1
) 
 
3.
9 
(3
.6
–4
.2
) 
 
3.
9 
(3
.6
–4
.2
) 
 
3.
7 
(3
.4
–3
.9
) 
 
3.
8 
(3
.6
–4
.1
) 
 
3.
9 
(3
.6
–4
.2
) 
 
3.
8 
(3
.6
–4
.1
) 
 
3.
7 
(3
.4
–4
.0
) 
 
3.
5 
(3
.2
–3
.7
) 
 
4.
0 
(3
.7
–4
.3
) 
—
 
E
ar
 
4.
0 
(3
.8
–4
.2
) 
 
3.
8 
(3
.6
–3
.9
) 
 
3.
8 
(3
.6
–3
.9
) 
 
3.
9 
(3
.7
–4
.1
) 
 
3.
7 
(3
.5
–3
.8
) 
 
3.
9 
(3
.7
–4
.1
) 
 
3.
7 
(3
.5
–3
.8
) 
 
3.
8 
(3
.6
–4
.0
) 
 
3.
5 
(3
.4
–3
.7
) 
 
3.
6 
(3
.5
–3
.8
) 

 
U
ro
lo
gy
 
3.
1 
(2
.9
–3
.2
) 
 
3.
1 
(3
.0
–3
.3
) 
 
3.
1 
(3
.0
–3
.3
) 
 
3.
3 
(3
.2
–3
.5
) 
 
3.
2 
(3
.1
–3
.4
) 
 
3.
2 
(3
.1
–3
.4
) 
 
3.
2 
(3
.0
–3
.3
) 
 
3.
5 
(3
.3
–3
.6
) 
 
3.
6 
(3
.5
–3
.8
) 
 
3.
5 
(3
.3
–3
.6
) 

 
E
ye
 
2.
8 
(2
.6
–2
.9
) 
 
2.
7 
(2
.5
–2
.8
) 
 
2.
6 
(2
.4
–2
.7
) 
 
2.
7 
(2
.6
–2
.8
) 
 
2.
5 
(2
.3
–2
.6
) 
 
2.
5 
(2
.4
–2
.6
) 
 
2.
4 
(2
.3
–2
.6
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
2 
(2
.1
–2
.4
) 
 
2.
3 
(2
.2
–2
.5
) 

 
(c
on
tin
ue
d)
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Ta
bl
e 
7.
3a
 (c
on
tin
ue
d)
: P
ro
bl
em
s 
m
an
ag
ed
 b
y 
IC
P
C
-2
 c
ha
pt
er
, 2
00
5–
06
 to
 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 (9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
IC
P
C
-2
 c
ha
pt
er
 
(n
 =
 1
01
,9
93
) 
 
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 (
n
 =
 9
6,
68
8)
 
 (n
 =
 1
01
,3
49
) 
 (
n
 =
 9
5,
83
9)
 
 (
n
 =
 9
9,
03
0)
 
 (
n
 =
 9
8,
56
4)
 
 (
n
 =
 9
5,
87
9)
 
 (
n
 =
 9
8,
72
8)
 
M
al
e 
ge
ni
ta
l s
ys
te
m
 
1.
9 
(1
.7
–2
.0
) 
 
1.
8 
(1
.7
–2
.0
) 
 
1.
8 
(1
.7
–1
.9
) 
 
2.
0 
(1
.9
–2
.2
) 
 
1.
9 
(1
.7
–2
.0
) 
 
1.
9 
(1
.7
–2
.0
) 
 
1.
8 
(1
.7
–2
.0
) 
 
1.
8 
(1
.7
–2
.0
) 
 
1.
9 
(1
.8
–2
.1
) 
 
1.
8 
(1
.7
–2
.0
) 
—
 
B
lo
od
 &
 b
lo
od
-fo
rm
in
g 
or
ga
ns
 
1.
5 
(1
.4
–1
.6
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
6 
(1
.5
–1
.8
) 
 
1.
5 
(1
.3
–1
.6
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
6 
(1
.4
–1
.7
) 
 
1.
6 
(1
.5
–1
.8
) 
 
1.
6 
(1
.5
–1
.8
) 
 
1.
7 
(1
.6
–1
.8
) 
 
1.
6 
(1
.5
–1
.8
) 
—
 
S
oc
ia
l p
ro
bl
em
s 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 

 
To
ta
l p
ro
bl
em
s 
14
6.
2 
(1
44
.2
–1
48
.2
) 
 
14
8.
5 
(1
46
.4
–1
50
.6
) 
 
15
1.
3 
(1
49
.2
–1
53
.4
) 
 
15
4.
6 
(1
52
.6
–1
56
.5
) 
 
15
3.
3 
(1
51
.1
–1
55
.5
) 
 
15
2.
5 
(1
50
.2
–1
54
.7
) 
 
15
3.
8 
(1
51
.4
–1
56
.1
) 
 
15
4.
7 
(1
52
.5
–1
57
.0
) 
 
15
8.
2 
(1
55
.7
–1
60
.7
) 
 
15
5.
1 
(1
53
.0
–1
57
.2
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; I
C
P
C
-2
 –
 In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 P
rim
ar
y 
C
ar
e 
- V
er
si
on
 2
. 
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Ta
bl
e 
7.
3b
: P
re
se
nc
e 
of
 a
t l
ea
st
 o
ne
 p
ro
bl
em
 m
an
ag
ed
 p
er
 IC
P
C
-2
 c
h
ap
te
r,
 2
00
5–
06
 to
 2
01
4–
15
 
 
P
er
 c
en
t o
f e
nc
ou
nt
er
s 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
IC
P
C
-2
 c
ha
pt
er
 
(n
 =
 1
01
,9
93
) 
 
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 (
n
 =
 9
6,
68
8)
 
 (n
 =
 1
01
,3
49
) 
 (
n
 =
 9
5,
83
9)
 
 (
n
 =
 9
9,
03
0)
 
 (
n
 =
 9
8,
56
4)
 
 (
n
 =
 9
5,
87
9)
 
 (
n
 =
 9
8,
72
8)
 
G
en
er
al
 a
nd
 u
ns
pe
ci
fie
d 
14
.4
 
(1
3.
9–
15
.0
) 
 
15
.4
 
(1
4.
9–
15
.9
) 
 
16
.8
 
(1
6.
2–
17
.4
) 
 
16
.1
 
(1
5.
5–
16
.6
) 
 
18
.1
 
(1
7.
4–
18
.8
) 
 
17
.9
 
(1
7.
2–
18
.5
) 
 
17
.3
 
(1
6.
7–
17
.9
) 
 
18
.0
 
(1
7.
3–
18
.6
) 
 
18
.7
 
(1
8.
0–
19
.4
) 
 
18
.4
 
(1
7.
7–
19
.0
) 

 
R
es
pi
ra
to
ry
 
19
.8
 
(1
9.
1–
20
.4
) 
 
18
.9
 
(1
8.
3–
19
.6
) 
 
18
.7
 
(1
8.
1–
19
.3
) 
 
20
.1
 
(1
9.
5–
20
.7
) 
 
21
.3
 
(2
0.
6–
22
.0
) 
 
19
.6
 
(1
8.
9–
20
.2
) 
 
19
.2
 
(1
8.
6–
19
.9
) 
 
19
.3
 
(1
8.
6–
20
.0
) 
 
18
.2
 
(1
7.
5–
18
.9
) 
 
17
.8
 
(1
7.
2–
18
.4
) 

 
M
us
cu
lo
sk
el
et
al
 
16
.4
 
(1
6.
0–
16
.9
) 
 
16
.4
 
(1
5.
9–
16
.8
) 
 
16
.5
 
(1
6.
0–
17
.0
) 
 
16
.5
 
(1
6.
1–
16
.9
) 
 
16
.1
 
(1
5.
4–
16
.8
) 
 
15
.9
 
(1
5.
4–
16
.3
) 
 
16
.6
 
(1
6.
2–
17
.1
) 
 
16
.9
 
(1
6.
4–
17
.4
) 
 
17
.4
 
(1
6.
9–
17
.9
) 
 
17
.5
 
(1
7.
0–
17
.9
) 

 
S
ki
n 
15
.8
 
(1
5.
3–
16
.3
) 
 
16
.5
 
(1
6.
0–
17
.1
) 
 
16
.1
 
(1
5.
6–
16
.7
) 
 
16
.1
 
(1
5.
7–
16
.5
) 
 
15
.6
 
(1
5.
1–
16
.2
) 
 
15
.9
 
(1
5.
4–
16
.3
) 
 
15
.7
 
(1
5.
2–
16
.2
) 
 
16
.0
 
(1
5.
5–
16
.5
) 
 
16
.8
 
(1
6.
2–
17
.4
) 
 
16
.2
 
(1
5.
7–
16
.7
) 
—
 
C
irc
ul
at
or
y 
15
.8
 
(1
5.
1–
16
.4
) 
 
16
.3
 
(1
5.
7–
17
.0
) 
 
16
.4
 
(1
5.
7–
17
.1
) 
 
17
.2
 
(1
6.
6–
17
.9
) 
 
15
.5
 
(1
4.
9–
16
.1
) 
 
15
.5
 
(1
4.
9–
16
.2
) 
 
16
.0
 
(1
5.
3–
16
.7
) 
 
15
.3
 
(1
4.
7–
16
.0
) 
 
16
.1
 
(1
5.
3–
16
.8
) 
 
14
.6
 
(1
4.
0–
15
.3
) 
—
 
P
sy
ch
ol
og
ic
al
 
10
.5
 
(1
0.
0–
11
.0
) 
 
10
.4
 
(9
.9
–1
0.
8)
 
 
10
.8
 
(1
0.
3–
11
.3
) 
 
11
.7
 
(1
1.
2–
12
.1
) 
 
11
.4
 
(1
0.
9–
11
.9
) 
 
11
.7
 
(1
1.
2–
12
.1
) 
 
12
.1
 
(1
1.
5–
12
.6
) 
 
12
.3
 
(1
1.
8–
12
.8
) 
 
12
.8
 
(1
2.
3–
13
.4
) 
 
12
.7
 
(1
2.
1–
13
.2
) 

 
E
nd
oc
rin
e 
an
d 
m
et
ab
ol
ic
 
10
.7
 
(1
0.
2–
11
.2
) 
 
11
.2
 
(1
0.
7–
11
.6
) 
 
11
.8
 
(1
1.
3–
12
.3
) 
 
12
.3
 
(1
1.
9–
12
.8
) 
 
11
.6
 
(1
1.
1–
12
.0
) 
 
11
.8
 
(1
1.
3–
12
.3
) 
 
12
.3
 
(1
1.
8–
12
.8
) 
 
12
.5
 
(1
1.
9–
13
.0
) 
 
12
.4
 
(1
1.
9–
12
.8
) 
 
11
.8
 
(1
1.
3–
12
.2
) 

 
D
ig
es
tiv
e 
9.
7 
(9
.5
–1
0.
0)
 
 
10
.1
 
(9
.8
–1
0.
4)
 
 
10
.4
 
(1
0.
1–
10
.7
) 
 
10
.1
 
(9
.8
–1
0.
4)
 
 
10
.3
 
(1
0.
0–
10
.6
) 
 
10
.3
 
(1
0.
0–
10
.6
) 
 
10
.7
 
(1
0.
4–
11
.0
) 
 
10
.5
 
(1
0.
2–
10
.9
) 
 
10
.7
 
(1
0.
4–
11
.0
) 
 
10
.9
 
(1
0.
6–
11
.2
) 

 
Fe
m
al
e 
ge
ni
ta
l s
ys
te
m
 
5.
3 
(5
.0
–5
.6
) 
 
5.
3 
(5
.0
–5
.7
) 
 
5.
4 
(5
.0
–5
.7
) 
 
5.
7 
(5
.3
–6
.0
) 
 
5.
0 
(4
.7
–5
.3
) 
 
5.
1 
(4
.8
–5
.4
) 
 
5.
0 
(4
.7
–5
.3
) 
 
4.
9 
(4
.6
–5
.2
) 
 
5.
2 
(4
.8
–5
.5
) 
 
5.
0 
(4
.7
–5
.3
) 
—
 
N
eu
ro
lo
gi
ca
l 
3.
5 
(3
.4
–3
.7
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
5 
(3
.4
–3
.7
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
4 
(3
.2
–3
.6
) 
 
3.
7 
(3
.5
–3
.8
) 
 
3.
5 
(3
.3
–3
.7
) 
 
3.
6 
(3
.4
–3
.8
) 
 
3.
9 
(3
.7
–4
.1
) 
 
4.
0 
(3
.9
–4
.2
) 

 
P
re
gn
an
cy
 a
nd
 fa
m
ily
 
pl
an
ni
ng
 
3.
7 
(3
.5
–4
.0
) 
 
3.
8 
(3
.6
–4
.1
) 
 
3.
8 
(3
.5
–4
.1
) 
 
3.
6 
(3
.3
–3
.8
) 
 
3.
7 
(3
.5
–4
.0
) 
 
3.
8 
(3
.5
–4
.1
) 
 
3.
7 
(3
.5
–4
.0
) 
 
3.
6 
(3
.3
–3
.9
) 
 
3.
4 
(3
.2
–3
.6
) 
 
3.
9 
(3
.6
–4
.2
) 
—
 
E
ar
 
4.
0 
(3
.8
–4
.1
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
7 
(3
.6
–3
.9
) 
 
3.
8 
(3
.7
–4
.0
) 
 
3.
6 
(3
.5
–3
.8
) 
 
3.
8 
(3
.7
–4
.0
) 
 
3.
6 
(3
.4
–3
.8
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at
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t c
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 c
on
fid
en
ce
 in
te
rv
al
; I
C
P
C
-2
 –
 In
te
rn
at
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at
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r d
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 c
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 c
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 d
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C
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C
P
C
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S
 c
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pp
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4,
 T
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le
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4.
1,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
). 
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 c
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fid
en
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rv
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O
S
 –
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ifi
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s 
ta
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in
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di
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al
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 p
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bl
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s 
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at
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e 
m
an
ag
ed
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t a
 ra
te
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f ≥
 1
.0
 p
er
 1
00
 e
nc
ou
nt
er
s 
in
 a
ny
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ea
r.
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 8 Overview of management 
This chapter provides an overview of the management of problems in general practice from each of 
the most recent 10 years of the BEACH study from 2005–06 to 2014–15. More detailed analyses of 
the overview of management in 2014–15 can be found in Chapter 8 in General practice activity in 
Australia 2014–15.1  
As discussed in Chapter 2, we can consider changes in GP management actions over time in terms of 
the number of the selected actions per 100 GP–patient encounters, or in terms of the number of 
problems managed. If the number of problems managed on average at encounters did not alter it 
would not matter which way change was measured. 
However, as reported in Chapter 7, there was a significant increase in the number of problems 
managed at GP–patient encounters over the decade of this study. If we simply compared 
management actions (for example, number of prescriptions) as a rate per 100 encounters, we would 
be ignoring the fact that more problems were managed in 2014–15 than in 2005–06. If more problems 
are managed, more management actions should result, without any change occurring in GP 
management behaviour. 
In this, and the following management chapters, changes over time are reported in two ways: 
• rate (of the selected action) per 100 problems managed 
• rate (of the selected action) per 100 encounters. 
The rate per 100 problems managed gives a clearer idea of how GP management actions have (or 
have not) changed. The rate per 100 encounters is used as the basis of extrapolation to national 
estimated change.  
The direction and type of change from 2005–06 to 2014–15 is indicated for each result in the far  
right column of the tables: / indicates a statistically significant change (increase or decrease) in 
2014–15 compared with 2005–06; / indicates a marginally significant change in 2014–15 
compared with 2005–06; — indicates there was no significant change in 2014–15 compared with 
2005–06; and § indicates a noteworthy change during the decade. 
Examples of extrapolations are provided in each of the specific management chapters (Chapters 9 to 
12, inclusive). The method used to extrapolate to national change estimates is described in 
Section 2.9. 
Between 2005–06 and 2014–15, some trends emerged in management actions per 100 problems 
managed (Table 8.1a), and per 100 encounters (Table 8.1b). The most noticeable changes (from 
Table 8.1a) are listed below. 
• There was a significant decrease in the rate of medications prescribed, supplied by the GP, or 
advised for over-the-counter purchase, from 71.4 per 100 problems managed in 2005–06 to 66.5 
per 100 problems in 2014–15. 
• The major contributors to the above change were significant decreases in the rates of prescribed 
medications over the time period, from 58.7 to 55.2 per 100 problems, and GP-supplied 
medications, from 6.0 to 5.2 per 100 problems. 
• The rate of other treatments increased significantly, from 29.9 to 32.8 per 100 problems, 
influenced by the significant increase in procedural treatments. The rate of GP-provided 
procedures increased from 9.9 to 10.9 per 100 problems over the decade. 
• The rate of referrals to other health providers significantly increased, from 8.2 to 10.3 per 100 
problems managed between 2005–06 and 2014–15, influenced by an 11% increase in referrals to 
medical specialists (from 5.6 to 6.2 per 100 problems managed) and a 65% increase in referrals to 
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allied health services over the period (from 2.0 to 3.3 per 100 problems managed). It was further 
influenced by a marginal increase in referrals to emergency departments (from 0.1 to 0.2 per 100 
problems managed).  
• The rate at which pathology tests/batteries were ordered significantly increased by 15%, from 26.4 
tests/batteries per 100 problems managed in 2005–06 to 30.3 per 100 in 2014–15.  
• The rate at which imaging was ordered increased significantly from 6.0 imaging orders per 
100 problems managed in 2005–06 to 7.4 per 100 in 2014–15, a rise of 23%. 
Similar changes between 2005–06 and 2014–15 were apparent in the percentage of problems 
(Table 8.2a), and the percentage of encounters where at least one management type was recorded 
(Table 8.2b).  
Table 8.2a shows that over the decade 2005–06 to 2014–15, the proportion of problems for which: 
• at least one medication or other treatment type was provided decreased significantly, from 73.5% 
of problems to 70.5% 
• at least one medication was provided decreased significantly (from 56.5% of problems to 51.8%), 
mainly influenced by a significant decrease in the proportion of problems for which medication was 
prescribed, from 47.7% to 43.8% over this time 
• at least one other treatment was provided increased significantly, from 26.9 to 29.4, mainly due to 
a significant increase in the proportion of problems for which at least one procedure was 
undertaken. This increased from 9.3% to 10.3% 
• at least one referral was given, increased significantly (from 8.2% of problems to 10.2%), 
particularly to medical specialists (5.6% to 6.3%), and allied health services (2.0% to 3.3%) 
• at least one investigation was ordered, increased significantly from 17.6% of problems to 19.0%.  
– In 2005–06, the likelihood of at least one imaging test being ordered was 5.5%, and this 
increased significantly to 6.6% in 2014–15.  
– This is the first 10-year period of BEACH data (since 1998) that there was not a significant 
increase in the likelihood of tests being ordered in the management of problems.  
– There was a significant decrease in the proportion of problems for which other investigations 
were ordered, from 0.7% to 0.5% over the 10-year data period. 
 
69
  
Ta
bl
e 
8.
1a
: S
um
m
ar
y 
of
 m
an
ag
em
en
t (
ra
te
 p
er
 1
00
 p
ro
bl
em
s)
, 2
00
5–
06
 to
 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
pr
ob
le
m
s 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
M
an
ag
em
en
t t
yp
e 
(n
 =
 1
49
,0
88
) 
 (
n
 =
 1
36
,3
33
) 
 (
n
 =
 1
45
,0
78
) 
 (
n
 =
 1
49
,4
62
) 
 (
n
 =
 1
55
,3
73
) 
 (
n
 =
 1
46
,1
41
) 
 (
n
 =
 1
52
,2
86
) 
 (
n
 =
 1
52
,5
17
) 
 (
n
 =
 1
51
,6
75
) 
 (
n
 =
 1
53
,1
33
) 
M
ed
ic
at
io
ns
 
71
.4
 
(6
9.
9–
72
.9
) 
 
68
.4
 
(6
7.
0–
69
.7
) 
 
67
.9
 
(6
6.
5–
69
.2
) 
 
68
.7
 
(6
7.
5–
70
.0
) 
 
69
.5
 
(6
7.
9–
71
.1
) 
 
69
.0
 
(6
7.
6–
70
.3
) 
 
69
.6
 
(6
8.
0–
71
.2
) 
 
66
.3
 
(6
4.
9–
67
.6
) 
 
64
.9
 
(6
3.
5–
66
.2
) 
 
66
.5
 
(6
5.
1–
67
.8
) 

 
 
P
re
sc
rib
ed
 
58
.7
 
(5
7.
2–
60
.3
) 
 
56
.1
 
(5
4.
7–
57
.4
) 
 
54
.5
 
(5
3.
2–
55
.8
) 
 
55
.9
 
(5
4.
5–
57
.2
) 
 
54
.4
 
(5
2.
8–
56
.0
) 
 
55
.8
 
(5
4.
5–
57
.1
) 
 
56
.5
 
(5
4.
9–
58
.1
) 
 
53
.8
 
(5
2.
5–
55
.1
) 
 
52
.8
 
(5
1.
5–
54
.1
) 
 
55
.2
 
(5
3.
8–
56
.5
) 

 
 
G
P
-s
up
pl
ie
d 
6.
0 
(5
.6
–6
.5
) 
 
6.
0 
(5
.5
–6
.5
) 
 
6.
7 
(6
.3
–7
.1
) 
 
7.
1 
(6
.6
–7
.6
) 
 
8.
9 
(8
.3
–9
.5
) 
 
6.
8 
(6
.2
–7
.3
) 
 
6.
3 
(5
.8
–6
.8
) 
 
6.
4 
(5
.9
–6
.9
) 
 
5.
6 
(5
.2
–6
.1
) 
 
5.
2 
(4
.8
–5
.5
) 

 
 
A
dv
is
ed
 O
TC
 
6.
7 
(6
.2
–7
.2
) 
 
6.
3 
(5
.8
–6
.8
) 
 
6.
7 
(6
.2
–7
.2
) 
 
5.
7 
(5
.3
–6
.1
) 
 
6.
2 
(5
.7
–6
.7
) 
 
6.
4 
(5
.9
–6
.9
) 
 
6.
8 
(6
.3
–7
.4
) 
 
6.
1 
(5
.5
–6
.7
) 
 
6.
5 
(6
.0
–6
.9
) 
 
6.
1 
(5
.7
–6
.6
) 
—
 
O
th
er
 tr
ea
tm
en
ts
 
29
.9
 
(2
8.
5–
31
.2
) 
 
30
.1
 
(2
8.
6–
31
.5
) 
 
33
.9
 
(3
2.
4–
35
.3
) 
 
32
.8
 
(3
1.
5–
34
.1
) 
 
34
.3
 
(3
2.
6–
36
.0
) 
 
34
.4
 
(3
2.
7–
36
.0
) 
 
35
.1
 
(3
3.
5–
36
.7
) 
 
34
.9
 
(3
3.
2–
36
.5
) 
 
35
.7
 
(3
4.
2–
37
.2
) 
 
32
.8
 
(3
1.
3–
34
.2
) 

 
 
C
lin
ic
al
* 
20
.0
 
(1
8.
8–
21
.2
) 
 
19
.9
 
(1
8.
7–
21
.1
) 
 
22
.8
 
(2
1.
6–
24
.1
) 
 
22
.0
 
(2
0.
8–
23
.2
) 
 
22
.8
 
(2
1.
3–
24
.3
) 
 
23
.3
 
(2
1.
8–
24
.8
) 
 
24
.0
 
(2
2.
6–
25
.5
) 
 
23
.6
 
(2
2.
2–
25
.1
) 
 
23
.8
 
(2
2.
4–
25
.1
) 
 
21
.8
 
(2
0.
6–
23
.1
) 
—
 
 
P
ro
ce
du
ra
l*
 
9.
9 
(9
.4
–1
0.
3)
 
 
10
.2
 
(9
.7
–1
0.
7)
 
 
11
.0
 
(1
0.
5–
11
.6
) 
 
10
.8
 
(1
0.
4–
11
.3
) 
 
11
.4
 
(1
0.
8–
12
.1
) 
 
11
.1
 
(1
0.
6–
11
.6
) 
 
11
.0
 
(1
0.
5–
11
.5
) 
 
11
.2
 
(1
0.
7–
11
.8
) 
 
11
.9
 
(1
1.
4–
12
.4
) 
 
10
.9
 
(1
0.
5–
11
.4
) 

 
R
ef
er
ra
ls
 &
 a
dm
is
si
on
s 
8.
2 
(7
.9
–8
.5
) 
 
8.
2 
(7
.9
–8
.6
) 
 
8.
3 
(8
.0
–8
.6
) 
 
8.
9 
(8
.6
–9
.2
) 
 
8.
7 
(8
.4
–9
.0
) 
 
9.
3 
(8
.9
–9
.6
) 
 
9.
4 
(9
.1
–9
.8
) 
 
9.
5 
(9
.2
–9
.9
) 
 
9.
9 
(9
.6
–1
0.
2)
 
 
10
.3
 
(9
.9
–1
0.
6)
 

 
 
M
ed
ic
al
 s
pe
ci
al
is
t*
 
5.
6 
(5
.4
–5
.8
) 
 
5.
4 
(5
.2
–5
.7
) 
 
5.
3 
(5
.1
–5
.5
) 
 
5.
8 
(5
.6
–6
.0
) 
 
5.
5 
(5
.3
–5
.7
) 
 
5.
6 
(5
.4
–5
.9
) 
 
5.
6 
(5
.3
–5
.8
) 
 
5.
7 
(5
.5
–6
.0
) 
 
6.
0 
(5
.8
–6
.3
) 
 
6.
2 
(5
.9
–6
.4
) 

 
 
A
lli
ed
 h
ea
lth
 s
er
vi
ce
s*
 
2.
0 
(1
.8
–2
.1
) 
 
2.
1 
(1
.9
–2
.2
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
6 
(2
.4
–2
.7
) 
 
2.
8 
(2
.6
–2
.9
) 
 
3.
0 
(2
.8
–3
.2
) 
 
3.
0 
(2
.8
–3
.2
) 
 
3.
1 
(2
.9
–3
.3
) 
 
3.
3 
(3
.1
–3
.5
) 

 
 
H
os
pi
ta
l*
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
 
E
m
er
ge
nc
y 
de
pa
rtm
en
t*
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 

 
 
O
th
er
 re
fe
rr
al
s*
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 

 
(c
on
tin
ue
d)
 
70
  
Ta
bl
e 
8.
1a
 (c
on
tin
ue
d)
: S
um
m
ar
y 
of
 m
an
ag
em
en
t (
ra
te
 p
er
 1
00
 p
ro
bl
em
s)
, 2
00
5–
06
 to
 2
01
4–
15
 
M
an
ag
em
en
t t
yp
e 
R
at
e 
pe
r 
10
0 
pr
ob
le
m
s 
(9
5%
 C
I)
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
(n
 =
 1
49
,0
88
) 
 (
n
 =
 1
36
,3
33
) 
 (
n
 =
 1
45
,0
78
) 
 (
n
 =
 1
49
,4
62
) 
 (
n
 =
 1
55
,3
73
) 
 (
n
 =
 1
46
,1
41
) 
 (
n
 =
 1
52
,2
86
) 
 (
n
 =
 1
52
,5
17
) 
 (
n
 =
 1
51
,6
75
) 
 (
n
 =
 1
53
,1
33
) 
P
at
ho
lo
gy
 
26
.4
 
(2
5.
3–
27
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.6
 
(2
8.
6–
30
.7
) 
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.8
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) 
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.4
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f c
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fo
r e
ac
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 
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at
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al
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fic
an
t c
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ng
e 
(in
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r d
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 c
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00
5–
06
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s 
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e 
w
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o 
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ifi
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e 
in
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 c
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pa
re
d 
w
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00
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06
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 in
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th
y 
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an
ge
 d
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in
g 
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e 
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de
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C
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5>
) 
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fid
en
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te
rv
al
; O
TC
 –
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th
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Th
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di
re
ct
io
n 
an
d 
ty
pe
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f c
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e 
fro
m
 2
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5–
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 to
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4–
15
 is
 in
di
ca
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d 
fo
r e
ac
h 
re
su
lt:
 
/
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di
ca
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s 
a 
st
at
is
tic
al
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an
t c
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ng
e 
(in
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 o
r d
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e)
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 2
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4–
15
 c
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pa
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w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
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m
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gi
na
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 s
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an
t c
ha
ng
e 
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4–
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 c
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pa
re
d 
w
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5–
06
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th
er
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w
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 n
o 
si
gn
ifi
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nt
 c
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e 
in
 2
01
4–
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 c
om
pa
re
d 
w
ith
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00
5–
06
; a
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 §
 in
di
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s 
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no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
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n
 =
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55
,3
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 =
 1
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.3
 
(5
3.
4–
55
.3
) 
 
54
.2
 
(5
3.
2–
55
.1
) 
 
54
.0
 
(5
3.
1–
55
.0
) 
 
54
.8
 
(5
3.
8–
55
.8
) 
 
52
.2
 
(5
1.
3–
53
.2
) 
 
50
.7
 
(4
9.
8–
51
.6
) 
 
51
.8
 
(5
0.
9–
52
.8
) 

 
 
 
 
P
re
sc
rip
tio
n 
47
.7
 
(4
6.
6–
48
.8
) 
 
45
.6
 
(4
4.
6–
46
.6
) 
 
44
.4
 
(4
3.
5–
45
.4
) 
 
44
.9
 
(4
3.
9–
45
.8
) 
 
43
.2
 
(4
2.
1–
44
.3
) 
 
44
.7
 
(4
3.
7–
45
.6
) 
 
45
.4
 
(4
4.
3–
46
.5
) 
 
43
.3
 
(4
2.
3–
44
.3
) 
 
41
.8
 
(4
0.
8–
42
.7
) 
 
43
.8
 
(4
2.
8–
44
.8
) 

 
 
 
 
G
P
-s
up
pl
ie
d 
4.
5 
(4
.2
–4
.9
) 
 
4.
7 
(4
.3
–5
.1
) 
 
5.
3 
(5
.0
–5
.7
) 
 
5.
7 
(5
.3
–6
.1
) 
 
7.
2 
(6
.7
–7
.7
) 
 
5.
4 
(5
.0
–5
.8
) 
 
5.
0 
(4
.7
–5
.4
) 
 
5.
1 
(4
.8
–5
.5
) 
 
5.
4 
(5
.0
–5
.8
) 
 
4.
1 
(3
.8
–4
.4
) 
§ 
 
 
 
A
dv
is
ed
 O
TC
 
6.
0 
(5
.6
–6
.5
) 
 
5.
8 
(5
.4
–6
.2
) 
 
6.
1 
(5
.6
–6
.5
) 
 
5.
3 
(4
.9
–5
.6
) 
 
5.
6 
(5
.1
–6
.0
) 
 
5.
8 
(5
.4
–6
.2
) 
 
6.
2 
(5
.7
–6
.7
) 
 
5.
5 
(5
.0
–6
.0
) 
 
5.
1 
(4
.7
–5
.4
) 
 
5.
5 
(5
.1
–5
.9
) 
—
 
 
 
O
th
er
 tr
ea
tm
en
t 
26
.9
 
(2
5.
8–
28
.1
) 
 
27
.0
 
(2
5.
8–
28
.2
) 
 
30
.2
 
(2
9.
1–
31
.4
) 
 
29
.3
 
(2
8.
2–
30
.4
) 
 
30
.3
 
(2
9.
0–
31
.7
) 
 
30
.4
 
(2
9.
1–
31
.7
) 
 
30
.7
 
(2
9.
4–
31
.9
) 
 
30
.6
 
(2
9.
3–
31
.9
) 
 
31
.6
 
(3
0.
4–
32
.8
) 
 
29
.4
 
(2
8.
2–
30
.6
) 

 
 
 
 
C
lin
ic
al
* 
18
.3
 
(1
7.
2–
19
.3
) 
 
18
.0
 
(1
7.
0–
19
.1
) 
 
20
.6
 
(1
9.
6–
21
.7
) 
 
20
.0
 
(1
8.
9–
21
.0
) 
 
20
.6
 
(1
9.
3–
21
.8
) 
 
20
.9
 
(1
9.
6–
22
.1
) 
 
21
.4
 
(2
0.
2–
22
.6
) 
 
21
.0
 
(1
9.
8–
22
.2
) 
 
21
.4
 
(2
0.
2–
22
.5
) 
 
19
.9
 
(1
8.
8–
21
.0
) 
—
 
 
 
 
P
ro
ce
du
ra
l*
 
9.
3 
(8
.9
–9
.7
) 
 
9.
6 
(9
.2
–1
0.
1)
 
 
10
.3
 
(9
.8
–1
0.
8)
 
 
10
.1
 
(9
.7
–1
0.
5)
 
 
10
.7
 
(1
0.
1–
11
.3
) 
 
10
.4
 
(9
.9
–1
0.
9)
 
 
10
.3
 
(9
.8
–1
0.
7)
 
 
10
.5
 
(1
0.
0–
11
.0
) 
 
11
.2
 
(1
0.
7–
11
.6
) 
 
10
.3
 
(9
.9
–1
0.
8)
 

 
 
R
ef
er
ra
ls
 &
 a
dm
is
si
on
s 
8.
2 
(7
.9
–8
.5
) 
 
8.
3 
(8
.0
–8
.6
) 
 
8.
3 
(8
.0
–8
.6
) 
 
8.
9 
(8
.5
–9
.2
) 
 
8.
7 
(8
.4
–9
.0
) 
 
9.
2 
(8
.9
–9
.5
) 
 
9.
3 
(9
.0
–9
.7
) 
 
9.
5 
(9
.1
–9
.8
) 
 
9.
8 
(9
.5
–1
0.
2)
 
 
10
.2
 
(9
.8
–1
0.
5)
 

 
 
 
M
ed
ic
al
 s
pe
ci
al
is
t*
 
5.
6 
(5
.4
–5
.9
) 
 
5.
5 
(5
.3
–5
.8
) 
 
5.
3 
(5
.1
–5
.5
) 
 
5.
9 
(5
.7
–6
.1
) 
 
5.
6 
(5
.4
–5
.8
) 
 
5.
7 
(5
.5
–5
.9
) 
 
5.
6 
(5
.4
–5
.9
) 
 
5.
8 
(5
.5
–6
.1
) 
 
6.
1 
(5
.9
–6
.3
) 
 
6.
3 
(6
.0
–6
.5
) 

 
A
lli
ed
 h
ea
lth
 s
er
vi
ce
s*
 
2.
0 
(1
.8
–2
.1
) 
 
2.
1 
(1
.9
–2
.2
) 
 
2.
3 
(2
.2
–2
.4
) 
 
2.
5 
(2
.4
–2
.7
) 
 
2.
6 
(2
.4
–2
.7
) 
 
2.
7 
(2
.6
–2
.9
) 
 
3.
0 
(2
.8
–3
.2
) 
 
3.
0 
(2
.8
–3
.2
) 
 
3.
1 
(2
.9
–3
.3
) 
 
3.
3 
(3
.1
–3
.5
) 

 
 
 
H
os
pi
ta
l*
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
(c
on
tin
ue
d)
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Ta
bl
e 
8.
2a
 (c
on
tin
ue
d)
: P
ro
bl
em
s 
fo
r 
w
hi
ch
 a
t l
ea
st
 o
ne
 m
an
ag
em
en
t w
as
 r
ec
or
de
d 
(p
er
 c
en
t o
f p
ro
bl
em
s)
, 2
00
5–
06
 to
 2
01
4–
15
 
 
P
er
 c
en
t o
f p
ro
bl
em
s 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
A
t 
le
as
t o
ne
 …
 
(n
 =
 1
49
,0
88
) 
 (
n
 =
 1
36
,3
33
) 
 (
n
 =
 1
45
,0
78
) 
 (
n
 =
 1
49
,4
62
) 
 (
n
 =
 1
55
,3
73
) 
 (
n
 =
 1
46
,1
41
) 
 (
n
 =
 1
52
,2
86
) 
 (
n
 =
 1
52
,5
17
) 
 (
n
 =
 1
51
,6
75
) 
 (
n
 =
 1
53
,1
33
) 
 
 
E
m
er
ge
nc
y 
de
pa
rtm
en
t*
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 

 
 
 
O
th
er
 re
fe
rr
al
s*
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 

 
 
In
ve
st
ig
at
io
n 
17
.6
 
(1
7.
1–
18
.1
) 
 
18
.2
 
(1
7.
7–
18
.7
) 
 
18
.1
 
(1
7.
6–
18
.6
) 
 
18
.5
 
(1
8.
0–
19
.0
) 
 
18
.1
 
(1
7.
6–
18
.6
) 
 
18
.2
 
(1
7.
7–
18
.7
) 
 
18
.6
 
(1
8.
1–
19
.2
) 
 
18
.6
 
(1
8.
1–
19
.2
) 
 
19
.1
 
(1
8.
6–
19
.6
) 
 
19
.0
 
(1
8.
5–
19
.5
) 

 
 
 
P
at
ho
lo
gy
 o
rd
er
 
12
.7
 
(1
2.
2–
13
.2
) 
 
13
.4
 
(1
3.
0–
13
.9
) 
 
13
.1
 
(1
2.
7–
13
.6
) 
 
13
.6
 
(1
3.
2–
14
.0
) 
 
13
.2
 
(1
2.
8–
13
.7
) 
 
13
.3
 
(1
2.
9–
13
.7
) 
 
13
.6
 
(1
3.
1–
14
.1
) 
 
13
.5
 
(1
3.
1–
14
.0
) 
 
13
.9
 
(1
3.
5–
14
.3
) 
 
13
.4
 
(1
3.
0–
13
.8
) 
—
 
 
 
Im
ag
in
g 
or
de
r 
5.
5 
(5
.3
–5
.7
) 
 
5.
5 
(5
.3
–5
.7
) 
 
5.
7 
(5
.4
–5
.9
) 
 
5.
7 
(5
.4
–5
.9
) 
 
5.
7 
(5
.5
–6
.0
) 
 
5.
7 
(5
.5
–5
.9
) 
 
5.
8 
(5
.6
–6
.1
) 
 
5.
9 
(5
.7
–6
.2
) 
 
6.
1 
(5
.9
–6
.4
) 
 
6.
6 
(6
.3
–6
.8
) 

 
 
 
O
th
er
 in
ve
st
ig
at
io
n 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4 
<h
dl
.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
) 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; O
TC
 –
 o
ve
r-
th
e-
co
un
te
r. 
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Ta
bl
e 
8.
2b
: P
ro
po
rt
io
n 
of
 to
ta
l e
nc
ou
nt
er
s 
at
 w
hi
ch
 a
t l
ea
st
 o
ne
 m
an
ag
em
en
t w
as
 r
ec
or
de
d 
(p
er
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en
t o
f e
nc
ou
nt
er
s)
, 2
00
5–
06
 to
 2
01
4–
15
 
 
P
er
 c
en
t o
f e
nc
ou
nt
er
s 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
A
t 
le
as
t o
ne
…
 
(n
 =
 1
01
,9
93
) 
 
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 
(n
 =
 9
6,
68
8)
 
 (
n
 =
 1
01
,3
49
) 
 
(n
 =
 9
5,
83
9)
 
 
(n
 =
 9
9,
03
0)
 
 
(n
 =
 9
8,
56
4)
 
 
(n
 =
 9
5,
87
9)
 
 
(n
 =
 9
8,
72
8)
 
M
an
ag
em
en
t t
yp
e 
91
.2
 
(9
0.
6–
91
.8
) 
 
90
.4
 
(8
9.
8–
91
.0
) 
 
91
.9
 
(9
1.
3–
92
.4
) 
 
92
.2
 
(9
1.
7–
92
.7
) 
 
91
.3
 
(9
0.
7–
91
.9
) 
 
91
.5
 
(9
0.
8–
92
.1
) 
 
91
.9
 
(9
1.
3–
92
.5
) 
 
90
.7
 
(9
0.
1–
91
.3
) 
 
91
.3
 
(9
0.
7–
92
.0
) 
 
90
.8
 
(9
0.
2–
91
.4
) 
—
 
 
M
ed
ic
at
io
n 
or
 o
th
er
 
 
tre
at
m
en
t 
81
.4
 
(8
0.
6–
82
.1
) 
 
79
.9
 
(7
9.
1–
80
.8
) 
 
82
.2
 
(8
1.
4–
82
.9
) 
 
82
.4
 
(8
1.
7–
83
.1
) 
 
81
.6
 
(8
0.
8–
82
.4
) 
 
81
.4
 
(8
0.
5–
82
.3
) 
 
81
.9
 
(8
1.
1–
82
.8
) 
 
80
.5
 
(7
9.
6–
81
.3
) 
 
80
.9
 
(8
0.
1–
81
.8
) 
 
79
.8
 
(7
8.
8–
80
.7
) 
—
 
 
 
M
ed
ic
at
io
n 
 
65
.2
 
(6
4.
3–
66
.2
) 
 
63
.9
 
(6
3.
0–
64
.9
) 
 
64
.4
 
(6
3.
4–
65
.3
) 
 
65
.1
 
(6
4.
3–
65
.9
) 
 
64
.6
 
(6
3.
6–
65
.5
) 
 
64
.7
 
(6
3.
8–
65
.6
) 
 
65
.1
 
(6
4.
2–
66
.0
) 
 
62
.8
 
(6
1.
9–
63
.7
) 
 
62
.1
 
(6
1.
2–
63
.0
) 
 
62
.3
 
(6
1.
4–
63
.3
) 

 
 
 
 
P
re
sc
rip
tio
n 
55
.6
 
(5
4.
5–
56
.6
) 
 
54
.1
 
(5
3.
2–
55
.1
) 
 
53
.6
 
(5
2.
6–
54
.5
) 
 
54
.6
 
(5
3.
7–
55
.5
) 
 
52
.4
 
(5
1.
3–
53
.4
) 
 
54
.3
 
(5
3.
3–
55
.2
) 
 
54
.5
 
(5
3.
5–
55
.5
) 
 
52
.8
 
(5
1.
8–
53
.7
) 
 
52
.1
 
(5
1.
2–
53
.1
) 
 
53
.1
 
(5
2.
1–
54
.0
) 

 
 
 
 
G
P
-s
up
pl
ie
d 
6.
4 
(6
.0
–6
.9
) 
 
6.
8 
(6
.3
–7
.3
) 
 
7.
9 
(7
.4
–8
.4
) 
 
8.
5 
(7
.9
–9
.1
) 
 
10
.5
 
(9
.8
–1
1.
2)
 
 
8.
0 
(7
.4
–8
.6
) 
 
7.
4 
(6
.9
–7
.9
) 
 
7.
7 
(7
.1
–8
.2
) 
 
8.
3 
(7
.6
–9
.0
) 
 
6.
1 
(5
.7
–6
.6
) 
§ 
 
 
 
A
dv
is
ed
 O
TC
 
8.
6 
(8
.0
–9
.2
) 
 
8.
4 
(7
.8
–8
.9
) 
 
8.
9 
(8
.3
–9
.6
) 
 
8.
0 
(7
.5
–8
.5
) 
 
8.
3 
(7
.6
–8
.9
) 
 
8.
6 
(8
.0
–9
.2
) 
 
9.
3 
(8
.9
–9
.9
) 
 
8.
2 
(7
.5
–9
.0
) 
 
7.
8 
(7
.2
–8
.4
) 
 
8.
3 
(7
.7
–8
.9
) 
—
 
 
 
O
th
er
 tr
ea
tm
en
t 
35
.1
 
(3
3.
7–
36
.6
) 
 
35
.3
 
(3
3.
8–
36
.9
) 
 
39
.9
 
(3
8.
3–
41
.4
) 
 
39
.6
 
(3
8.
3–
41
.0
) 
 
40
.3
 
(3
8.
5–
42
.0
) 
 
40
.1
 
(3
8.
4–
41
.7
) 
 
40
.5
 
(3
8.
9–
42
.1
) 
 
40
.7
 
(3
9.
0–
42
.3
) 
 
42
.6
 
(4
1.
0–
44
.2
) 
 
39
.4
 
(3
7.
8–
41
.0
) 

 
 
 
 
C
lin
ic
al
* 
24
.0
 
(2
2.
7–
25
.4
) 
 
23
.8
 
(2
2.
5–
25
.2
) 
 
27
.5
 
(2
6.
1–
28
.9
) 
 
27
.3
 
(2
6.
0–
28
.6
) 
 
27
.7
 
(2
6.
1–
29
.2
) 
 
27
.9
 
(2
6.
3–
29
.5
) 
 
28
.5
 
(2
6.
9–
30
.0
) 
 
28
.3
 
(2
6.
8–
29
.9
) 
 
29
.3
 
(2
7.
8–
30
.8
) 
 
26
.9
 
(2
5.
4–
28
.3
) 

 
 
 
 
P
ro
ce
du
ra
l*
 
13
.2
 
(1
2.
6–
13
.8
) 
 
13
.8
 
(1
3.
2–
14
.5
) 
 
15
.0
 
(1
4.
3–
15
.7
) 
 
15
.0
 
(1
4.
4–
15
.6
) 
 
15
.7
 
(1
4.
8–
16
.6
) 
 
15
.1
 
(1
4.
4–
15
.8
) 
 
15
.2
 
(1
4.
5–
15
.8
) 
 
15
.6
 
(1
4.
9–
16
.3
) 
 
16
.8
 
(1
6.
1–
17
.5
) 
 
15
.4
 
(1
4.
7–
16
.0
) 

 
 
R
ef
er
ra
ls
 &
 a
dm
is
si
on
s 
11
.3
 
(1
0.
9–
11
.8
) 
 
11
.5
 
(1
1.
0–
11
.9
) 
 
11
.8
 
(1
1.
3–
12
.2
) 
 
12
.8
 
(1
2.
3–
13
.2
) 
 
12
.4
 
(1
1.
9–
12
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 9 Medications 
This chapter summarises the medications prescribed, advised or supplied by general practitioners in 
each year of the BEACH study from 2005–06 to 2014–15. The direction and type of change over the 
study period is indicated for each result in the far right column of the tables: / indicates a 
statistically significant change (increase or decrease) in 2014–15 compared with 2005–06; / 
indicates a marginally significant change in 2014–15 compared with 2005–06; — indicates there was 
no significant change in 2014–15 compared with 2005–06; and § indicates a noteworthy change 
during the decade. 
Significant change in the rate per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the number of prescribed, supplied, or advised medications between the first 
and last years of the study period. Some examples of extrapolated changes are given in this chapter. 
The method used to extrapolate to national change estimates is described fully in Section 2.9. In 
2014–15, there were 36.2 million more encounters claimed through Medicare than there were in 
2005–06 (137.3 million versus 101.1 million). It should be noted that because of this increase, it is 
possible that a significant decrease in a medication rate per 100 encounters can result in an increase 
in the extrapolated national estimates of that medication over time.  
GPs could record up to four medications for each of four problems – a maximum of 16 medications 
per encounter. Each medication could be recorded as prescribed (the default), supplied by the GP, or 
recommended for over-the-counter (OTC) purchase. More detailed analyses of medication recorded in 
BEACH in 2014–15 can be found in Chapter 9 of General practice activity in Australia 2014–15.1 
Medication data for the 10 years 2005–06 to 2014–15, are reported in two ways in this chapter: as 
rates per 100 problems managed and as rates per 100 encounters. In describing data over time, the 
rates per 100 problems are reported as the primary measure, because there was a significant 
increase in the number of problems managed per encounter over the decade (see Chapter 7).  
The tables with rates per 100 encounters are included to show the basis for the extrapolations 
discussed above. On the other hand, changes discussed in the examples below are per 100 problems 
managed and are taken from results shown in the ‘a’ tables (Tables 9.1a, 9.2a, 9.3a, 9.4a, 9.5a and 
9.6a). The extrapolations are based on rate per 100 encounters so that they are equivalent to the 
national encounter data from Medicare. They therefore rely on results shown in the ‘b’ tables (Tables 
9.1b, 9.2b, 9.3b, 9.4b, 9.5b and 9.6b). 
Figure 9.1 and Table 9.1a show that between 2005–06 and 2014–15, there was a significant decrease 
in prescribed medication and total medication rates per 100 problems managed. However, Table 9.1b 
shows those changes were not significant per 100 encounters.  
GP-supplied medications showed a significant decrease per 100 problems managed but no change 
per 100 encounters between 2005–06 and 2014–15 (Tables 9.1a and 9.1b).  
The rates at which GPs advised medications for OTC purchase remained stable over the decade, both 
as a rate per 100 problems managed and per 100 encounters (Tables 9.1a and 9.1b). 
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Note: Data are drawn from Table 9.1a. 
Figure 9.1: All medications and prescribed medications: rates per 100 problems managed, 
2005–06 to 2014–15 (95% confidence intervals) 
9.1 Prescribed medications 
The rate at which medications were prescribed per 100 problems managed decreased significantly 
from 2005–06 (58.7 per 100 problems) to 2014–15 (55.2 per 100) (Table 9.1a). There was no 
significant change per 100 encounters (Table 9.1b). However, the extrapolated national effect of the 
increased number of encounters (described above) resulted in an estimated 30.6 million more 
prescriptions being given nationally by GPs in 2014–15 than in 2005–06.  
Tables 9.2a and 9.2b show prescribing rates of common drug groups over the 10-year period at ATC 
drug group Level 2, because these groups are more consistent over time than the lower ATC levels. 
There were significant changes in GP prescribing rates per 100 problems managed for a wide range 
of drug groups (Table 9.2a). In particular, there were measured increases in the prescription rate of:  
• psychoanaleptics (the group includes antidepressants, psychostimulants and antidementia drugs), 
from 2.3 per 100 problems managed in 2005–06 to 3.0 in 2014–15. The extrapolated national 
effect of this change (calculated from the encounter rate from Table 9.2b) was about 3.1 million 
more prescriptions for drugs in this group given in 2014–15 than in 2005–06 
• lipid modifying agents, from 2.3 per 100 problems in 2005–06 to 2.5 in 2014–15. The extrapolated 
national effect of this marginal change was that about 2.2 million more prescriptions for drugs in 
this group were given in 2014–15 than in 2005–06 
• drugs for acid-related digestive disorders, from 2.1 per 100 problems in 2005–06 to 2.5 in  
2014–15. The extrapolated national effect of this change was that about 2.1 million more 
prescriptions for drugs in this group were given in 2014–15 than in 2005–06 
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• corticosteroids for systemic use, from 0.9 per 100 problems in 2005–06 marginally up to 1.1 in 
2014–15, an estimated 1.0 million more prescriptions nationally in 2014–15 than in 2005–06 
• antiepileptics, from 0.4 per 100 problems in 2005–06 to 0.9 in 2014–15, with an extrapolated 
national effect of 1.2 million more prescriptions nationally in 2014–15  
• thyroid therapy, from 0.5 per 100 problems in 2005–06 to 0.6 in 2014–15, which resulted in an 
extrapolated national effect of 670,000 million more prescriptions nationally in 2014–15 than in 
2005–06.  
There were also significant decreases in the prescribing rate per 100 problems managed for several 
drug groups. With the increase in number of Medicare encounters, the majority of estimates 
extrapolated from decreased medication rates represented a national increase in total prescriptions. 
As shown in Table 9.2a, some of the measured decreases in the prescription rate per 100 problems 
were for:  
• antibacterials for systemic use, from 10.0 per 100 problems managed in 2005–06 to 8.7 in  
2014–15, but the extrapolated national effect of this change (calculated on the encounter rate from 
Table 9.2b) was that about 3.8 million more prescriptions for drugs in this group were given in 
2014–15 than in 2005–06 due to the increase in encounter numbers nationally 
• drugs for obstructive airway disease, from 2.7 per 100 problems managed in 2005–06 to 
(marginally lower) 2.3 in 2014–15, but the estimated national effect of this change was that about 
1 million more prescriptions for drugs in this group were given in 2014–15 than in 2005–06 due to 
the increase in encounter numbers  
• anti-inflammatory and antirheumatic products, from 2.7 per 100 problems in 2005–06 to 2.0 in 
2014–15, with an extrapolated national effect of about 180,000 more prescriptions for these 
products nationally in 2014–15 than in 2005–06 
• sex hormones and modulators of the genital system, from 2.1 per 100 problems in 2005–06 to 1.6 
in 2014–15, which led to an extrapolated national effect of about 260,000 more prescriptions for 
this drug group nationally in 2014–15 than in 2005–06 
• beta blocking agents, from 1.3 per 100 problems in 2005–06 to 1.1 in 2014–15, leading to an 
extrapolated national effect of about 280,000 more prescriptions for them nationally in 2014–15 
than in 2005–06 
• ophthalmologicals, from 1.2 per 100 problems in 2005–06 to 0.9 in 2014–15, but an estimated 
increase of 100,000 prescriptions nationally in 2014–15 than in 2005–06 
• calcium channel blockers, from 1.5 per 100 problems in 2005–06 to 0.9 in 2014–15, leading to an 
extrapolated national effect of about 300,000 fewer prescriptions for them nationally in 2014–15 
than in 2005–06 
• vaccines, from 1.7 per 100 problems in 2005–06 to 0.6 in 2014–15, an estimated decrease of 1.2 
million vaccine prescriptions given nationally in 2014–15 than in 2005–06. 
Some of the changes referred to here can be linked to changes in the patterns of morbidity managed. 
For example, the rise in psychoanaleptics coincides with the significant increase in management rates 
of depression, and the rise in drugs for acid-related disorders matches the increase in the rate of 
gastro-oesophageal reflux disease management. Other changes coincide with policy initiatives such 
as the rise in rates of antiepileptic agents which accelerated in 2013–14 when a new indication for 
subsidised access to one of these medications was added to the Pharmaceutical Benefits Scheme 
(PBS). 
Decreases in prescribing rates of drug groups can sometimes be linked to medications within the 
group becoming available over-the-counter (for example, salbutamol); becoming more likely to be 
supplied directly to the patient by the GP (for example, vaccines); or being included in combination 
medication products (for example, cardiovascular agents such as calcium channel blockers and 
diuretics). The decrease in systemic antibacterials over the decade may be linked to improving public 
awareness of the negative effects of antibiotic overuse. It could also be associated with the significant 
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decreases in management rates of infections overall, and respiratory problems, particularly tonsillitis, 
as seen in Chapter 7.  
When no statistically significant change occurs in the prescribing rate per 100 problems managed, or 
in rate per 100 encounters, there may still be a national increase due to the increased GP attendance 
rates. An example of this is the prescribing of drugs used in diabetes, the rate of which remained 
steady over the study period. However, we estimate that due to the increase in GP attendances, about 
1.2 million more drugs used in diabetes were prescribed in 2014–15 than in 2005–06.  
Tables 9.3a and 9.3b show prescribed medication rates at the individual generic level. The same 
effect of the increased number of Medicare encounters over time applies to these individual drugs. 
There was significant change in the prescribing rate per 100 problems for a number of drugs, 
including:  
• the proton pump inhibitor esomeprazole, which rose from 0.6 per 100 problems in 2005–06 to 1.1 
per 100 in 2014–15, with an extrapolated national effect of 1.6 million more esomeprazole 
prescriptions given in 2014–15 than in 2005–06 (calculated from the encounter rate in Table 9.3b) 
• the opioid oxycodone, which more than doubled from 0.5 per 100 problems managed in 2005–06 
to 1.1 in 2014–15, with an extrapolated national effect of about 1.5 million more prescriptions for 
oxycodone nationally in 2014–15 than 10 years earlier  
• the lipid modifying agent rosuvastatin, which was first listed on the PBS in December 2006, and 
rose from 0.2 per 100 problems in 2007–08 to 0.9 per 100 in 2014–15, an estimated 1 million 
more prescriptions than in 2007–08 
• another proton pump inhibitor, pantoprazole, rose from 0.3 per 100 problems in 2005–06 to 0.5 in 
2014–15, an extrapolated increase of 590,000 more pantoprazole prescriptions between the two 
study points 
• the antiepileptic pregabalin, which was first listed in 2005 as an anticonvulsant and in 2012 as a 
treatment for neuropathic pain, rose from 0.0 to 0.5 per 100 problems, an estimated 960,000 more 
prescriptions in 2014–15 than 10 years earlier. 
In 2014–15, a large number of medications were prescribed less frequently than in 2005–06, some 
decreases being associated with a decrease in problems managed with that medication (for example, 
amoxycillin); low-cost over-the-counter availability, particularly from supermarkets (for example, 
paracetamol); becoming part of combination medications (for example, irbesartan); or by being 
superseded by newer drugs within the group (for example, atorvastatin). Some of the decreases 
observed in the prescription rate per 100 problems were for:  
• the broad spectrum penicillin amoxycillin, from 2.4 per 100 problems in 2005–06 to 2.0 per 100 
problems in 2014–15, with an extrapolated national effect of about 480,000 more prescriptions for 
this product nationally in 2014–15 than in 2005–06 (due to the increase in attendances) 
• plain paracetamol, from 2.1 per 100 problems in 2005–06 to 1.6 per 100 problems in 2014–15, but 
this decrease showed an extrapolated national effect of about 260,000 more prescriptions for this 
medication nationally in 2014–15 than in 2005–06 
• paracetamol in combinations with codeine, from 1.4 per 100 problems in 2005–06 to 1.1 per 100 
problems in 2014–15, with this decrease showing an extrapolated national effect of about 450,000 
more prescriptions for these products nationally in 2014–15 than in 2005–06 
• the lipid modifying agent atorvastatin, from 1.1 per 100 problems in 2005–06 to 0.9 in 2014–15, 
but this decrease suggested 300,000 more prescriptions nationally for atorvastatin in 2014–15 
than in 2005–06 
• the angiotensin II antagonist irbesartan, from 0.7 per 100 problems in 2005–06 to 0.5 in 2014–15, 
suggesting 150,000 fewer prescriptions nationally for irbesartan as a single agent in 2014–15 than 
in 2005–06  
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• the beta blocking agent atenolol, from 0.7 per 100 problems in 2005–06 to 0.4 in 2014–15, 
resulting in an estimated 50,000 fewer prescriptions for this drug as a single agent. Both 
irbesartan and atenolol now generally form part of combination medications. 
Number of repeats ordered 
The pattern of the number of repeat prescriptions recorded by GPs changed between 2005–06 and 
2014–15 (Table 9.4). There was a significant decrease in the proportion of prescribed medications 
with one repeat ordered. On the other hand, there was a significant increase in the proportion for 
which five repeats were recorded. The proportion of prescriptions given with five repeats increased 
from 31.7% in 2005–06 to 36.6% in 2014–15. This is probably associated with the increased 
management rate of chronic problems for which medications are commonly prescribed with five 
repeats. 
9.2 Medications supplied by GPs 
The rate of total GP-supplied medications per 100 problems managed was significantly lower in  
2014–15 (5.2) than in 2005–06 (6.0) (Table 9.5a). The peak in 2009–10 reflects the high rate of 
influenza virus vaccine (which accounts for a considerable proportion of all GP-supplied drugs) 
supplied at the time of the H1N1 influenza pandemic. 
Table 9.5a shows rates per 100 problems managed of individual medications most frequently supplied 
by GPs between 2005–06 and 2014–15. Eight of the top 10 were vaccines, and rates of most 
childhood vaccines increased. The peak in supply of influenza virus vaccine can be seen in 2009–10 
but influenza vaccine supply decreased significantly from 2005–06 to 2014–15 as did the prescribing 
rate (Table 9.3a). There was also a significant decrease from 2013–14 to 2014–15. The latter finding 
can be associated with the delay in supply of influenza vaccine in 2015 (late April instead of early 
March) causing the peak flu vaccination period to fall outside this study period. The significant 
decrease in immunisation as a problem managed (Chapter 7) is also influenced by the change in 
influenza vaccination rate, as childhood vaccinations have generally increased either significantly or 
marginally. However, the notable decrease over the decade could also be associated with the growing 
likelihood of the vaccine being given by practice nurses and therefore not always included in the 
encounter data recorded by the GP, and the move in most Australian States towards suitably trained 
pharmacists and nurses administering the vaccine at pharmacies and nurse-run clinics. 
Other changes in GP-supplied medications were the supply of vitamin B12 which increased 
significantly, and supply of meloxicam, the frequency of which decreased. 
9.3 Medications advised for over-the-counter 
purchase 
Table 9.6a shows there was no change in the rate per 100 problems managed for total advised OTC 
medications. Individual medication rates largely remained steady over the decade. The exception was 
a significant increase in the rate at which vitamin D3 (cholecalciferol) was advised. The increase 
began to be apparent in 2008–09, about the same time as a doubling of the management rate of 
nutritional/vitamin deficiency, which has maintained the much higher rate (see Chapter 7). 
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fo
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ac
h 
re
su
lt:
 
/
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ca
te
s 
a 
st
at
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tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
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 2
01
4–
15
 c
om
pa
re
d 
w
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 2
00
5–
06
; 
/
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di
ca
te
s 
a 
m
ar
gi
na
lly
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ig
ni
fic
an
t c
ha
ng
e 
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 2
01
4–
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 c
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pa
re
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w
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00
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06
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te
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gn
ifi
ca
nt
 c
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ng
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01
4–
15
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pa
re
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w
ith
 2
00
5–
06
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N
ot
e:
 C
I –
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on
fid
en
ce
 in
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rv
al
; A
TC
 –
 A
na
to
m
ic
al
 T
he
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pe
ut
ic
 C
he
m
ic
al
 in
de
x.
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 10 Other treatments 
This chapter summarises other (non-pharmacological) treatments (including clinical and procedural 
treatments) provided at, or in conjunction with, recorded GP–patient encounters in each of the 10 
years of the BEACH study, 2005–06 to 2014–15. Clinical and procedural treatments are defined in 
Appendix 4, Tables A4.4 and A4.5. 
The survey form allowed GPs to record up to two other treatments for each problem managed at the 
encounter, and to indicate if each of these was done by a practice nurse (PN) or Aboriginal health 
worker (AHW). Routine clinical measurements or observations, such as measurements of blood 
pressure and physical examinations, were not recorded if they were undertaken by the GP. However 
GPs were instructed to record clinical measurements or observations if these were undertaken by the 
PN or AHW in conjunction with the GP at the encounter. 
In Sections 10.1 and 10.2, all ‘other treatments’ are reported, irrespective of whether they were done 
by the GP or by the PN/AHW at the encounter. That is, the non-pharmacological management 
provided at general practice patient encounters is described, rather than management provided 
specifically by the GP. In the analysis of procedural treatments (Section 10.2), injections given in the 
provision of vaccines were removed, as this action has already been counted and reported in Section 
9.2 Medications supplied by GPs. 
In Section 10.3, treatments provided by the PN/AHW (including injections given for vaccination) are 
reported separately, to provide a picture of the work they undertake in association with GP–patient 
encounters. 
In Section 10.4, changes over time in the share of clinical and procedural treatments done by the GP 
and the PN/AHW, in association with the encounter, are investigated. The procedures analysed in 
Section 10.4 also include the injections given for immunisations. 
Other treatments data for the 10 years from 2005–06 to 2014–15, are reported in two ways: as rates 
per 100 problems managed (for example, Table 10.1a) and as rates per 100 encounters (for example, 
Table 10.1b). In the text describing changes over time, the rates per 100 problems are reported as the 
primary measure, because there was a significant increase in the number of problems managed per 
encounter over the study period – this increases the chance of one or more other treatments being 
given at the encounter. 
The direction and type of change from 2005–06 to 2014–15 is indicated for each result in the far right 
column of the tables: / indicates a statistically significant change (increase or decrease) comparing 
2014–15 with 2005–06; / indicates a marginally significant change comparing 2014–15 with  
2005–06; — indicates there was no significant change across the decade; and § indicates no change 
comparing 2014–15 with 2005–06 but a noteworthy change within the decade. 
Changes in the rate per 100 encounters are extrapolated to estimate the national increase or 
decrease in the other treatments provided between 2005–06 and 2014–15. Examples of extrapolated 
change are given. The method used to extrapolate to national change estimates is described in 
Section 2.9. Readers interested in the national impact of a specific measured change can apply this 
extrapolation method to any reported change. 
More detailed analyses of other treatments recorded in BEACH in 2014–15 can be found in 
Chapter 10 of General practice activity in Australia 2014–15.1 
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Figure 10.1 shows that despite a significant increase in the rate at which clinical treatments were 
provided per 100 problems managed from 2006–07 to 2007–08, the rate has since remained relatively 
steady; in 2014–15 the clinical treatment rate did not significantly differ from that of 2005–06. In 
contrast, there was a significant increase in the rate at which procedural treatments were performed 
over the decade, peaking in 2013–14, but remaining significant in 2014–15. 
 
 
 
  
 
  
Note: Data are drawn from Tables 10.1a and 10.3a. 
Figure 10.1: Clinical and procedural treatments per 100 problems, 2005–06 to 2014–15 
(95% confidence intervals) 
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10.1 Clinical treatments by GP, practice nurse, or 
 Aboriginal health worker 
Between 2006–07 and 2007–08, there was a significant increase in the rate at which clinical 
treatments were provided by the GP or the PN/AHW at GP–patient encounters, from 19.9 to 22.9 per 
100 problems managed. The rate then remained relatively steady, but in 2014–15 clinical treatments 
were provided at a rate that did not significantly differ from that of 10 years earlier, at 21.8 clinical 
treatments per 100 problems (Table 10.1a). 
• General advice and education was the most frequently recorded clinical treatment throughout the 
decade, provided at a rate of 3.9 per 100 problems managed in 2014–15. There was no significant 
change in the rate between 2005–06 and 2014–15. 
• The rate at which advice/education about medication, other administrative procedures/documents 
and counselling/advice about lifestyle were provided all significantly increased over time. 
• There was a marginal decrease in the rate at which counselling/advice about nutrition/weight and 
exercise was provided between 2005–06 and 2014–15. Considering the rise in the prevalence of 
overweight and obesity among Australian general practice patients (see Section 13.1) it is hoped 
that the decrease since 2005–06 reflects a shift of this role to PNs, AHWs and/or other allied 
health professionals. 
Although there was no significant change over the decade in the rate at which clinical treatments were 
provided per 100 problems (Table 10.1a), there was a significant increase in the rate per 100 
encounters, from 29.3 per 100 encounters in 2005–06 to 33.9 per 100 in 2014–15 (Table 10.1b). This 
was due to the increased number of problems managed per encounter over the decade (see Section 
7.1). There was also a massive increase in the number of encounters claimed through Medicare due 
to the increased visit rate (see Table 2.1). The combination of increased number of problems 
managed at encounters and the increased attendance rate over the study period affects the number of 
clinical treatments provided nationally. We estimate that as a result, 16.9 million more clinical 
treatments were provided at GP–patient encounters nationally in 2014–15 than in 2005–06. 
For every 100 GP–patient encounters in 2005–06, one or more clinical treatments were provided in 
the management of 26.7 problems. In 2014–15, this had significantly increased to 30.9 problems per 
100 encounters (Table 10.2). 
• In 2014–15, upper respiratory tract infection (URTI) was the most common problem managed with 
clinical treatment and there was no change in the frequency of clinical treatment management of 
URTI between 2005–06 and 2014–15. 
• There was a significant increase in the rate at which clinical treatments were provided in the 
management of general check-ups (0.3 per 100 encounters in 2005–06 to 0.5 per 100 in  
2014–15). Extrapolation of this increase to all Medicare-claimed GP consultation items suggests 
that there were 380,000 more occasions nationally where clinical treatment was provided at a 
general check-up in 2014–15 than in 2005–06. 
• There were marginal increases in the rates of clinical treatments for diabetes (0.8 per 
100 encounters in 2005–06 to 1.0 per 100 in 2014–15) and acute stress reaction (0.4 to 0.5 per 
100 encounters). Extrapolation of these increases suggest that across Australia, there were 
560,000 more occasions where clinical treatments were provided in the management of diabetes, 
and 280,000 more occasions for acute stress reaction in 2014–15 compared with a decade earlier. 
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10.2 Procedures by GP, practice nurse, or Aboriginal 
 health worker 
There was a significant increase in the rate at which procedures were performed, from 9.8 per 100 
problems in 2005–06 to 10.9 per 100 in 2014–15 (Table 10.3a). The extrapolated effect of this 
increase, from 14.4 procedures per 100 encounters in 2005–06 to 17.0 per 100 in 2014–15 
(Table 10.3b), is that nationally in 2014–15 there were an estimated 8.8 million more procedures 
undertaken at GP–patient encounters than there were a decade earlier. 
• The most frequently recorded group of procedures throughout the decade was excision/removal 
tissue/biopsy/destruction/debridement/cauterisation. In 2014–15, procedures of this group were 
provided at a rate of 1.9 per 100 problems managed. There was no significant change in the rate 
between 2005–06 and 2014–15. 
• There was a marginal increase in the rate of dressing/pressure/compression/tamponade, from 1.4 
per 100 problems in 2005–06 to 1.6 per 100 in 2014–15 (Table 10.3a). The extrapolated effect of 
the increase from 2.1 to 2.5 per 100 encounters (Table 10.3b) is that 1.3 million more procedures 
classified as dressing/pressure/compression/tamponade were provided in general practice 
nationally in 2014–15 than a decade earlier. 
For every 100 GP–patient encounters in 2005–06, one or more procedures were used in the 
management of 13.5 problems. By 2014–15, this had significantly increased to 16.0 problems per 100 
encounters (Table 10.4). Extrapolation of this result suggests that across Australia, about 8.3 million 
more problems were managed with a procedure in 2014–15 than a decade earlier. 
• In 2014–15, solar keratosis/sunburn was the most common problem managed with a procedural 
treatment (0.8 per 100 encounters). There was no significant change in the rate between 2005–06 
and 2014–15. 
• Over the decade, there were significant increases in the rate at which one or more procedures 
were undertaken for the management of general check-ups (from 0.2 per 100 encounters in  
2005–06 to 0.5 per 100 in 2014–15) and atrial fibrillation/flutter (0.1 to 0.4 per 100 encounters). 
Extrapolation of these increases suggest that across Australia, there were 480,000 more 
occasions where a procedure was undertaken for a general check-up, and 450,000 more 
occasions for the management of atrial fibrillation/flutter in 2014–15 compared with a decade 
earlier.
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Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
4,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
) 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
; e
xc
l –
 e
xc
lu
di
ng
. T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 p
ro
bl
em
s 
th
at
 h
ad
 c
lin
ic
al
 tr
ea
tm
en
ts
 g
iv
en
 a
t a
 ra
te
 o
f m
or
e 
th
an
 o
r e
qu
al
 to
 0
.5
 p
er
 1
00
 e
nc
ou
nt
er
s 
in
 
an
y 
ye
ar
, a
nd
 a
ny
 o
th
er
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
of
 in
te
re
st
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pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
4,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
) 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
.; 
N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
; e
xc
l –
 e
xc
lu
di
ng
. T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 p
ro
bl
em
s 
th
at
 h
ad
 c
lin
ic
al
 tr
ea
tm
en
ts
 g
iv
en
 a
t a
 ra
te
 o
f m
or
e 
th
an
 o
r e
qu
al
 to
 0
.5
 p
er
 1
00
 e
nc
ou
nt
er
s 
in
 
an
y 
ye
ar
, a
nd
 a
ny
 o
th
er
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
of
 in
te
re
st
. 
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Ta
bl
e 
10
.2
: T
he
 m
os
t c
om
m
on
 p
ro
bl
em
s 
m
an
ag
ed
 w
ith
 c
lin
ic
al
 tr
ea
tm
en
ts
, 2
00
5–
06
 to
 2
01
4–
15
 
 
R
at
e 
at
 w
hi
ch
 a
 s
el
ec
te
d 
pr
o
bl
em
 w
as
 m
an
ag
ed
 w
ith
 o
ne
 o
r 
m
or
e 
cl
in
ic
al
 t
re
at
m
en
ts
, p
er
 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
P
ro
bl
em
 m
an
ag
ed
 
(n
 =
 1
01
,9
93
) 
 (
n
 =
 9
1,
80
5)
 
 (
n
 =
 9
5,
89
8)
 
 (
n
 =
 9
6,
68
8)
 
 (n
 =
 1
01
,3
49
) 
 (
n
 =
 9
5,
83
9)
 
 (
n
 =
 9
9,
03
0)
 
 (
n
 =
 9
8,
56
4)
 
 (
n
 =
 9
5,
87
9)
 
 (
n
 =
 9
8,
72
8)
 
U
pp
er
 re
sp
ira
to
ry
 tr
ac
t 
in
fe
ct
io
n 
1.
6 
(1
.3
–1
.8
) 
 
1.
4 
(1
.3
–1
.6
) 
 
1.
8 
(1
.6
–2
.0
) 
 
1.
7 
(1
.5
–1
.9
) 
 
1.
9 
(1
.6
–2
.2
) 
 
1.
7 
(1
.4
–1
.9
) 
 
1.
7 
(1
.5
–1
.9
) 
 
2.
0 
(1
.6
–2
.3
) 
 
1.
6 
(1
.4
–1
.8
) 
 
1.
8 
(1
.6
–2
.1
) 
—
 
D
ep
re
ss
io
n*
  
1.
6 
(1
.5
–1
.8
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
8 
(1
.6
–1
.9
) 
 
1.
8 
(1
.7
–2
.0
) 
 
1.
9 
(1
.7
–2
.1
) 
 
1.
8 
(1
.6
–1
.9
) 
 
1.
8 
(1
.6
–2
.0
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
9 
(1
.7
–2
.1
) 
 
1.
7 
(1
.5
–1
.8
) 
—
 
D
ia
be
te
s 
– 
al
l* 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
1 
(0
.9
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
0 
(0
.9
–1
.1
) 

 
A
nx
ie
ty
* 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
1 
(1
.0
–1
.2
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
H
yp
er
te
ns
io
n*
 
1.
0 
(0
.9
–1
.2
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.8
–1
.1
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
1 
(1
.0
–1
.3
) 
 
1.
0 
(0
.9
–1
.2
) 
 
1.
1 
(0
.9
–1
.2
) 
 
0.
9 
(0
.7
–1
.0
) 
—
 
Li
pi
d 
di
so
rd
er
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.8
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
—
 
G
as
tro
en
te
rit
is
* 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
—
 
B
ac
k 
co
m
pl
ai
nt
* 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
—
 
A
cu
te
 s
tre
ss
 re
ac
tio
n 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 

 
Te
st
 re
su
lts
* 
 
0.
5 
(0
.3
–0
.6
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
—
 
G
en
er
al
 c
he
ck
-u
p*
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 

 
O
st
eo
ar
th
rit
is
* 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 

 
A
dm
in
is
tra
tiv
e 
pr
oc
ed
ur
e 
– 
al
l* 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 

 
V
ira
l d
is
ea
se
, o
th
er
/N
O
S
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
—
 
 (c
on
tin
ue
d)
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Ta
bl
e 
10
.2
 (c
on
tin
ue
d)
: T
he
 m
os
t c
om
m
on
 p
ro
bl
em
s 
m
an
ag
ed
 w
ith
 c
lin
ic
al
 tr
ea
tm
en
ts
, 2
00
5–
06
 t
o 
20
14
–1
5 
 
R
at
e 
at
 w
hi
ch
 a
 s
el
ec
te
d 
pr
o
bl
em
 w
as
 m
an
ag
ed
 w
ith
 o
ne
 o
r 
m
or
e 
cl
in
ic
al
 tr
ea
tm
en
ts
, p
er
 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
P
ro
bl
em
 m
an
ag
ed
 
(n
 =
 1
01
,9
93
) 
 (
n
 =
 9
1,
80
5)
 
 (
n
 =
 9
5,
89
8)
 
 (
n
 =
 9
6,
68
8)
 
 (n
 =
 1
01
,3
49
) 
 (
n
 =
 9
5,
83
9)
 
 (
n
 =
 9
9,
03
0)
 
 (
n
 =
 9
8,
56
4)
 
 (
n
 =
 9
5,
87
9)
 
 (
n
 =
 9
8,
72
8)
 
A
st
hm
a 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.3
–0
.4
) 
—
 
O
be
si
ty
 (B
M
I >
 3
0)
  
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
—
 
To
ba
cc
o 
ab
us
e 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 

 
To
ta
l p
ro
bl
em
s 
w
ith
 
cl
in
ic
al
 t
re
at
m
en
ts
 
26
.7
 
(2
5.
1–
28
.3
) 
 
26
.8
 
(2
5.
2–
28
.5
) 
 
31
.3
 
(2
9.
5–
33
.0
) 
 
30
.9
 
(2
9.
3–
32
.6
) 
 
31
.6
 
(2
9.
6–
33
.6
) 
 
31
.9
 
(2
9.
9–
33
.9
) 
 
33
.0
 
(3
1.
0–
35
.0
) 
 
32
.6
 
(3
0.
7–
34
.6
) 
 
33
.9
 
(3
1.
9–
35
.8
) 
 
30
.9
 
(2
9.
0–
32
.7
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
1,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
). 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
O
S
 –
 n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
; B
M
I –
 b
od
y 
m
as
s 
in
de
x.
 T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 p
ro
bl
em
s 
th
at
 h
ad
 c
lin
ic
al
 tr
ea
tm
en
ts
 g
iv
en
 a
t a
 ra
te
 o
f m
or
e 
th
an
 o
r e
qu
al
 to
 0
.5
 p
er
 1
00
 
en
co
un
te
rs
 in
 a
ny
 y
ea
r, 
an
d 
an
y 
ot
he
r s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
of
 in
te
re
st
. 
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Ta
bl
e 
10
.3
a:
 T
he
 m
os
t f
re
qu
en
t p
ro
ce
du
ra
l t
re
at
m
en
ts
 (r
at
e 
pe
r 
10
0 
pr
ob
le
m
s)
, 2
00
5–
06
 to
 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
pr
ob
le
m
s 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 1
49
,0
88
) 
 (n
 =
 1
36
,3
33
) 
 (n
 =
 1
45
,0
78
) 
 (n
 =
 1
49
,4
62
) 
 (n
 =
 1
55
,3
73
) 
 (n
 =
 1
46
,1
41
) 
 (n
 =
 1
52
,2
86
) 
 (n
 =
 1
52
,5
17
) 
 (n
 =
 1
51
,6
75
) 
 (n
 =
 1
53
,1
33
) 
E
xc
is
io
n/
re
m
ov
al
 ti
ss
ue
/ 
bi
op
sy
/d
es
tru
ct
io
n/
 
de
br
id
em
en
t/c
au
te
ris
at
io
n*
 
1.
9 
(1
.8
–2
.1
) 
 
2.
1 
(1
.9
–2
.4
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
0 
(1
.8
–2
.2
) 
 
1.
9 
(1
.7
–2
.0
) 
 
1.
8 
(1
.7
–2
.0
) 
 
1.
7 
(1
.6
–1
.9
) 
 
1.
9 
(1
.7
–2
.0
) 
 
2.
0 
(1
.8
–2
.2
) 
 
1.
9 
(1
.7
–2
.1
) 
—
 
D
re
ss
in
g/
pr
es
su
re
/ 
co
m
pr
es
si
on
/ta
m
po
na
de
* 
1.
4 
(1
.3
–1
.5
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
6 
(1
.4
–1
.7
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
6 
(1
.4
–1
.7
) 
 
1.
8 
(1
.7
–1
.9
) 
 
1.
6 
(1
.5
–1
.7
) 

 
Lo
ca
l i
nj
ec
tio
n/
 
in
fil
tra
tio
n*
(b
)  
1.
3 
(1
.2
–1
.5
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
6 
(1
.5
–1
.8
) 
 
1.
6 
(1
.4
–1
.8
) 
 
1.
4 
(1
.3
–1
.5
) 
 
1.
5 
(1
.4
–1
.7
) 
 
1.
6 
(1
.5
–1
.8
) 
 
1.
5 
(1
.4
–1
.6
) 
—
 
P
hy
si
ca
l m
ed
ic
in
e/
 
re
ha
bi
lit
at
io
n 
– 
al
l* 
0.
9 
(0
.8
–1
.1
) 
 
0.
7 
(0
.6
–0
.9
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.1
) 
 
0.
9 
(0
.7
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
—
 
In
ci
si
on
/d
ra
in
ag
e/
 
flu
sh
in
g/
as
pi
ra
tio
n/
 
re
m
ov
al
 b
od
y 
flu
id
* 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 

 
P
ap
 s
m
ea
r*
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 

 
R
ep
ai
r/f
ix
at
io
n 
– 
su
tu
re
/ 
ca
st
/p
ro
st
he
tic
 d
ev
ic
e 
(a
pp
ly
/r
em
ov
e)
* 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 

 
O
th
er
 th
er
ap
eu
tic
 
pr
oc
ed
ur
es
/m
in
or
 s
ur
ge
ry
* 
0.
6 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.3
–1
.1
) 
 
0.
5 
(0
.4
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.5
–0
.8
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.7
) 
—
 
IN
R
 te
st
* 
N
/A
 
 
 
0.
1 
(0
.0
–0
.1
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 

 
E
le
ct
ric
al
 tr
ac
in
gs
* 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 

 
To
ta
l p
ro
ce
du
ra
l 
tr
ea
tm
en
ts
 
9.
8 
(9
.4
–1
0.
3)
 
 
10
.2
 
(9
.7
–1
0.
7)
 
 
11
.0
 
(1
0.
4–
11
.5
) 
 
10
.8
 
(1
0.
3–
11
.2
) 
 
11
.4
 
(1
0.
7–
12
.1
) 
 
11
.0
 
(1
0.
5–
11
.5
) 
 
11
.0
 
(1
0.
5–
11
.5
) 
 
11
.2
 
(1
0.
6–
11
.7
) 
 
11
.8
 
(1
1.
3–
12
.4
) 
 
10
.9
 
(1
0.
5–
11
.4
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
(b
) 
E
xc
lu
de
s 
al
l l
oc
al
 in
je
ct
io
n/
in
fil
tra
tio
ns
 p
er
fo
rm
ed
 fo
r i
m
m
un
is
at
io
ns
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
s 
A
4.
5 
an
d 
A
4.
6,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
). 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; I
N
R
 –
 in
te
rn
at
io
na
l n
or
m
al
is
ed
 ra
tio
; N
/A
 –
 n
ot
 a
pp
lic
ab
le
; P
N
 –
 p
ra
ct
ic
e 
nu
rs
e;
 A
H
W
 –
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r. 
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Ta
bl
e 
10
.3
b:
 T
he
 m
os
t f
re
qu
en
t p
ro
ce
du
ra
l t
re
at
m
en
ts
 (r
at
e 
pe
r 
10
0 
en
co
un
te
rs
), 
20
05
–0
6 
to
 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 (
95
%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 1
01
,9
93
) 
 (
n
 =
 9
1,
80
5)
 
 (
n
 =
 9
5,
89
8)
 
 (
n
 =
 9
6,
68
8)
 
 (n
 =
 1
01
,3
49
) 
 (
n
 =
 9
5,
83
9)
 
 (
n
 =
 9
9,
03
0)
 
 (
n
 =
 9
8,
56
4)
 
 (
n
 =
 9
5,
87
9)
 
 (
n
 =
 9
8,
72
8)
 
E
xc
is
io
n/
re
m
ov
al
 ti
ss
ue
/ 
bi
op
sy
/d
es
tru
ct
io
n/
 
de
br
id
em
en
t/c
au
te
ris
at
io
n*
 
2.
8 
(2
.6
–3
.1
) 
 
3.
2 
(2
.9
–3
.5
) 
 
3.
3 
(3
.0
–3
.7
) 
 
3.
1 
(2
.8
–3
.3
) 
 
2.
9 
(2
.6
–3
.1
) 
 
2.
8 
(2
.5
–3
.0
) 
 
2.
7 
(2
.5
–2
.9
) 
 
2.
9 
(2
.6
–3
.2
) 
 
3.
2 
(2
.9
–3
.5
) 
 
3.
0 
(2
.7
–3
.2
) 
—
 
D
re
ss
in
g/
pr
es
su
re
/ 
co
m
pr
es
si
on
/ta
m
po
na
de
* 
2.
1 
(1
.9
–2
.3
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
2 
(2
.1
–2
.4
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
5 
(2
.4
–2
.7
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
9 
(2
.6
–3
.1
) 
 
2.
5 
(2
.3
–2
.6
) 

 
Lo
ca
l i
nj
ec
tio
n/
 
in
fil
tra
tio
n*
(b
)  
2.
0 
(1
.8
–2
.2
) 
 
1.
9 
(1
.7
–2
.1
) 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
3 
(2
.1
–2
.6
) 
 
2.
6 
(2
.3
–2
.8
) 
 
2.
3 
(2
.2
–2
.5
) 

 
P
hy
si
ca
l m
ed
ic
in
e/
 
re
ha
bi
lit
at
io
n 
– 
al
l* 
1.
4 
(1
.1
–1
.6
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
3 
(1
.1
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.0
–1
.5
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
4 
(1
.2
–1
.6
) 
 
1.
4 
(1
.2
–1
.7
) 
 
1.
4 
(1
.2
–1
.6
) 
 
1.
2 
(1
.1
–1
.4
) 
—
 
In
ci
si
on
/d
ra
in
ag
e/
flu
sh
in
g/
 
as
pi
ra
tio
n/
re
m
ov
al
 b
od
y 
flu
id
* 
1.
3 
(1
.2
–1
.4
) 
 
1.
3 
(1
.1
–1
.4
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 

 
P
ap
 s
m
ea
r*
 
1.
0 
(0
.8
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
1 
(0
.9
–1
.2
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
0 
(0
.9
–1
.2
) 
 
1.
0 
(0
.8
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
1.
0 
(0
.8
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
R
ep
ai
r/f
ix
at
io
n 
– 
su
tu
re
/ 
ca
st
/p
ro
st
he
tic
 d
ev
ic
e 
(a
pp
ly
/r
em
ov
e)
* 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
8 
(0
.7
–0
.9
) 

 
O
th
er
 th
er
ap
eu
tic
 
pr
oc
ed
ur
es
/m
in
or
 s
ur
ge
ry
* 
0.
9 
(0
.8
–1
.1
) 
 
0.
9 
(0
.7
–1
.0
) 
 
0.
9 
(0
.7
–1
.1
) 
 
1.
1 
(0
.9
–1
.2
) 
 
1.
1 
(0
.5
–1
.7
) 
 
0.
8 
(0
.6
–1
.0
) 
 
0.
9 
(0
.7
–1
.1
) 
 
1.
0 
(0
.8
–1
.2
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
8 
(0
.6
–1
.0
) 
—
 
IN
R
 te
st
* 
 
N
/A
 
 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
7 
(0
.6
–0
.9
) 

 
C
he
ck
-u
p 
– 
P
N
/A
H
W
* 
N
/A
 
 
 
0.
2 
(0
.1
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.2
–0
.5
) 
 
0.
7 
(0
.3
–1
.0
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
7 
(0
.5
–0
.8
) 
 
0.
7 
(0
.5
–0
.8
) 
 
0.
7 
(0
.5
–0
.8
) 

 
E
le
ct
ric
al
 tr
ac
in
gs
* 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.7
) 

 
O
th
er
 p
re
ve
nt
iv
e 
pr
oc
ed
ur
es
/h
ig
h-
ris
k 
m
ed
ic
at
io
n*
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 

 
(c
on
tin
ue
d)
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Ta
bl
e 
10
.3
b 
(c
on
tin
ue
d)
: T
he
 m
os
t f
re
qu
en
t p
ro
ce
du
ra
l t
re
at
m
en
ts
 (r
at
e 
pe
r 
10
0 
en
co
un
te
rs
), 
20
05
–0
6 
to
 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 (
95
%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 1
01
,9
93
) 
 (
n
 =
 9
1,
80
5)
 
 (
n
 =
 9
5,
89
8)
 
 (
n
 =
 9
6,
68
8)
 
 (n
 =
 1
01
,3
49
) 
 (
n
 =
 9
5,
83
9)
 
 (
n
 =
 9
9,
03
0)
 
 (
n
 =
 9
8,
56
4)
 
 (
n
 =
 9
5,
87
9)
 
 (
n
 =
 9
8,
72
8)
 
P
hy
si
ca
l f
un
ct
io
n 
te
st
* 
0.
4 
(0
.3
–0
.5
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
—
 
To
ta
l p
ro
ce
du
ra
l 
tr
ea
tm
en
ts
 
14
.4
 
(1
3.
7–
15
.1
) 
 
15
.1
 
(1
4.
3–
15
.9
) 
 
16
.6
 
(1
5.
8–
17
.5
) 
 
16
.7
 
(1
6.
0–
17
.4
) 
 
17
.5
 
(1
6.
4–
18
.5
) 
 
16
.8
 
(1
6.
0–
17
.7
) 
 
16
.8
 
(1
6.
0–
17
.7
) 
 
17
.3
 
(1
6.
4–
18
.2
) 
 
18
.7
 
(1
7.
9–
19
.6
) 
 
17
.0
 
(1
6.
2–
17
.8
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
(b
) 
E
xc
lu
de
s 
al
l l
oc
al
 in
je
ct
io
n/
in
fil
tra
tio
ns
 p
er
fo
rm
ed
 fo
r i
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10.3 Practice nurse/Aboriginal health worker activity  
This section describes changes over the decade in the activities of practice nurses (PNs) and 
Aboriginal health workers (AHWs) that were recorded in association with the GP–patient encounters 
detailed by the BEACH GP participants. 
In 2004, four Medicare item numbers were introduced into the MBS that allowed GPs to claim for 
specified tasks done by a PN under the direction of the GP.46 In 2005–06, the BEACH recording form 
was amended to capture this information. For the past decade GPs have been able to record up to 
three Medicare item numbers where appropriate.  
In the ‘other treatments’ section for each problem managed, GPs were asked to tick the ‘practice 
nurse’ box if the treatment recorded was provided by the PN or AHW rather than by the GP. If the box 
was not ticked, it was assumed the GP gave the treatment. Other treatments include all clinical and 
procedural treatments provided at the encounters. These groups are defined in Appendix 4, Tables 
A4.4 and A4.5. 
Over the years, new PN item numbers were added and some items were broadened to cover work 
done by AHWs. In January 2012, the Australian Government significantly altered the payment 
structure for practice nurse and AHW activities in general practice, such that the range of claimable 
MBS item numbers was reduced and the Practice Nurse Incentive Program (PNIP) introduced. Most 
of the MBS PN/AHW items were removed and the funds redirected into a single payment to eligible 
general practices.47 
The following section investigates: the proportion of encounters involving the PN/AHW; the proportion 
of encounters claimable with a Medicare item number; the distribution of the PN/AHW items recorded; 
treatments provided by PNs/AHWs in association with the GP encounters; the problems for which 
these treatments were provided. 
These results do not include PN/AHW activities undertaken during the GP’s BEACH recording period 
that were not associated with the recorded encounter. Such activities could include Medicare-
claimable activities (for example, chronic disease management) provided under instruction from the 
GP but not at the time of the encounter recorded in BEACH, or provision of other services not 
claimable from Medicare (for example, dietary advice on a one-to-one basis or in a group situation). 
Overview of practice nurse/Aboriginal health worker activity 
Encounters involving a PN/AHW as a proportion of all encounters more than doubled from 4.2% in 
2005–06 to peak at 9.0% in 2009–10. Since then, PN/AHW involvement in GP–patient encounters 
has significantly decreased, with 7.2% of encounters in 2014–15 involving a PN/AHW (Table 10.5). 
Following a similar pattern of change, the proportion of problems managed with PN/AHW involvement 
at GP–patient encounters increased significantly from 2.8% in 2005–06 to 6.1% in 2009–10, and then 
gradually decreased to reach 4.8% in 2014–15. 
In 2005–06, GPs recorded one or more PN/AHW MBS item numbers at 39.2% of encounters with 
recorded PN/AHW activity. By 2009–10, this had risen to 45.5%. In 2011–12, a data year that 
included 3 months of the new 2012 PNIP, GPs recorded a PN/AHW item at only 27.4% of encounters 
involving a PN/AHW. In 2014–15, PN/AHW activities were claimable from Medicare at only 3.8% of 
encounters with which they were associated.  
When this result is considered in terms of the total GP–patient encounters recorded in BEACH, a 
PN/AHW Medicare item number was claimable at 4.1% of all GP encounters in 2009–10 but only 
0.3% in 2014–15 (Table 10.5). 
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Treatments provided by practice nurses and Aboriginal health 
workers  
The rate at which procedures (including injections and tests) were undertaken by PNs/AHWs in 
association with the recorded GP–patient encounters more than doubled from 4.0 per 100 encounters 
in 2005–06 to 9.2 per 100 in 2009–10. The rate then decreased in 2011–12, to 7.2 per 100 
encounters, with no further significant change in the ensuing years.  
While the provision of clinical treatments (such as advice and health education) by PNs/AHWs 
remained infrequent at GP–patient encounters, there was a steady increase over the study period, 
from 0.2 clinical treatments per 100 encounters in 2005–06 to 1.1 per 100 in 2012–13 and then 
remaining steady through to 2014–15 (Table 10.6). 
Individual treatments 
Through all years, where the PN/AHW provided a treatment associated with a GP–patient encounter, 
only one action was usually recorded. However, there was a small (statistically significant) increase in 
the number of treatments provided, from 107.4 per 100 PN/AHW-involved encounters in 2005–06, to 
111.1 per 100 in 2014–15 (Table 10.7). 
Procedures: the rate at which PNs/AHWs provided local injections/infiltration at GP encounters was 
at its peak in 2009–10 (50.3 per 100 encounters in which PNs/AHWs were involved). With the 
removal of the MBS item number for PN/AHW provision of injections in early 2012, the rate 
immediately decreased and was 30.9 per 100 in 2014–15. 
In 2014–15, check-ups were conducted by PNs/AHWs at a rate of 9.3 per 100 GP–patient encounters 
in which they were involved, more than double that of 2006–07. International normalised ratio (INR) 
blood testing frequency more than tripled, from 1.8 per 100 PN/AHW involved encounters in 2006–07 
to 7.2 per 100 in 2014–15, but the results for each of the last 4 years did not differ, suggesting a 
levelling out of the frequency of INR testing by PNs/AHWs associated with GP–patient encounters. 
Clinical treatments: PN/AHW carried out administrative procedures (excluding sickness certificates) 
in association with the GP–patient encounters at an ever-increasing rate, rising from 0.7 per 100 
PN/AHW-involved encounters in 2005–06 to 5.8 per 100 in 2012–13, and did not change significantly 
in 2013–14 and 2014–15. Increases also occurred in their provision of advice/education about 
treatment, and about medication (Table 10.7). 
Problems managed with PN/AHW involvement at encounters 
Changes in the problems for which PNs/AHWs were involved in management are shown in Table 
10.8 and largely reflect the changes in the activities undertaken. Their assistance in the management 
of immunisation/vaccination at GP encounters significantly decreased from 30.9 per 100 PN/AHW-
involved encounters in 2005–06 to 18.8 per 100 in 2014–15. There were significant increases in the 
rate at which they were involved in the management of check-ups, diabetes, atrial fibrillation/flutter, 
and vitamin/nutritional deficiency. Some of these increases may well have been stimulated by the 
introduction of MBS item 10997 for services provided by a PN/AHW to a person with a chronic 
disease in 2007–08. Their involvement with problems labelled as ‘administrative procedure’ increased 
over the decade, but has remained steady for the past 3 years (Table 10.8). 
114
  
 
Ta
bl
e 
10
.5
: S
um
m
ar
y 
of
 P
N
 a
nd
 A
H
W
 in
vo
lv
em
en
t a
t e
n
co
un
te
r 
an
d 
cl
ai
m
s 
m
ad
e,
 2
00
5–
06
 to
 2
01
4–
15
 
 
N
um
be
r 

(a
)  
 
 
V
ar
ia
bl
e 
20
05
–0
6 
20
06
–0
7 
20
07
–0
8 
20
08
–0
9 
20
09
–1
0 
20
10
–1
1 
20
11
–1
2 
20
12
–1
3 
20
13
–1
4 
20
14
–1
5 
 
To
ta
l e
nc
ou
nt
er
s 
 
10
1,
99
3 
91
,8
05
 
95
,8
98
 
96
,6
88
 
10
1,
34
9 
95
,8
39
 
99
,0
30
 
98
,5
64
 
95
,8
79
 
98
,7
28
 
. .
 
E
nc
ou
nt
er
s 
in
vo
lv
in
g 
P
N
 o
r A
H
W
 
4,
29
5 
4,
76
9 
5,
79
1 
6,
18
3 
9,
15
4 
7,
62
5 
7,
29
3 
7,
31
8 
7,
69
0 
7,
07
5 
. .
 
 
E
nc
ou
nt
er
s 
at
 w
hi
ch
 P
N
 a
ct
iv
ity
 
de
sc
rib
ed
 
4,
01
3 
4,
71
0 
5,
71
2 
6,
05
2 
8,
99
9 
7,
43
2 
7,
21
0 
7,
23
4 
7,
61
5 
7,
01
8 
. .
 
 
E
nc
ou
nt
er
s 
w
ith
 P
N
 it
em
 n
um
be
r b
ut
 
ac
tiv
ity
 n
ot
 d
es
cr
ib
ed
 
28
2 
59
 
79
 
13
1 
15
5 
19
5 
82
 
84
 
75
 
58
 
. .
 
E
nc
ou
nt
er
s 
at
 w
hi
ch
 o
ne
 o
r m
or
e 
M
B
S
 
P
N
 it
em
 n
um
be
rs
 w
er
e 
re
co
rd
ed
 a
s 
cl
ai
m
ab
le
  
1,
68
3 
1,
82
3 
2,
06
0 
2,
41
6 
4,
16
1 
3,
06
8 
1,
99
7 
28
7 
38
6 
27
0 
. .
 
To
ta
l p
ro
bl
em
s 
m
an
ag
ed
  
14
9,
08
8 
13
6,
33
3 
14
5,
07
8 
14
9,
46
2 
15
5,
37
3 
14
6,
14
1 
15
2,
28
6 
15
2,
51
7 
15
1,
67
5 
15
3,
13
3 
. .
 
P
ro
bl
em
s 
m
an
ag
ed
 w
ith
 P
N
 
in
vo
lv
em
en
t 
4,
11
1 
4,
92
2 
5,
90
9 
6,
28
1 
9,
54
2 
7,
82
6 
7,
55
4 
7,
60
7 
8,
04
1 
7,
32
4 
. .
 
 
P
er
 c
en
t (
95
%
 C
I) 
 
E
nc
ou
nt
er
s 
in
vo
lv
in
g 
th
e 
P
N
/A
H
W
 a
s 
a 
pr
op
or
tio
n 
of
 to
ta
l e
nc
ou
nt
er
s 
 
4.
2 
(3
.7
–4
.7
) 
5.
2 
(4
.6
–5
.8
) 
6.
0 
(5
.5
–6
.6
) 
6.
4 
(5
.8
–7
.0
) 
9.
0 
(8
.2
–9
.9
) 
8.
0 
(7
.3
–8
.7
) 
7.
4 
(6
.7
–8
.0
) 
7.
4 
(6
.8
–8
.0
) 
8.
0 
(7
.3
–8
.7
) 
7.
2 
(6
.6
–7
.7
) 

 
P
ro
bl
em
s 
in
vo
lv
in
g 
th
e 
P
N
/A
H
W
 a
s 
a 
pr
op
or
tio
n 
of
 to
ta
l p
ro
bl
em
s 
 
2.
8 
(2
.4
–3
.1
) 
3.
6 
(3
.2
–4
.1
) 
4.
1 
(3
.7
–4
.5
) 
4.
2 
(3
.8
–4
.6
) 
6.
1 
(5
.6
–6
.7
) 
5.
4 
(4
.9
–5
.8
) 
5.
0 
(4
.5
–5
.4
) 
5.
0 
(4
.6
–5
.4
) 
5.
3 
(4
.9
–5
.8
) 
4.
8 
(4
.4
–5
.2
) 

 
P
N
/A
H
W
-c
la
im
ab
le
 e
nc
ou
nt
er
s 
as
 a
 
pr
op
or
tio
n 
of
 to
ta
l e
nc
ou
nt
er
s 
1.
7 
(1
.4
–1
.9
) 
2.
0 
(1
.7
–2
.3
) 
2.
1 
(1
.9
–2
.4
) 
2.
5 
(2
.2
–2
.8
) 
4.
1 
(3
.6
–4
.1
) 
3.
2 
(2
.8
–3
.6
) 
2.
0 
(1
.7
–2
.3
) 
0.
3 
(0
.1
–0
.5
) 
0.
4 
(0
.3
–0
.5
) 
0.
3 
(0
.2
–0
.4
) 
§ 
P
ro
po
rti
on
 o
f P
N
/A
H
W
-in
vo
lv
ed
 
en
co
un
te
rs
 fo
r w
hi
ch
 o
ne
 o
r m
or
e 
M
B
S
 
P
N
 it
em
 n
um
be
rs
 w
er
e 
re
co
rd
ed
  
39
.2
 
(3
4.
7–
43
.6
) 
38
.2
 
(3
4.
0–
42
.4
) 
35
.6
 
(3
2.
4–
38
.8
) 
39
.1
 
(3
5.
9–
42
.3
) 
45
.5
 
(4
2.
1–
48
.8
) 
40
.2
 
(3
6.
9–
43
.6
) 
27
.4
 
(2
4.
3–
30
.4
) 
3.
9 
(1
.7
–6
.1
) 
5.
0 
(3
.4
–6
.7
) 
3.
8 
(2
.7
–5
.0
) 
§ 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
N
ot
e:
 P
N
/A
H
W
 –
 p
ra
ct
ic
e 
nu
rs
e 
or
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r; 
C
I –
 c
on
fid
en
ce
 in
te
rv
al
; M
B
S
 –
 M
ed
ic
ar
e 
B
en
ef
its
 S
ch
ed
ul
e.
 S
om
e 
of
 th
es
e 
re
su
lts
 m
ay
 d
iff
er
 fr
om
 th
os
e 
pr
ev
io
us
ly
 p
ub
lis
he
d,
 b
ec
au
se
 th
es
e 
da
ta
 w
er
e 
 
re
-a
na
ly
se
d 
fo
r a
ll 
ye
ar
s 
to
 in
cl
ud
e 
in
 th
e 
co
un
t o
f P
N
/A
H
W
 a
ct
iv
ity
 th
os
e 
en
co
un
te
rs
 a
t w
hi
ch
 a
n 
ite
m
 n
um
be
r w
as
 re
co
rd
ed
 b
ut
 n
o 
P
N
 a
ct
iv
ity
 w
as
 d
es
cr
ib
ed
. 
115
  
 
Ta
bl
e 
10
.6
: S
um
m
ar
y 
of
 tr
ea
tm
en
ts
 p
ro
vi
d
ed
 b
y 
P
N
s 
or
 A
H
W
s,
 2
00
5–
06
 to
 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 (
95
%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 1
01
,9
93
) 
 
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 
(n
 =
 9
6,
68
8)
 
 (
n
 =
 1
01
,3
49
) 
 
(n
 =
 9
5,
83
9)
 
 
(n
 =
 9
9,
03
0)
 
 
(n
 =
 9
8,
56
4)
 
 
(n
 =
 9
5,
87
9)
 
 
(n
 =
 9
8,
72
8)
 
P
ro
ce
du
ra
l 
tre
at
m
en
ts
(b
)  
4.
0 
(3
.5
–4
.5
) 
 
5.
2 
(4
.6
–5
.8
) 
 
6.
1 
(5
.5
–6
.7
) 
 
6.
4 
(5
.8
–7
.1
) 
 
9.
2 
(8
.3
–1
0.
2)
 
 
8.
0 
(7
.3
–8
.8
) 
 
7.
2 
(6
.6
–7
.9
) 
 
7.
2 
(6
.5
–7
.8
) 
 
7.
8 
(7
.1
–8
.5
) 
 
6.
9 
(6
.3
–7
.5
) 

 
C
lin
ic
al
 tr
ea
tm
en
ts
 
0.
2 
(0
.1
–0
.3
) 
 
0.
5 
(0
.3
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
7 
(0
.5
–0
.9
) 
 
0.
7 
(0
.6
–0
.9
) 
 
0.
9 
0.
7–
1.
1)
 
 
1.
1 
(1
.0
–1
.3
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
0 
(0
.8
–1
.2
) 

 
A
ll 
ot
he
r 
tr
ea
tm
en
ts
 
4.
2 
(3
.7
–4
.8
) 
 
5.
7 
(4
.9
–6
.4
) 
 
6.
5 
(5
.9
–7
.2
) 
 
6.
9 
(6
.2
–7
.6
) 
 
9.
9 
(8
.9
–1
0.
9)
 
 
8.
7 
(7
.9
–9
.6
) 
 
8.
1 
(7
.4
–8
.9
) 
 
8.
3 
(7
.6
–9
.0
) 
 
8.
9 
(8
.1
–9
.8
) 
 
7.
9 
(7
.2
–8
.6
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
(b
) 
P
ro
ce
du
ra
l t
re
at
m
en
ts
 h
er
e 
in
cl
ud
e 
al
l i
nj
ec
tio
ns
 fo
r i
m
m
un
is
at
io
ns
/v
ac
ci
na
tio
ns
. T
he
se
 a
re
 n
ot
 in
cl
ud
ed
 in
 th
e 
su
m
m
ar
y 
of
 th
e 
co
nt
en
t o
f e
nc
ou
nt
er
 in
 T
ab
le
 5
.1
, s
um
m
ar
y 
of
 m
an
ag
em
en
t i
n 
Ta
bl
e 
8.
1 
or
 in
 th
e 
an
al
ys
es
 o
f o
th
er
 tr
ea
tm
en
ts
 in
 C
ha
pt
er
 1
0,
 b
ec
au
se
 th
e 
im
m
un
is
at
io
n/
va
cc
in
at
io
n 
is
 a
lre
ad
y 
co
un
te
d 
as
 a
 p
re
sc
rip
tio
n 
or
 G
P
-s
up
pl
ie
d 
m
ed
ic
at
io
n.
 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; P
N
/A
H
W
 –
 p
ra
ct
ic
e 
nu
rs
e 
or
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r. 
 
 Ta
bl
e 
10
.7
: M
os
t f
re
qu
en
t t
re
at
m
en
ts
 d
on
e 
by
 P
N
s 
or
 A
H
W
s,
 2
00
5–
06
 to
 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 w
he
re
 P
N
/A
H
W
 a
ct
iv
it
y 
de
sc
ri
be
d 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 4
,0
13
) 
 
(n
 =
 4
,7
10
) 
 
(n
 =
 5
,7
12
) 
 
(n
 =
 6
,0
52
) 
 
(n
 =
 8
,9
99
) 
 
(n
 =
 7
,6
25
) 
 
(n
 =
 7
,2
10
) 
 
(n
 =
 7
,2
34
) 
 
(n
 =
 7
,6
15
) 
 
(n
 =
 7
,0
18
) 
P
ro
ce
du
ra
l t
re
at
m
en
ts
 
(in
cl
ud
in
g 
te
st
s)
 
10
2.
2 
(1
00
.1
–1
04
.3
) 
 
10
1.
3 
(9
9.
2–
10
3.
5)
  
10
2.
3 
(1
00
.7
–1
04
.0
) 
 
10
2.
5 
(1
00
.5
–1
04
.5
) 
 
10
4.
1 
(1
02
.4
–1
05
.9
) 
 
10
3.
5 
(1
01
.6
–1
05
.4
) 
 
99
.3
 
(9
6.
5–
10
2.
0)
  
97
.6
 
(9
5.
7–
99
.5
) 
 
98
.5
 
(9
6.
1–
10
0.
9)
  
97
.3
 
(9
5.
2–
99
.5
) 

 
 
Lo
ca
l i
nj
ec
tio
n/
in
fil
tra
tio
n*
 
41
.0
 
(3
6.
6–
45
.4
) 
 
37
.3
 
(3
3.
0–
41
.6
) 
 
37
.7
 
(3
4.
7–
40
.7
) 
 
38
.2
 
(3
4.
9–
41
.6
) 
 
50
.3
 
(4
7.
0–
53
.6
) 
 
41
.1
 
(3
7.
7–
44
.5
) 
 
35
.5
 
(3
2.
4–
38
.6
) 
 
33
.0
 
(3
0.
2–
35
.9
) 
 
34
.0
 
(3
1.
0–
37
.1
) 
 
30
.9
 
(2
8.
4–
33
.4
) 

 
 
D
re
ss
in
g/
pr
es
su
re
/ 
co
m
pr
es
si
on
/ta
m
po
na
de
* 
23
.7
 
(2
1.
3–
26
.2
) 
 
22
.4
 
(1
9.
8–
24
.9
) 
 
20
.7
 
(1
8.
7–
22
.8
) 
 
21
.2
 
(1
9.
2–
23
.2
) 
 
15
.8
 
(1
4.
2–
17
.5
) 
 
19
.5
 
(1
7.
8–
21
.2
) 
 
20
.0
 
(1
8.
2–
21
.8
) 
 
18
.3
 
(1
6.
4–
20
.2
) 
 
19
.6
 
(1
7.
8–
21
.5
) 
 
19
.7
 
(1
7.
9–
21
.6
) 
—
 
 
C
he
ck
-u
p 
– 
P
N
/A
H
W
* 
N
A
v  
 
4.
0 
(2
.3
–5
.6
) 
 
6.
1 
(4
.8
–7
.4
) 
 
6.
3 
(4
.0
–8
.6
) 
 
7.
6 
(4
.0
–1
1.
1)
 
 
7.
3 
(5
.2
–9
.5
) 
 
8.
0 
(6
.1
–9
.8
) 
 
8.
9 
(7
.6
–1
0.
3)
 
 
8.
3 
(6
.2
–1
0.
3)
 
 
9.
3 
(7
.0
–1
1.
6)
 

 
 
IN
R
 te
st
* 
N
A
v  
 
1.
8 
(1
.0
–2
.6
) 
 
4.
9 
(3
.6
–6
.2
) 
 
6.
4 
(4
.9
–7
.9
) 
 
4.
5 
(3
.5
–5
.5
) 
 
6.
8 
(5
.5
–8
.1
) 
 
6.
6 
(5
.4
–7
.8
) 
 
7.
2 
(5
.9
–8
.5
) 
 
7.
5 
(6
.2
–8
.8
) 
 
7.
2 
(6
.1
–8
.4
) 

 
 (c
on
tin
ue
d)
 
 
116
  
 
Ta
bl
e 
10
.7
 (c
on
tin
ue
d)
: M
os
t f
re
qu
en
t t
re
at
m
en
ts
 d
on
e 
by
 P
N
s 
or
 A
H
W
s,
 2
00
5–
06
 t
o 
20
14
–1
5 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 w
he
re
 P
N
/A
H
W
 a
ct
iv
it
y 
de
sc
ri
be
d 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 4
,0
13
) 
 
(n
 =
 4
,7
10
) 
 
(n
 =
 5
,7
12
) 
 
(n
 =
 6
,0
52
) 
 
(n
 =
 8
,9
99
) 
 
(n
 =
 7
,6
25
) 
 
(n
 =
 7
,2
10
) 
 
(n
 =
 7
,2
34
) 
 
(n
 =
 7
,6
15
) 
 
(n
 =
 7
,0
18
) 
 
In
ci
si
on
/d
ra
in
ag
e/
flu
sh
in
g/
 
as
pi
ra
tio
n/
re
m
ov
al
 b
od
y 
flu
id
* 
8.
1 
(6
.2
–1
0.
0)
 
 
8.
8 
(6
.7
–1
1.
0)
 
 
6.
8 
(5
.6
–7
.9
) 
 
7.
4 
(6
.0
–8
.8
) 
 
6.
8 
(5
.4
–8
.1
) 
 
5.
7 
(4
.7
–6
.7
) 
 
5.
5 
(4
.2
–6
.7
) 
 
5.
9 
(4
.5
–7
.2
) 
 
5.
5 
(4
.6
–6
.3
) 
 
5.
9 
(4
.9
–6
.8
) 
—
 
 
E
le
ct
ric
al
 tr
ac
in
gs
* 
5.
4 
(4
.1
–6
.7
) 
 
4.
5 
(3
.7
–5
.2
) 
 
5.
2 
(4
.3
–6
.1
) 
 
4.
4 
(3
.6
–5
.2
) 
 
3.
6 
(3
.1
–4
.2
) 
 
4.
3 
(3
.7
–5
.0
) 
 
5.
2 
(4
.5
–6
.0
) 
 
4.
6 
(3
.9
–5
.2
) 
 
5.
8 
(4
.8
–6
.9
) 
 
5.
2 
(4
.4
–6
.0
) 
—
 
 
R
ep
ai
r/f
ix
at
io
n 
– 
su
tu
re
/ 
ca
st
/p
ro
st
he
tic
 d
ev
ic
e 
(a
pp
ly
/r
em
ov
e)
* 
6.
4 
(5
.0
–7
.8
) 
 
6.
0 
(5
.0
–7
.0
) 
 
5.
0 
(4
.2
–5
.7
) 
 
4.
3 
(3
.6
–5
.0
) 
 
4.
0 
(3
.3
–4
.6
) 
 
4.
4 
(3
.6
–5
.1
) 
 
4.
0 
(3
.3
–4
.6
) 
 
4.
9 
(4
.2
–5
.6
) 
 
4.
4 
(3
.7
–5
.2
) 
 
4.
7 
(4
.0
–5
.3
) 
—
 
 
E
xc
is
io
n/
re
m
ov
al
 ti
ss
ue
/ 
bi
op
sy
/d
es
tru
ct
io
n/
 
de
br
id
em
en
t/c
au
te
ris
at
io
n*
 
6.
4 
(5
.0
–7
.8
) 
 
6.
0 
(5
.0
–7
.0
) 
 
5.
0 
(4
.2
–5
.7
) 
 
4.
3 
(3
.6
–5
.0
) 
 
4.
0 
(3
.3
–4
.6
) 
 
4.
4 
(3
.6
–5
.1
) 
 
4.
0 
(3
.3
–4
.6
) 
 
4.
9 
(4
.2
–5
.6
) 
 
4.
4 
(3
.7
–5
.2
) 
 
4.
7 
(4
.0
–5
.3
) 
—
 
 
P
hy
si
ca
l f
un
ct
io
n 
te
st
* 
3.
9 
(2
.6
–5
.3
) 
 
4.
3 
(2
.8
–5
.7
) 
 
3.
5 
(2
.3
–4
.7
) 
 
2.
7 
(2
.0
–3
.4
) 
 
2.
9 
(2
.1
–3
.6
) 
 
2.
6 
(2
.0
–3
.3
) 
 
2.
8 
(2
.1
–3
.5
) 
 
2.
6 
(2
.0
–3
.1
) 
 
2.
9 
(2
.3
–3
.6
) 
 
3.
0 
(2
.2
–3
.7
) 
—
 
 
O
th
er
 th
er
ap
eu
tic
 p
ro
ce
du
re
s*
 
1.
4 
(0
.9
–1
.9
) 
 
1.
2 
(0
.8
–1
.6
) 
 
1.
6 
(1
.1
–2
.1
) 
 
1.
4 
(0
.8
–2
.1
) 
 
1.
1 
(0
.8
–1
.5
) 
 
1.
1 
(0
.7
–1
.5
) 
 
1.
4 
(0
.9
–1
.9
) 
 
1.
5 
(1
.0
–2
.1
) 
 
1.
0 
(0
.7
–1
.3
) 
 
1.
3 
(0
.9
–1
.7
) 
—
 
 
U
rin
e 
te
st
* 
1.
4 
(0
.8
–2
.0
) 
 
1.
4 
(0
.8
–2
.0
) 
 
2.
1 
(1
.3
–3
.0
) 
 
1.
7 
(1
.0
–2
.4
) 
 
1.
3 
(0
.8
–1
.8
) 
 
2.
3 
(1
.6
–3
.0
) 
 
2.
1 
(1
.5
–2
.8
) 
 
2.
3 
(1
.6
–3
.0
) 
 
1.
5 
(1
.0
–2
.0
) 
 
1.
2 
(0
.9
–1
.6
) 
—
 
 
O
th
er
 d
ia
gn
os
tic
 p
ro
ce
du
re
s*
 
0.
9 
(0
.3
–1
.4
) 
 
1.
4 
(0
.0
–2
.9
) 
 
0.
5 
(0
.3
–0
.7
) 
 
0.
5 
(0
.2
–0
.8
) 
 
0.
7 
(0
.4
–1
.0
) 
 
1.
3 
(0
.2
–2
.3
) 
 
0.
8 
(0
.4
–1
.2
) 
 
0.
8 
(0
.6
–1
.1
) 
 
1.
0 
(0
.6
–1
.4
) 
 
1.
0 
(0
.7
–1
.4
) 
—
 
 
G
lu
co
se
 te
st
* 
0.
7 
(0
.3
–1
.1
) 
 
1.
0 
(0
.4
–1
.5
) 
 
1.
0 
(0
.7
–1
.3
) 
 
1.
0 
(0
.6
–1
.3
) 
 
0.
6 
(0
.4
–0
.8
) 
 
1.
5 
(0
.7
–2
.3
) 
 
1.
2 
(0
.8
–1
.7
) 
 
1.
2 
(0
.7
–1
.6
) 
 
0.
7 
(0
.4
–1
.0
) 
 
0.
8 
(0
.5
–1
.2
) 
—
 
 
P
ap
 s
m
ea
r*
 
0.
3 
(0
.0
–0
.6
) 
 
0.
6 
(0
.2
–0
.9
) 
 
0.
5 
(0
.3
–0
.8
) 
 
0.
7 
(0
.1
–1
.3
) 
 
0.
7 
(0
.4
–0
.9
) 
 
0.
9 
(0
.5
–1
.2
) 
 
0.
6 
(0
.3
–0
.9
) 
 
0.
5 
(0
.2
–0
.7
) 
 
0.
6 
(0
.3
–1
.0
) 
 
0.
6 
(0
.3
–0
.8
) 
—
 
 (c
on
tin
ue
d)
 
 
117
  
 
Ta
bl
e 
10
.7
 (c
on
tin
ue
d)
: M
os
t f
re
qu
en
t t
re
at
m
en
ts
 d
on
e 
by
 P
N
s 
or
 A
H
W
s,
 2
00
5–
06
 t
o 
20
14
–1
5 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 w
he
re
 P
N
/A
H
W
 a
ct
iv
it
y 
de
sc
ri
be
d 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 4
,0
13
) 
 
(n
 =
 4
,7
10
) 
 
(n
 =
 5
,7
12
) 
 
(n
 =
 6
,0
52
) 
 
(n
 =
 8
,9
99
) 
 
(n
 =
 7
,6
25
) 
 
(n
 =
 7
,2
10
) 
 
(n
 =
 7
,2
34
) 
 
(n
 =
 7
,6
15
) 
 
(n
 =
 7
,0
18
) 
C
lin
ic
al
 tr
ea
tm
en
ts
 
5.
2 
(3
.7
–6
.7
) 
 
8.
9 
(5
.6
–1
2.
1)
 
 
7.
7 
(6
.2
–9
.2
) 
 
7.
4 
(6
.0
–8
.8
) 
 
7.
9 
(5
.9
–9
.9
) 
 
9.
3 
(7
.6
–1
1.
1)
 
 
12
.2
 
(9
.6
–1
4.
8)
 
 
15
.6
 
(1
3.
3–
17
.9
) 
 
14
.0
 
(1
1.
6–
16
.4
) 
 
13
.8
 
(1
1.
8–
15
.8
) 

 
 
O
th
er
 a
dm
in
is
tra
tiv
e 
pr
oc
ed
ur
e/
do
cu
m
en
t 
(e
xc
lu
di
ng
 s
ic
kn
es
s 
ce
rti
fic
at
e)
* 
0.
7 
(0
.4
–1
.1
) 
 
1.
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(0
.7
–1
.7
) 
 
2.
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(1
.4
–2
.6
) 
 
2.
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(1
.7
–3
.1
) 
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(1
.6
–3
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) 
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(1
.7
–2
.9
) 
 
3.
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(2
.9
–4
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) 
 
5.
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–7
.0
) 
 
4.
7 
(3
.6
–5
.9
) 
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7 
(3
.7
–5
.6
) 

 
 
A
dv
ic
e/
ed
uc
at
io
n 
N
E
C
* 
0.
9 
(0
.4
–1
.3
) 
 
1.
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(0
.6
–2
.4
) 
 
1.
4 
(0
.8
–2
.1
) 
 
0.
8 
(0
.5
–1
.1
) 
 
1.
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(0
.6
–1
.9
) 
 
1.
0 
(0
.5
–1
.4
) 
 
1.
1 
(0
.7
–1
.5
) 
 
1.
2 
(0
.7
–1
.6
) 
 
1.
0 
(0
.7
–1
.3
) 
 
1.
3 
(0
.8
–1
.9
) 
—
 
 
A
dv
ic
e/
ed
uc
at
io
n 
– 
tre
at
m
en
t*
 
0.
2 
(0
.1
–0
.4
) 
 
0.
9 
(0
.5
–1
.3
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
9 
(0
.5
–1
.3
) 
 
0.
4 
(0
.2
–0
.6
) 
 
0.
5 
(0
.3
–0
.7
) 
 
0.
9 
(0
.6
–1
.2
) 
 
1.
2 
(0
.7
–1
.7
) 
 
1.
0 
(0
.6
–1
.3
) 
 
1.
3 
(0
.9
–1
.7
) 

 
 
C
ou
ns
el
lin
g 
– 
pr
ob
le
m
* 
0.
9 
(0
.2
–1
.5
) 
 
0.
8 
(0
.3
–1
.3
) 
 
0.
6 
(0
.3
–0
.8
) 
 
0.
5 
(0
.2
–0
.7
) 
 
0.
6 
(0
.3
–0
.9
) 
 
1.
2 
(0
.6
–1
.8
) 
 
1.
8 
(0
.1
–3
.4
) 
 
1.
1 
(0
.7
–1
.5
) 
 
1.
2 
(0
.8
–1
.6
) 
 
1.
1 
(0
.6
–1
.6
) 
—
 
 
C
ou
ns
el
lin
g/
ad
vi
ce
 –
 
nu
tri
tio
n/
w
ei
gh
t*
 
0.
6 
(0
.2
–0
.9
) 
 
1.
2 
(0
.2
–2
.1
) 
 
0.
5 
(0
.1
–0
.9
) 
 
0.
7 
(0
.4
–1
.1
) 
 
0.
6 
(0
.3
–0
.8
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
4 
(0
.2
–0
.6
) 
 
1.
4 
(0
.8
–2
.0
) 
 
1.
4 
(0
.7
–2
.1
) 
 
1.
0 
(0
.4
–1
.7
) 
—
 
 
A
dv
ic
e/
ed
uc
at
io
n 
– 
m
ed
ic
at
io
n*
 
0.
2 
(0
.0
–0
.3
) 
 
0.
3 
(0
.1
–0
.5
) 
 
0.
4 
(0
.2
–0
.7
) 
 
0.
2 
(0
.0
–0
.4
) 
 
0.
4 
(0
.2
–0
.6
) 
 
0.
5 
(0
.3
–0
.8
) 
 
0.
7 
(0
.4
–1
.1
) 
 
1.
3 
(0
.9
–1
.7
) 
 
1.
1 
(0
.5
–1
.8
) 
 
0.
7 
(0
.4
–1
.0
) 

 
 
C
on
su
lta
tio
n 
w
ith
 p
rim
ar
y 
ca
re
 p
ro
vi
de
r*
 
0  
 
0.
2 
(0
.0
–0
.3
) 
 
0.
4 
(0
.2
–0
.7
) 
 
0.
1 
(0
.0
–0
.2
) 
 
0.
4 
(0
.2
–0
.6
) 
 
0.
7 
(0
.4
–1
.0
) 
 
0.
6 
(0
.3
–0
.8
) 
 
1.
0 
(0
.7
–1
.4
) 
 
0.
7 
(0
.4
–1
.1
) 
 
0.
7 
(0
.4
–0
.9
) 

 
To
ta
l P
N
/A
H
W
 a
ct
iv
iti
es
 a
t 
G
P
–p
at
ie
nt
 e
nc
ou
nt
er
s 
10
7.
4 
(1
05
.0
–1
08
.9
) 
 
11
0.
2 
(1
07
.7
–1
12
.8
) 
 
11
0.
0 
(1
08
.4
–1
11
.6
) 
 
10
9.
9 
(1
08
.1
–1
11
.6
) 
 
11
2.
0 
(1
10
.3
–1
13
.7
) 
 
11
2.
8 
(1
10
.9
–1
14
.7
) 
 
11
0.
5 
(1
10
.1
–1
12
.9
) 
 
11
3.
2 
(1
11
.7
–1
14
.7
) 
 
11
2.
5 
(1
10
.7
–1
14
.4
) 
 
11
1.
1 
(1
09
.6
–1
12
.6
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; a
nd
 —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
1,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
). 
N
ot
e:
 P
N
/A
H
W
 –
 p
ra
ct
ic
e 
nu
rs
e 
or
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r; 
in
cl
ud
es
 o
nl
y 
th
os
e 
ac
tiv
iti
es
 d
on
e 
by
 P
N
s/
A
H
W
s 
at
 a
 ra
te
 o
f 0
.5
 o
r m
or
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
in
vo
lv
in
g 
a 
P
N
/A
H
W
 in
 a
ny
 o
f t
he
 y
ea
rs
 re
po
rte
d.
 C
I –
 c
on
fid
en
ce
 
in
te
rv
al
; N
A
v 
– 
no
t a
va
ila
bl
e;
 N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
; P
N
 –
 p
ra
ct
ic
e 
nu
rs
e;
 A
H
W
 –
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r; 
IN
R
 –
 in
te
rn
at
io
na
l n
or
m
al
is
ed
 ra
tio
.  
 
 
118
  
 
Ta
bl
e 
10
.8
: T
he
 2
0 
m
os
t c
o
m
m
on
 p
ro
bl
em
s 
m
an
ag
ed
 w
ith
 in
vo
lv
em
en
t o
f P
N
 o
r 
A
H
W
, 2
00
5–
06
 t
o 
20
14
–1
5 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 w
he
re
 P
N
/A
H
W
 a
ct
iv
it
y 
de
sc
ri
be
d 
(9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 4
,0
13
) 
 
(n
 =
 4
,7
10
) 
 
(n
 =
 5
,7
12
) 
 
(n
 =
 6
,0
52
) 
 
(n
 =
 8
,9
99
) 
 
(n
 =
 7
,6
25
) 
 
(n
 =
 7
,2
10
) 
 
(n
 =
 7
,2
34
) 
 
(n
 =
 7
,6
15
) 
 
(n
 =
 7
,0
18
) 
Im
m
un
is
at
io
n/
va
cc
in
at
io
n 
– 
al
l* 
30
.9
 
(2
6.
9–
34
.9
) 
 
30
.8
 
(2
6.
5–
35
.0
) 
 
29
.5
 
(2
6.
7–
32
.2
) 
 
29
.5
 
(2
6.
2–
32
.7
) 
 
40
.6
 
(3
7.
3–
43
.9
) 
 
30
.7
 
(2
7.
3–
34
.0
) 
 
25
.5
 
(2
2.
7–
28
.3
) 
 
23
.1
 
(2
0.
4–
25
.8
) 
 
22
.8
 
(1
9.
8–
25
.7
) 
 
18
.8
 
(1
6.
8–
20
.9
) 

 
C
he
ck
-u
p 
– 
al
l* 
3.
8 
(2
.8
–4
.8
) 
 
4.
4 
(3
.4
–5
.4
) 
 
5.
2 
(4
.0
–6
.4
) 
 
5.
1 
(3
.9
–6
.2
) 
 
5.
5 
(4
.6
–6
.3
) 
 
5.
0 
(4
.1
–5
.9
) 
 
5.
8 
(4
.9
–6
.8
) 
 
6.
9 
(5
.9
–7
.8
) 
 
6.
2 
(5
.4
–7
.0
) 
 
7.
2 
(6
.3
–8
.2
) 

 
La
ce
ra
tio
n/
cu
t 
6.
4 
(5
.0
–7
.8
) 
 
6.
2 
(5
.2
–7
.2
) 
 
6.
0 
(5
.0
–7
.0
) 
 
6.
4 
(5
.5
–7
.3
) 
 
4.
5 
(3
.8
–5
.1
) 
 
6.
0 
(5
.1
–6
.8
) 
 
5.
9 
(5
.1
–6
.7
) 
 
6.
3 
(5
.4
–7
.2
) 
 
5.
9 
(5
.2
–6
.7
) 
 
7.
0 
(6
.1
–8
.0
) 
—
 
D
ia
be
te
s 
– 
al
l* 
1.
5 
(0
.8
–2
.1
) 
 
2.
0 
(1
.4
–2
.6
) 
 
2.
9 
(2
.2
–3
.5
) 
 
3.
1 
(2
.4
–3
.7
) 
 
2.
0 
(1
.5
–2
.4
) 
 
3.
5 
(2
.6
–4
.3
) 
 
3.
9 
(3
.2
–4
.7
) 
 
4.
6 
(3
.8
–5
.4
) 
 
4.
4 
(3
.5
–5
.3
) 
 
4.
6 
(3
.7
–5
.4
) 

 
C
hr
on
ic
 u
lc
er
 s
ki
n 
(in
cl
ud
in
g 
va
ric
os
e 
ul
ce
r)
 
7.
1 
(5
.9
–8
.3
) 
 
6.
5 
(5
.3
–7
.7
) 
 
4.
8 
(3
.9
–5
.7
) 
 
5.
9 
(4
.9
–6
.9
) 
 
4.
0 
(3
.3
–4
.8
) 
 
4.
4 
(3
.7
–5
.1
) 
 
4.
9 
(4
.1
–5
.6
) 
 
4.
2 
(3
.5
–4
.9
) 
 
4.
2 
(3
.5
–4
.9
) 
 
4.
4 
(3
.7
–5
.1
) 

 
A
tri
al
 fi
br
ill
at
io
n/
flu
tte
r 
 
1.
2 
(0
.6
–1
.7
) 
 
1.
4 
(0
.8
–2
.0
) 
 
2.
8 
(2
.0
–3
.6
) 
 
3.
4 
(2
.6
–4
.3
) 
 
2.
5 
(1
.8
–3
.2
) 
 
3.
6 
(2
.8
–4
.4
) 
 
3.
6 
(2
.5
–4
.6
) 
 
4.
2 
(3
.2
–5
.1
) 
 
4.
4 
(3
.6
–5
.2
) 
 
3.
8 
(3
.0
–4
.6
) 

 
E
xc
es
si
ve
 e
ar
 w
ax
 
2.
2 
(1
.6
–2
.9
) 
 
3.
0 
(2
.4
–3
.6
) 
 
2.
8 
(2
.2
–3
.4
) 
 
2.
5 
(2
.0
–3
.0
) 
 
2.
0 
(1
.5
–2
.4
) 
 
2.
3 
(1
.9
–2
.7
) 
 
2.
3 
(1
.8
–2
.7
) 
 
2.
6 
(2
.1
–3
.1
) 
 
2.
8 
(2
.3
–3
.3
) 
 
3.
4 
(2
.8
–3
.9
) 
—
 
M
al
ig
na
nt
 n
eo
pl
as
m
, s
ki
n 
3.
1 
(2
.2
–4
.1
) 
 
2.
9 
(2
.1
–3
.6
) 
 
2.
5 
(1
.8
–3
.3
) 
 
2.
5 
(1
.8
–3
.2
) 
 
2.
1 
(1
.6
–2
.6
) 
 
1.
8 
(1
.4
–2
.2
) 
 
2.
2 
(1
.7
–2
.8
) 
 
2.
3 
(1
.8
–2
.8
) 
 
2.
6 
(1
.9
–3
.3
) 
 
2.
8 
(2
.1
–3
.5
) 
—
 
V
ita
m
in
/n
ut
rit
io
na
l d
ef
ic
ie
nc
y 
0.
9 
(0
.5
–1
.3
) 
 
0.
5 
(0
.3
–0
.8
) 
 
1.
0 
(0
.6
–1
.4
) 
 
1.
6 
(1
.2
–2
.1
) 
 
1.
0 
(0
.8
–1
.3
) 
 
1.
2 
(0
.9
–1
.6
) 
 
1.
6 
(1
.2
–2
.0
) 
 
1.
5 
(1
.2
–1
.9
) 
 
1.
9 
(1
.4
–2
.3
) 
 
2.
2 
(1
.7
–2
.7
) 

 
A
dm
in
is
tra
tiv
e 
pr
oc
ed
ur
e 
– 
al
l* 
0  
 
0.
2 
(0
.0
–0
.4
) 
 
0.
5 
(0
.2
–0
.8
) 
 
0.
5 
(0
.3
–0
.7
) 
 
0.
8 
(0
.4
–1
.2
) 
 
0.
7 
(0
.4
–1
.1
) 
 
1.
3 
(0
.7
–1
.8
) 
 
1.
7 
(1
.1
–2
.2
) 
 
1.
7 
(0
.8
–2
.6
) 
 
1.
7 
(1
.1
–2
.3
) 

 
A
st
hm
a 
1.
5 
(1
.0
–2
.0
) 
 
2.
3 
(1
.6
–3
.0
) 
 
1.
2 
(0
.9
–1
.6
) 
 
1.
1 
(0
.7
–1
.5
) 
 
0.
9 
(0
.6
–1
.1
) 
 
1.
2 
(0
.8
–1
.5
) 
 
1.
1 
(0
.8
–1
.5
) 
 
1.
3 
(1
.0
–1
.7
) 
 
1.
3 
(1
.0
–1
.7
) 
 
1.
6 
(1
.2
–1
.9
) 
—
 
R
ep
ai
r/f
ix
at
io
n 
– 
su
tu
re
/c
as
t/ 
pr
os
th
et
ic
 d
ev
ic
e 
(a
pp
ly
/r
em
ov
e)
* 
 
1.
3 
(0
.7
–1
.9
) 
 
1.
4 
(1
.0
–1
.9
) 
 
1.
4 
(1
.0
–1
.7
) 
 
1.
1 
(0
.8
–1
.5
) 
 
1.
0 
(0
.7
–1
.2
) 
 
1.
2 
(0
.9
–1
.6
) 
 
0.
9 
(0
.7
–1
.2
) 
 
1.
5 
(1
.2
–1
.8
) 
 
1.
3 
(1
.0
–1
.6
) 
 
1.
6 
(1
.2
–1
.9
) 
—
 
H
yp
er
te
ns
io
n*
 
1.
1 
(0
.6
–1
.5
) 
 
1.
6 
(1
.0
–2
.2
) 
 
1.
8 
(1
.2
–2
.3
) 
 
1.
8 
(1
.2
–2
.4
) 
 
1.
8 
(1
.2
–2
.4
) 
 
1.
5 
(1
.0
–1
.9
) 
 
2.
3 
(1
.4
–3
.1
) 
 
1.
4 
(1
.0
–1
.8
) 
 
1.
9 
(1
.3
–2
.4
) 
 
1.
5 
(1
.1
–2
.0
) 
—
 
 (c
on
tin
ue
d)
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Ta
bl
e 
10
.8
 (c
on
tin
ue
d)
: T
he
 2
0 
m
os
t c
om
m
on
 p
ro
bl
em
s 
m
an
ag
ed
 w
ith
 in
vo
lv
em
en
t o
f P
N
 o
r 
A
H
W
, 2
00
5–
06
 to
 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 w
he
re
 P
N
/A
H
W
 a
ct
iv
it
y 
de
sc
ri
be
d 
(9
5%
 C
I)
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7 
 
20
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–0
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20
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–1
0 
 
20
10
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1 
 
20
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2 
 
20
12
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3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 4
,0
13
) 
 
(n
 =
 4
,7
10
) 
 
(n
 =
 5
,7
12
) 
 
(n
 =
 6
,0
52
) 
 
(n
 =
 8
,9
99
) 
 
(n
 =
 7
,6
25
) 
 
(n
 =
 7
,2
10
) 
 
(n
 =
 7
,2
34
) 
 
(n
 =
 7
,6
15
) 
 
(n
 =
 7
,0
18
) 
S
ki
n 
in
fe
ct
io
n,
 o
th
er
 
1.
8 
(1
.3
–2
.3
) 
 
1.
7 
(1
.2
–2
.2
) 
 
1.
6 
(1
.0
–2
.1
) 
 
1.
9 
(1
.5
–2
.3
) 
 
1.
8 
(1
.3
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.2
) 
 
1.
6 
(1
.2
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.0
) 
 
1.
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(1
.3
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.1
) 
 
1.
1 
(0
.8
–1
.3
) 
 
1.
4 
(1
.0
–1
.7
) 
 
1.
4 
(1
.0
–1
.8
) 
—
 
B
lo
od
 te
st
 –
 a
ll*
 
0.
6 
(0
.2
–1
.0
) 
 
1.
1 
(0
.4
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.8
) 
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.7
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.2
) 
 
1.
6 
(1
.1
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1.
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(1
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.4
) 
 
2.
0 
(1
.0
–3
.0
) 
 
1.
5 
(1
.1
–2
.0
) 
 
1.
3 
(0
.8
–1
.9
) 
—
 
S
ki
n 
sy
m
pt
om
/c
om
pl
ai
nt
, o
th
er
 
1.
2 
(0
.7
–1
.7
) 
 
1.
2 
(0
.8
–1
.7
) 
 
1.
0 
(0
.7
–1
.3
) 
 
0.
9 
(0
.6
–1
.2
) 
 
0.
9 
(0
.7
–1
.2
) 
 
0.
8 
(0
.5
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.1
) 
 
0.
8 
(0
.6
–1
.1
) 
 
1.
1 
(0
.8
–1
.5
) 
 
0.
9 
(0
.7
–1
.2
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 11 Referrals and admissions  
A referral is defined as the process by which the responsibility for part, or all, of the care of a patient is 
temporarily transferred to another health care provider. GPs were instructed only to record new 
referrals arising at the encounter (that is, not to record continuations). For each encounter, GPs could 
record up to two referrals, and each referral was linked by the GP to the problem(s) for which the 
patient was referred. Referrals included those to medical specialists, allied health services, hospitals 
for admission, emergency departments, and to other services (including outpatient clinics and other 
GPs). 
Referral data for the 10 years from 2005–06 to 2014–15, are reported in two ways: as rates per 100 
problems managed (Table 11.1a) and as rates per 100 encounters (Table 11.1b). In the text 
describing changes over time, the rates per 100 problems are reported as the primary measure, 
because there was a significant increase in the average number of problems managed per encounter 
over the study period reported here.  
The direction and type of change from 2005–06 to 2014–15 is indicated for each result in the far right 
column of the tables: / indicates a statistically significant change (increase or decrease) in  
2014–15 compared with 2005–06; / indicates a marginally significant change in 2014–15 
compared with 2005–06; — indicates there was no significant change in 2014–15 compared with 
2005–06; and § indicates a noteworthy change during the decade. Significant changes in the rate per 
100 encounters can be extrapolated to estimate the national increase or decrease in the measured 
event between 2005–06 and 2014–15. Examples of extrapolated change are given. The method used 
to extrapolate is described in Section 2.9. 
The number of GP–patient encounters claimed through the Medicare Benefits Schedule nationally 
increased by 35.8% between 2005–06 (101.1 million encounters) and 2014–15 (137.3 million 
encounters).6,10 As a result, a decreased rate of a particular ‘measured event’ per 100 encounters may 
occasionally yield a national increase in the estimated number of events. 
More specific analyses of referrals recorded by participating GPs in the 2014–15 BEACH year can be 
found in the companion report, General practice activity in Australia 2014–15.1 
11.1 Results 
Figure 11.1 illustrates the proportion of encounters and problems managed where one or more 
referrals were made, and referral rates per 100 encounters and per 100 problems, over the decade 
2005–06 to 2014–15. As described in detail below, there was an increase in the likelihood that  
GP–patient encounters would involve one or more referrals, and that a problem being managed at 
encounter would be referred. There were also significant increases in the overall rates of referrals per 
100 encounters and per 100 problems managed.  
The likelihood that a problem being managed at encounter would be referred increased significantly 
over the study period, with 8.2% of problems referred in 2005–06 and 10.2% in 2014–15. There was a 
significant increase in the overall rate of referrals, from 8.2 per 100 problems managed in 2005–06 to 
10.3 per 100 in 2014–15, largely due to increased referral rates to medical specialists and to allied 
health professionals (Table 11.1a).  
The rate of referral to medical specialists per 100 problems managed increased from 5.6 in 2005–06 
to 6.2 per 100 in 2014–15. There were no changes in the rate of referrals to the most frequent 
individual medical specialist types, except for a marginally significant increase in referrals to 
orthopaedic surgeons and a marginally significant decrease in referrals to ophthalmologists. Although 
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the rate of referrals to individual types of specialists may have changed only marginally, the significant 
increase in the referral rate to specialists overall is consistent with a slight increase across many 
specialist types.  
The rate of referral to allied health services per 100 problems managed increased from 2.0 in 2005–06 
to 3.3 per 100 in 2014–15 (an increase of 65%). Strong contributions to the overall rate arose from a 
four-fold increase in referrals to psychologists (from 0.2. to 0.8 per 100 problems) and a doubling of 
the rate of referrals to podiatrists/chiropodists (from 0.2 to 0.4) (Table 11.1a). 
Table 11.1b also shows that over time there was an increased likelihood that GP–patient encounters 
would involve one or more referrals (11.3% involving a referral in 2005–06 and 14.5% in 2014–15). 
Overall, referrals increased significantly from 12.0 per 100 encounters in 2005–06 to 15.9 per 100 in 
2014–15. Extrapolation of this change suggests there were about 9.7 million more GP referrals 
nationally in 2014–15 than in 2005–06. These included about 4.9 million more referrals to medical 
specialists and about 4.2 million more to allied health services. Of these 4.2 million additional allied 
health referrals, 1.5 million were to psychologists, probably largely due to the government’s 
introduction of the Better Outcomes48 and later the Better Access49 mental health programs. There 
were also about 810,000 more referrals to physiotherapists, which may be due to more patients with 
chronic disease or due to government policy, such as the introduction of MBS item numbers for a 
limited number of physiotherapy services for selected patients referred by a GP.45 
 
 
 
 
 Note: Data are drawn from Tables 11.1a and 11.1b. 
Figure 11.1: Proportion of encounters and problems managed where referrals were made, 
and referral rates per 100 encounters and per 100 problems, 2005–06 to 2014–15 
(95% confidence intervals) 
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) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
—
 
 
P
ae
di
at
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ia
n 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
—
 
 
R
he
um
at
ol
og
is
t 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
—
 
A
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ed
 h
ea
lth
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s*
 
2.
0 
(1
.8
–2
.1
) 
 
2.
1 
(1
.9
–2
.2
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
6 
(2
.4
–2
.7
) 
 
2.
8 
(2
.6
–2
.9
) 
 
3.
0 
(2
.8
–3
.2
) 
 
3.
0 
(2
.8
–3
.2
) 
 
3.
1 
(2
.9
–3
.3
) 
 
3.
3 
(3
.1
–3
.5
) 

 
 
P
hy
si
ot
he
ra
py
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
9 
(0
.8
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
 
P
sy
ch
ol
og
is
t 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 

 
 
P
od
ia
tri
st
/c
hi
ro
po
di
st
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 

 
 
D
ie
tit
ia
n/
nu
tri
tio
ni
st
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
 
D
en
tis
t 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
—
 
H
os
pi
ta
l*
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
E
m
er
ge
nc
y 
de
pa
rtm
en
t*
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
—
 
O
th
er
 re
fe
rr
al
s*
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
—
 
To
ta
l r
ef
er
ra
ls
 
8.
2 
(7
.9
–8
.5
) 
 
8.
2 
(7
.9
–8
.5
) 
 
8.
3 
(8
.0
–8
.6
) 
 
8.
9 
(8
.6
–9
.2
) 
 
8.
7 
(8
.4
–9
.0
) 
 
9.
3 
(8
.9
–9
.6
) 
 
9.
4 
(9
.1
–9
.8
) 
 
9.
5 
(9
.2
–9
.9
) 
 
9.
9 
(9
.6
–1
0.
2)
 
 
10
.3
 
(9
.9
–1
0.
6)
 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4 
<h
dl
.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
) 
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 T
he
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os
t f
re
qu
en
t r
ef
er
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ls
 (r
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e 
pe
r 
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0 
en
co
un
te
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), 
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–0
6 
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 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 (9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
) 
 
 
R
ef
er
ra
l 
(n
 =
 1
01
,9
93
) 
 
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 
(n
 =
 9
6,
68
8)
 
 (
n
 =
 1
01
,3
49
) 
 
(n
 =
 9
5,
83
9)
 
 
(n
 =
 9
9,
03
0)
 
 
(n
 =
 9
8,
56
4)
 
 
(n
 =
 9
5,
87
9)
 
 
(n
 =
 9
8,
72
8)
 
A
t l
ea
st
 o
ne
 re
fe
rr
al
 
11
.3
 
(1
0.
9–
11
.8
) 
 
11
.5
 
(1
1.
0–
11
.9
) 
 
11
.8
 
(1
1.
3–
12
.2
) 
 
12
.8
 
(1
2.
3–
13
.2
) 
 
12
.4
 
(1
1.
9–
12
.9
) 
 
13
.0
 
(1
2.
5–
13
.5
) 
 
13
.3
 
(1
2.
8–
13
.8
) 
 
13
.5
 
(1
3.
0–
14
.1
) 
 
14
.4
 
(1
3.
9–
14
.9
) 
 
14
.5
 
(1
4.
0–
15
.1
) 

 
M
ed
ic
al
 s
pe
ci
al
is
t*
 
8.
2 
(7
.8
–8
.5
) 
 
8.
1 
(7
.7
–8
.4
) 
 
8.
0 
(7
.6
–8
.3
) 
 
9.
0 
(8
.7
–9
.3
) 
 
8.
4 
(8
.1
–8
.8
) 
 
8.
6 
(8
.2
–9
.0
) 
 
8.
6 
(8
.2
–8
.9
) 
 
8.
9 
(8
.5
–9
.3
) 
 
9.
5 
(9
.1
–9
.9
) 
 
9.
6 
(9
.2
–1
0.
0)
 

 
 
S
ur
ge
on
 
0.
8 
(0
.7
–0
.8
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
8 
(0
.8
–0
.9
) 
—
 
 
O
rth
op
ae
di
c 
su
rg
eo
n 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
—
 
 
C
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di
ol
og
is
t 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
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.7
) 
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) 
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) 
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) 
 
0.
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) 
 
0.
7 
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.8
) 
 
0.
8 
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.9
) 

 
 
D
er
m
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og
is
t 
0.
7 
(0
.6
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.8
) 
 
0.
6 
(0
.5
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.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
—
 
 
G
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en
te
ro
lo
gi
st
 
0.
5 
(0
.5
–0
.6
) 
 
0.
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(0
.4
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.5
) 
 
0.
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) 
 
0.
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.5
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) 
 
0.
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) 
 
0.
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.5
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) 
 
0.
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.5
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) 
 
0.
6 
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.5
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.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 

 
 
O
ph
th
al
m
ol
og
is
t 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.6
–0
.7
) 

 
 
G
yn
ae
co
lo
gi
st
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 
—
 
 
E
ar
, n
os
e 
an
d 
th
ro
at
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
—
 
 
U
ro
lo
gi
st
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
—
 
 
N
eu
ro
lo
gi
st
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
—
 
 
P
sy
ch
ia
tri
st
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.3
) 
—
 
(c
on
tin
ue
d)
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b 
(c
on
tin
ue
d)
: T
he
 m
os
t f
re
qu
en
t r
ef
er
ra
ls
 (r
at
e 
pe
r 
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0 
en
co
un
te
rs
), 
20
05
–0
6 
to
 2
01
4–
15
 
 
R
at
e 
pe
r 
10
0 
en
co
un
te
rs
 (9
5%
 C
I)
 
 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
) 
 
 
R
ef
er
ra
l 
(n
 =
 1
01
,9
93
) 
 
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 
(n
 =
 9
6,
68
8)
 
 (
n
 =
 1
01
,3
49
) 
 
(n
 =
 9
5,
83
9)
 
 
(n
 =
 9
9,
03
0)
 
 
(n
 =
 9
8,
56
4)
 
 
(n
 =
 9
5,
87
9)
 
 
(n
 =
 9
8,
72
8)
 
 
C
lin
ic
/c
en
tre
 
0.
1 
(0
.1
–0
.1
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 

 
 
E
nd
oc
rin
ol
og
is
t 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
A
lli
ed
 h
ea
lth
 s
er
vi
ce
s*
 
2.
9 
(2
.7
–3
.1
) 
 
3.
1 
(2
.9
–3
.3
) 
 
3.
4 
(3
.2
–3
.7
) 
 
3.
9 
(3
.6
–4
.1
) 
 
3.
9 
(3
.7
–4
.2
) 
 
4.
2 
(3
.9
–4
.5
) 
 
4.
7 
(4
.4
–5
.0
) 
 
4.
7 
(4
.4
–5
.0
) 
 
4.
9 
(4
.6
–5
.2
) 
 
5.
2 
(4
.9
–5
.5
) 

 
 
P
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 12 Investigations 
Investigations ordered by GPs or undertaken in the practice for each of the 10 years from 2005–06 to 
2014–15 are reported in two ways: as rates per 100 problems managed (for example, Table 12.2a) 
and as rates per 100 encounters (for example, Table 12.2b). In the text describing changes over time, 
the rates per 100 problems are reported as the primary measure, because there was a significant 
increase over the decade in the number of problems managed per encounter.  
The direction and type of change from 2005–06 to 2014–15 is indicated for each result in the far right 
column of the tables: / indicates a statistically significant change (increase or decrease) in  
2014–15 compared with 2005–06; / indicates a marginally significant change in 2014–15 
compared with 2005–06; — indicates there was no significant change in 2014–15 compared with 
2005–06; and § indicates a noteworthy change during the decade. 
Significant changes in the rate per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the investigations ordered between 2005–06 and 2014–15. Examples of 
extrapolated change are given, and the method used is described in Section 2.9. 
The GPs participating in BEACH were asked to record (in free text) any pathology, imaging or other 
tests ordered or done at the encounter, and to nominate the patient problem(s) associated with each 
test order. This allows a test order to be linked to a single problem or multiple problems. Up to five 
orders for pathology and two for imaging and other tests could be recorded at each encounter. A 
single test may have been ordered for the management of multiple problems, and multiple tests may 
have been used in the management of a single problem. 
A pathology test order may be for a single test (for example, Pap smear, HbA1c) or for a battery of 
tests (for example, lipids, full blood count). Where a battery of tests was ordered, the battery name 
was recorded rather than each individual test. GPs also recorded the body site for any imaging 
ordered (for example, x-ray chest, computerised tomography head). 
More detailed analyses of investigations ordered by GPs in 2014–15 can be found in Chapter 12 of 
General practice activity in Australia 2014–15.1 
Comprehensive investigation of GPs’ pathology and imaging ordering using BEACH data has been 
published in several reports. Interested readers may wish to consult: 
• a comprehensive report on pathology ordering by GPs in Australia in 1998, published on the 
internet by the then Department of Health and Aged Care50 
• a report on imaging orders by GPs in Australia in 1999–2000, published as an AIHW–University of 
Sydney book in the GP series in 200151 
• a report on changes in pathology ordering by GPs from 1998 to 2001, published as an AIHW–
University of Sydney book in the GP series in 200352 
• a review of pathology ordering in the National Health Priority Areas and other selected problems 
from 2000 to 2008, in General practice in Australia, health priorities and policies 1998 to 200853 
• a report Evidence-practice gap in GP pathology test ordering: a comparison of BEACH pathology 
data and recommended testing, prepared for the Australian Government Quality Use of Pathology 
Program in June 200954 
• a 2013 PhD thesis, Evaluation of pathology ordering by general practitioners in Australia55 
• a 2014 report, Evaluation of imaging ordering by general practitioners in Australia 2002–03 to 
2011–12, which described changes in GPs’ imaging ordering over time and evaluated the 
alignment between guidelines and GP test ordering for selected problems.56 This was funded by a 
grant from the Diagnostic Imaging Quality Program, Australian Government Department of Health. 
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12.1  Pathology ordering 
There was no change in the proportion of problems for which GPs ordered pathology, with at least one 
pathology test ordered for 12.7% of all problems managed in 2005–06 and 13.4% in 2014–15 (Table 
12.1a). This is the first 10-year period of BEACH data (since 1998) that there was not a significant 
increase in the likelihood of tests being ordered in the management of problems. In contrast, the 
proportion of encounters involving at least one pathology test increased over the decade from 16.4% 
of encounters to 18.1% (Table 12.1b), equating to approximately 8.3 million more encounters at which 
pathology was ordered nationally in 2014–15 than 10 years earlier. It is noteworthy that most of this 
change occurred between 2005–06 and 2006–07, and has remained stable from 2006–07 to 2014–15. 
Figure 12.1 shows graphically, the change in the likelihood of ordering pathology at encounters, and 
the increased rates of total pathology ordering per 100 problems and per 100 encounters, over the 10 
years to 2014–15. 
The number of pathology tests (or batteries of tests) ordered increased from 26.4 per 100 problems 
managed in 2005–06 to 30.3 per 100 problems in 2014–15 (Table 12.2a). The number of tests 
ordered per 100 encounters increased from 38.6 tests (or batteries of tests) per 100 encounters in 
2005–06 to 47.0 in 2014–15 (Table 12.2b), which, when combined with the increase in GP attendance 
rate, extrapolates to approximately 25.5 million more tests (or batteries of tests) ordered in 2014–15 
than in 2005–06 nationally.  
Readers should consider the impact of the changes in the number and types of problems on the rates 
of pathology tests ordered by GPs. For example, the number of problems managed rose from 146.2 to 
155.1 per 100 encounters (reported in Chapter 5), and has contributed to the increased testing rate 
per 100 encounters. Similarly, the increased rate of problems labelled as “test results” reported in 
Chapter 7, Section 7.2, may have an impact on GPs’ test ordering behaviour. 
In summary, the national increase in number of pathology tests ordered by GPs in Australia is not due 
to any change in the likelihood of GPs’ ordering pathology for a problem. Rather, it is due to the 
combined effect of: 
• the increased number of tests ordered when the decision to test was made, rising from an average 
2.08 tests/batteries per tested problem in 2005–0639 to 2.35 in 2014–151 
• the increased number of problems managed per encounter, rising from 146.2 to 155.1 per 100 
encounters over the decade (see Chapter 5)  
• the increased GP attendance rate in Australia.10 
Pathology test orders by MBS groups 
Tables 12.2a and 12.2b show the changes in the distribution of tests ordered by MBS pathology 
groups.57 
Orders for chemical pathology tests increased from 14.8 per 100 problems in 2005–06 to 17.6 per 100 
in 2014–15, an increase of 19%. Immunology tests almost doubled over the decade, from 0.4 to 0.7 
per 100 problems, and there were marginal increases in the rates of tissue pathology and ‘simple’ 
tests. Order rates for the other test groups did not change (Table 12.2a).  
Orders for chemistry tests increased by 25.8%, from 21.7 per 100 encounters in 2005–06 to 27.3 in 
2014–15. This extrapolates to an estimated 15.5 million more chemistry test orders nationally in  
2014–15 than 10 years earlier. Haematology tests increased at a slower rate, from 7.3 tests per 100 
encounters in 2005–06 to 8.4 in 2014–15, a national increase of approximately 4.2 million tests. 
Microbiology test orders increased from 5.6 per 100 encounters in 2005–06 to 6.4 in 2014–15, 
extrapolating to an increase of about 3.1 million additional test orders nationally in 2014–15. There 
were also significant increases in order rates for immunology tests and ‘other’ tests, marginal 
increases in tissue pathology and simple tests, and no changes in the other test groups. 
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Note: Data are drawn from Tables 12.1a, 12.1b, 12.2a, and 12.2b. 
Figure 12.1: Proportion of encounters and problems where pathology was ordered, and pathology test 
order rates per 100 encounters and per 100 problems, 2005–06 to 2014–15 (95% confidence intervals) 
12.2  Imaging ordering 
Table 12.1a shows there was a significant increase in the proportion of problems for which imaging 
was ordered, from 5.5% in 2005–06 to 6.6% in 2014–15. Between 2005–06 and 2014–15, the number 
of problems managed per 100 encounters rose from 146.2 to 155.1 (Table 5.1). Both the rise in the 
proportion of problems generating imaging orders and the rise in the number of problems managed 
per encounter contributed to an overall increase in the proportion of encounters involving an imaging 
test (Table 12.1b). This increased from 7.8% in 2005–06 to 9.8% in 2014–15, resulting in an estimated 
5.6 million more encounters nationally at which imaging was ordered in 2014–15 than in 2005–06. 
Total imaging test orders increased significantly from 6.0 per 100 problems managed in 2005–06 to 
7.4 per 100 in 2014–15. The rate of imaging test orders per 100 encounters also increased 
significantly from 8.8 in 2005–06 to 11.5 in 2014–15 (Table 12.3b), an increase of 30.7% which 
equates to approximately 6.9 million more imaging orders nationally in 2014–15 than 10 years earlier. 
Figure 12.2 provides a graphical view of the change in the likelihood of GPs ordering imaging and the 
increases in the rates of imaging tests ordered per 100 problems and per 100 encounters over the 
10 years to 2014–15. 
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Imaging test orders by MBS group 
Tables 12.3a and 12.3b show the changes in imaging orders by MBS imaging group from 2005–06 to 
2014–15. There were changes in the types of imaging tests ordered, with a move away from 
diagnostic radiology toward ultrasound imaging. The rate of ultrasound orders increased by 55.0% 
over the decade, from 2.0 tests per 100 problems in 2005–06 to 3.1 per 100 in 2014–15. In contrast, 
the rate of diagnostic radiology marginally decreased (from 3.3 to 2.9 per 100 problems). This is the 
first time since BEACH began in 1998 that ultrasound imaging orders outnumbered those for 
diagnostic radiology. 
There were also significant increases in the order rate of computerised tomography (from 0.7 to 0.9 
per 100 problems) and magnetic resonance imaging (from less than 0.05 per 100 problems in  
2005–06 to 0.3 in 2014–15). The order rate of nuclear medicine did not change over the decade 
(Table 12.3a). 
Ultrasound imaging orders increased from 2.9 tests per 100 encounters in 2005–06 to 4.9 per 100 in 
2014–15, a national increase of about 3.8 million ultrasound orders in 2014–15 than a decade earlier. 
Computerised tomography increased from 1.0 per 100 encounters in 2005–06 to 1.5 in 2014–15, 
equating to 1.0 million more orders for computerised tomography in 2014–15 than a decade earlier. 
Magnetic resonance imaging orders increased from less than 0.05 per 100 encounters in 2005–06 to 
0.5 in 2014–15. Order rates of diagnostic radiology and nuclear medicine did not change over this 
period. 
 
 
 
Note: Data are drawn from Tables 12.1a, 12.1b, 12.3a, and 12.3b. 
Figure 12.2: Proportion of encounters and problems where imaging was ordered, and 
imaging test order rates per 100 encounters and per 100 problems, 2005–06 to 2014–15 
(95% confidence intervals) 
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 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
. 
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lo
gy
 o
rd
er
s 
b
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M
B
S
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ho
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up
s 
(r
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e 
pe
r 
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0 
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m
s)
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00
5–
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 2
01
4–
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R
at
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r 
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0 
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ob
le
m
s 
(9
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 C
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20
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–0
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20
06
–0
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20
07
–0
8 
 
20
08
–0
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20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 

(a
)  
 
 
P
at
ho
lo
g
y 
te
st
 o
rd
er
ed
 
(n
 =
 1
49
,0
88
) 
 (
n
 =
 1
36
,3
33
) 
 (
n
 =
 1
45
,0
78
) 
 (
n
 =
 1
49
,4
62
) 
 (
n
 =
 1
55
,3
73
) 
 (
n
 =
 1
46
,1
41
) 
 (
n
 =
 1
52
,2
86
) 
 (
n
 =
 1
52
,5
17
) 
 (
n
 =
 1
51
,6
75
) 
 (
n
 =
 1
53
,1
33
) 
C
he
m
is
try
* 
14
.8
 
(1
4.
1–
15
.6
) 
 
16
.5
 
(1
5.
7–
17
.2
) 
 
16
.4
 
(1
5.
6–
17
.2
) 
 
17
.4
 
(1
6.
7–
18
.1
) 
 
16
.9
 
(1
6.
1–
17
.6
) 
 
17
.1
 
(1
6.
4–
17
.8
) 
 
17
.9
 
(1
7.
1–
18
.8
) 
 
17
.9
 
(1
7.
2–
18
.6
) 
 
18
.1
 
(1
7.
4–
18
.8
) 
 
17
.6
 
(1
6.
9–
18
.4
) 

 
H
ae
m
at
ol
og
y*
 
5.
0 
(4
.7
–5
.3
) 
 
5.
3 
(5
.0
–5
.6
) 
 
5.
2 
(5
.0
–5
.5
) 
 
5.
3 
(5
.0
–5
.5
) 
 
5.
4 
(5
.1
–5
.7
) 
 
5.
3 
(5
.0
–5
.5
) 
 
5.
5 
(5
.2
–5
.8
) 
 
5.
4 
(5
.2
–5
.7
) 
 
5.
4 
(5
.1
–5
.6
) 
 
5.
4 
(5
.1
–5
.6
) 
—
 
M
ic
ro
bi
ol
og
y*
 
3.
8 
(3
.6
–4
.1
) 
 
3.
9 
(3
.7
–4
.2
) 
 
3.
7 
(3
.5
–4
.0
) 
 
3.
7 
(3
.5
–3
.9
) 
 
4.
1 
(3
.9
–4
.3
) 
 
4.
3 
(3
.9
–4
.6
) 
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(3
.8
–4
.3
) 
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1 
(3
.8
–4
.3
) 
 
4.
2 
(4
.0
–4
.4
) 
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1 
(3
.9
–4
.3
) 
—
 
C
yt
op
at
ho
lo
gy
* 
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2 
(1
.1
–1
.3
) 
 
1.
1 
(1
.0
–1
.3
) 
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(1
.1
–1
.4
) 
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–1
.4
) 
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(1
.0
–1
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) 
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–1
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) 
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(1
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–1
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) 
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–1
.1
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
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.5
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.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
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) 

 
O
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E
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* 
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(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
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(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
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(0
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–0
.8
) 
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–0
.7
) 
—
 
Ti
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.6
) 
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–0
.6
) 
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0.
4 
(0
.3
–0
.5
) 
 
0.
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.6
–0
.7
) 
 
0.
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
 
S
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e 
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st
s*
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
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(0
.1
–0
.2
) 
 
0.
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(0
.1
–0
.1
) 
 
0.
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(0
.1
–0
.2
) 
 
0.
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(0
.1
–0
.2
) 
 
0.
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(0
.1
–0
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0.
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(0
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.2
) 
 
0.
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(0
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.2
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
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fe
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0.
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) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
—
 
To
ta
l p
at
ho
lo
g
y 
te
st
s 
26
.4
 
(2
5.
3–
27
.5
) 
 
28
.6
 
(2
7.
5–
29
.6
) 
 
28
.5
 
(2
7.
4–
29
.6
) 
 
29
.5
 
(2
8.
4–
30
.5
) 
 
29
.3
 
(2
8.
2–
30
.4
) 
 
29
.6
 
(2
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6–
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.7
) 
 
30
.6
 
(2
9.
3–
31
.8
) 
 
30
.4
 
(2
9.
3–
31
.5
) 
 
31
.0
 
(3
0.
0–
32
.1
) 
 
30
.3
 
(2
9.
3–
31
.4
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; a
nd
 —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
.  
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 a
nd
 IC
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
8,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
). 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; M
B
S
 –
 M
ed
ic
ar
e 
B
en
ef
its
 S
ch
ed
ul
e;
 N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
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at
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 C
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
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y*
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2 
(0
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–0
.3
) 
 
0.
2 
(0
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–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
To
ta
l p
at
ho
lo
g
y 
te
st
s 
38
.6
 
(3
6.
9–
40
.3
) 
 
42
.4
 
(4
0.
7–
44
.2
) 
 
43
.1
 
(4
1.
3–
45
.0
) 
 
45
.6
 
(4
3.
8–
47
.4
) 
 
45
.0
 
(4
3.
1–
46
.9
) 
 
45
.2
 
(4
3.
4–
47
.0
) 
 
47
.0
 
(4
4.
9–
49
.1
) 
 
47
.1
 
(4
5.
1–
49
.0
) 
 
49
.1
 
(4
7.
1–
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.0
) 
 
47
.0
 
(4
5.
2–
48
.9
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 a
nd
 IC
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
8,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
13
76
5>
). 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; M
B
S
 –
 M
ed
ic
ar
e 
B
en
ef
its
 S
ch
ed
ul
e;
 N
E
C
 –
 n
ot
 e
ls
ew
he
re
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S
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R
at
e 
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m
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 C
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
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 
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 =
 1
49
,0
88
) 
 (
n
 =
 1
36
,3
33
) 
 (
n
 =
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 =
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 =
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 =
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 =
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
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 13 Patient risk factors 
General practice is a useful intervention point for health promotion because the majority of the 
population visit a GP at least once per year — in 2014–15, 85.8% of Australians visited a GP at least 
once (personal communication, DoH, June 2015). GPs have substantial knowledge of population 
health and screening programs. They are in an ideal position to advise patients about the benefits of 
health screening, and to individually counsel patients about their lifestyle choices. 
Since the beginning of the BEACH program (1998), a section on the bottom of each encounter form 
has been used to investigate aspects of patient health or healthcare delivery not covered by general 
practice encounter-based information. These additional substudies are referred to as Supplementary 
Analysis of Nominated Data (SAND). The SAND methods are described in Chapter 2, Section 2.6. 
• In brief, measured patient risk factors include self-reported height and weight (to calculate body 
mass index or BMI), alcohol consumption and smoking status. Each GP completes risk factor 
questions for patients at a subsample of 40 encounters. An example of the encounter form with 
the patient risk factor SAND questions is provided in Appendix 1. The methods used to investigate 
each risk factor are summarised in this chapter. Further detail is provided in Chapter 13 of the 
companion report, General practice activity in Australia 2014–15.1 
This chapter includes unweighted data about the risk behaviours of general practice patients from 
each of the most recent 10 years of the BEACH study from 2005–06 to 2014–15 (Tables 13.1a, 13.2a, 
13.3a). Unweighted data are presented for comparability over time as this was reported in all annual 
reports. Medicare claims data (from DoH), were used to calculate more precise estimates of 
prevalence, after adjusting to the general practice attending population. These data were only 
provided from 2007–08 onwards, so risk factor prevalence after adjustment for general practice 
attendance patterns by age–sex are presented for each of the eight most recent years (Tables 13.1b, 
13.2b, 13.3b).  
The direction and type of change from 2005–06 to 2014–15 is indicated for each result in the far  
right column of the tables: / indicates a statistically significant change (increase or decrease) in 
2014–15 compared with 2005–06; / indicates a marginally significant change in 2014–15 
compared with 2005–06; — indicates there was no significant change in 2014–15 compared with 
2005–06; and § indicates a noteworthy change during the decade.  
13.1 Body mass index 
Patient BMI was investigated for a subsample of 40 patients per GP. Each GP was instructed to ask 
the patient (or their carer in the case of children): 
• What is your height in centimetres (without shoes)? 
• What is your weight in kilograms (unclothed)? 
Metric conversion tables (feet and inches; stones and pounds) were provided to the GP. 
The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) squared. 
The WHO recommendations58 for BMI groups were used, which specify that an adult (18 years and 
over) with a BMI: 
• less than 18.5 is underweight 
• greater than or equal to 18.5 and less than 25 is normal 
• greater than or equal to 25 and less than 30 is overweight 
• of 30 or more is obese. 
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The BEACH data on BMI are presented separately for adults (aged 18 years and over) and children 
(aged 2–17 years). The standard BMI cut-offs described above were applied for the adult sample, and 
the method described by Cole et al. (2000 & 2007) was used for children (aged 2–17 years).59,60 
Adults 
Overall prevalence of overweight/obesity in adults sampled at general practice encounters increased 
significantly from 56.7% in 2005–06 (95% CI: 55.9–57.6) to 62.1% in 2014–15 (95% CI: 61.3–63.0) 
(results not tabulated). 
• The prevalence of obesity in adults rose from 22.2% in 2005–06 to 28.0% in 2014–15 
(Table 13.1a), and this significant increase was apparent among both male and female patients 
(Tables 13.2a and 13.3a). The increase in obesity was evident between 2005–06 and 2010–11 
(from 22.2% to 26.7%), and was then static at about 27% for the 3 years 2010–11 to 2012–13. In  
2013–14, there was a further increase by over one percentage point (to 27.8%) which was 
maintained in 2014–15 (28.0%). 
• In contrast, prevalence of overweight remained steady over the decade at about 35% of surveyed 
adult patients. 
• The proportion of adults who were in the normal weight range decreased significantly from 40.5% 
in 2005–06 to 35.5% in 2014–15 (Table 13.1a). This significant decrease was apparent among 
both males and females (Tables 13.2a and 13.3a). The decrease in normal weight was evident 
between 2005–06 and 2010–11 (from 40.5% to 35.8%), and was then static at about 36% for the 
3 years from 2010–11 to 2012–13. In 2014–15, there was a further decrease by over one 
percentage point (to 35.1% in 2013–14 and maintained in 2014–15), corresponding with the 
increase in obesity. 
• In summary, for both male and female patients between 2005–06 and 2014–15, there was a 
significant increase in the rates of obesity for both sexes and a corresponding decrease in normal 
weight. Effectively a significant proportion of patients moved from the normal weight range into the 
overweight range, and a similar proportion of those who were overweight moved into the obese 
weight range. This upward movement from normal weight to overweight, and overweight to 
obesity, occurred by 2013–14 and was maintained in 2014–15.  
• The estimates for the adult GP–patient attending population (after adjusting for age–sex general 
practice attendance patterns) showed an increase in prevalence of obesity between 2007–08 and 
2014–15, from 23.4% to 27.2%, and a corresponding decrease in the prevalence of normal 
weight, from 38.9% to 36.6% (Table 13.1b). This pattern was noted among female patients, but 
only the increase in obesity was apparent in male patients (Tables 13.2b and 13.3b). 
Children 
The prevalence of overweight and obesity among sampled children aged 2–17 years remained static 
for 7 years from 2005–06 to 2011–12 (around 18% and 10% respectively). There was a marginal 
decrease in obesity to around 9% in 2014–15 (Table 13.1a). Similar patterns were present among 
both male and female children; however, there were no statistically significant change among either 
boys or girls over the decade (Tables 13.2a and 13.3a). 
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13.2 Smoking 
GPs were instructed to ask adult patients (18 years and over): 
• What best describes your smoking status?  Smoke daily 
 Smoke occasionally 
 Previous smoker 
 Never smoked 
Results 
There was a significant decrease in the rates of current daily smoking and occasional smoking among 
sampled adults aged 18 years and over attending general practice, from 17.1% and 3.6% respectively 
in 2005–06 to 14.1% and 2.2% in 2014–15 (Table 13.1a). These decreases were apparent among 
both sexes (Tables 13.2a and 13.3a). There was also a significant increase in the proportion who had 
never smoked, from 52.3% in 2005–06 to 55.9% in 2014–15, also apparent among both male and 
female patients. 
Rates of daily smoking were significantly higher among male patients than female patients in all years. 
In 2014–15, prevalence was 17.4% of males and 11.9% of females. 
The estimates for the adult GP–patient attending population (after adjusting for age–sex general 
practice attendance patterns) showed a decrease in prevalence of daily smoking between 2007–08 
and 2014–15 from 19.3% to 16.5%, and a corresponding increase in prevalence of patients who had 
never smoked from 51.5% to 55.5% (Table 13.1b). This pattern was noted for male patients, but 
among female patients only a significant increase in never smoking was noted (Tables 13.2b 
and 13.3b).  
13.3 Alcohol consumption 
To measure alcohol consumption, BEACH uses AUDIT-C61 which is the first three items from the 
WHO Alcohol Use Disorders Identification Test (AUDIT),62 with scoring for an Australian setting.63 The 
AUDIT-C has demonstrated validity and internal consistency and performs as well as the full AUDIT 
tool.64 The three–AUDIT-C tool is practical and valid in a primary care setting to assess ‘at-risk’ alcohol 
consumption (heavy drinking and/or active alcohol dependence).61 The scores for each question range 
from zero to four. A total (sum of all three questions) score of five or more for males, or four or more 
for females, suggests that the person’s drinking level is placing him or her at risk.63 
GPs were instructed to ask adult patients (18 years and over): 
• How often do you have a drink containing alcohol? Never 
 Monthly or less 
 Once a week/fortnight 
 2–3 times a week 
 4 times a week or more 
• How many standard drinks do you have on a typical day when you are drinking?  
 _______________ 
• How often do you have six or more standard drinks on one occasion? 
 Never 
 Less than monthly 
 Monthly 
 Weekly 
 Daily or almost daily 
A standard drinks chart was provided to each GP to help the patient identify the number of standard 
drinks consumed. 
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Results 
Rates of at-risk levels of alcohol consumption among sampled adults declined from about 26% in 
2005–06 to 23% in 2014–15. There was a corresponding increase in the proportion who were non-
drinkers, from about 29% in 2005–06 to 34% in 2014–15 (Table 13.1a). The significant decrease in at-
risk levels of alcohol consumption and increase in non-drinking was apparent among both male and 
female patients (Tables 13.2a and 13.3a). 
The estimates for the adult GP–patient attending population (after adjusting for age–sex general 
practice attendance patterns) showed a decrease in prevalence of at-risk levels of alcohol 
consumption between 2007–08 and 2014–15 from 29.3% to 26.1%, and a corresponding increase in 
the proportion of non-drinkers, from 26.5% to 30.8% (Table 13.1b). This pattern in adults was noted 
for both male and female patients (Tables 13.2b and 13.3b). 
13.4 Risk factor profile of adult patients 
All patient risk factor questions (BMI, smoking and alcohol consumption) were asked of the same 
subsample of adult patients. This allows us to build a risk profile for this sample for the three risk 
elements: overweight or obese weight status; daily smoking; and at-risk drinking. Each adult can have 
between zero and three of these risk factors. 
Results 
There was a significant increase in the proportion of sampled adults with one risk factor, from 49.2% in 
2005–06 to 52.2% in 2014–15 (Table 13.1a). The increase was apparent among both male and 
female adult patients (Tables 13.2a and 13.3a). There was a significant decrease in the proportion of 
patients with three risk factors from 3.9% to 3.2% — corresponding with the increase in the proportion 
with one risk factor. 
The estimates for the adult GP–patient attending population (after adjusting for age–sex general 
practice attendance patterns) showed an increase in prevalence of one risk factor between 2007–08 
and 2014–15 from 48.2% to 50.1%, and a corresponding decrease in prevalence of all three risk 
factors from 5.1% to 3.9% (Table 13.1b). This pattern in adults applied among male patients, but not 
among female patients (Tables 13.2b and 13.3b). 
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5–
34
.7
) 
—
 
 
N
or
m
al
 
40
.5
 
(3
9.
7–
41
.4
) 
 
39
.0
 
(3
8.
1–
39
.8
) 
 
38
.3
 
(3
7.
4–
39
.2
) 
 
36
.1
 
(3
5.
3–
36
.8
) 
 
37
.3
 
(3
6.
5–
38
.2
) 
 
35
.8
 
(3
5.
0–
36
.7
) 
 
36
.2
 
(3
5.
3–
37
.0
) 
 
36
.2
 
(3
5.
4–
37
.0
) 
 
35
.1
 
(3
4.
3–
35
.9
) 
 
35
.5
 
(3
4.
7–
36
.3
) 

 
 
U
nd
er
w
ei
gh
t 
2.
8 
(2
.5
–3
.0
) 
 
2.
6 
(2
.4
–2
.8
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
6 
(2
.4
–2
.8
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
4 
(2
.2
–2
.6
) 
—
 
S
m
ok
in
g 
st
at
us
 (n
) 
33
,5
58
 
 
31
,1
76
 
 
31
,6
52
 
 
34
,1
94
 
 
32
,7
44
 
 
32
,1
60
 
 
33
,0
86
 
 
32
,4
99
 
 
32
,1
66
 
 
33
,6
85
 
 
 
D
ai
ly
 
17
.1
 
(1
6.
3–
17
.8
) 
 
16
.1
 
(1
5.
4–
16
.9
) 
 
16
.5
 
(1
5.
8–
17
.3
) 
 
15
.3
 
(1
4.
6–
15
.9
) 
 
15
.1
 
(1
4.
4–
15
.8
) 
 
14
.8
 
(1
4.
2–
15
.5
) 
 
14
.7
 
(1
4.
0–
15
.3
) 
 
14
.4
 
(1
3.
7–
15
.1
) 
 
13
.5
 
(1
2.
9–
14
.2
) 
 
14
.1
 
(1
3.
4–
14
.7
) 

 
 
O
cc
as
io
na
l 
3.
6 
(3
.4
–3
.9
) 
 
3.
2 
(2
.9
–3
.4
) 
 
2.
9 
(2
.7
–3
.2
) 
 
2.
6 
(2
.4
–2
.9
) 
 
2.
7 
(2
.5
–2
.9
) 
 
2.
7 
(2
.4
–2
.9
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
6 
(2
.3
–2
.8
) 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
2 
(2
.0
–2
.4
) 

 
 
P
re
vi
ou
s 
27
.1
 
(2
6.
3–
27
.8
) 
 
28
.8
 
(2
8.
0–
29
.6
) 
 
27
.9
 
(2
7.
1–
28
.6
) 
 
28
.8
 
(2
8.
1–
29
.6
) 
 
28
.2
 
(2
7.
4–
29
.0
) 
 
28
.3
 
(2
7.
5–
29
.1
) 
 
27
.9
 
(2
7.
2–
28
.7
) 
 
27
.7
 
(2
7.
0–
28
.5
) 
 
28
.6
 
(2
7.
8–
29
.4
) 
 
27
.8
 
(2
7.
0–
28
.6
) 
—
 
 
N
ev
er
 
52
.3
 
(5
1.
3–
53
.2
) 
 
51
.9
 
(5
0.
9–
52
.9
) 
 
52
.7
 
(5
1.
7–
53
.6
) 
 
53
.3
 
(5
2.
4–
54
.2
) 
 
54
.0
 
(5
3.
1–
55
.0
) 
 
54
.2
 
(5
3.
3–
55
.2
) 
 
54
.9
 
(5
3.
9–
55
.8
) 
 
55
.3
 
(5
4.
4–
56
.3
) 
 
55
.6
 
(5
4.
6–
56
.6
) 
 
55
.9
 
(5
4.
9–
56
.9
) 

 
A
lc
oh
ol
 c
on
su
m
pt
io
n 
(n
) 
32
,7
53
 
 
30
,3
47
 
 
30
,7
96
 
 
33
,3
47
 
 
31
,7
71
 
 
31
,1
90
 
 
33
,2
57
 
 
31
,6
40
 
 
31
,3
69
 
 
32
,8
35
 
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
25
.9
 
(2
5.
0–
26
.8
) 
 
27
.0
 
(2
6.
1–
28
.0
) 
 
26
.2
 
(2
5.
3–
27
.1
) 
 
25
.2
 
(2
4.
3–
26
.0
) 
 
26
.5
 
(2
5.
7–
27
.4
) 
 
24
.8
 
(2
3.
9–
25
.7
) 
 
24
.5
 
(2
3.
7–
25
.4
) 
 
24
.1
 
(2
3.
3–
24
.9
) 
 
23
.0
 
(2
2.
2–
23
.8
) 
 
23
.3
 
(2
2.
5–
24
.2
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
44
.8
 
(4
4.
0–
45
.7
) 
 
44
.6
 
(4
3.
7–
45
.5
) 
 
44
.6
 
(4
3.
7–
45
.5
) 
 
45
.2
 
(4
4.
3–
46
.1
) 
 
44
.4
 
(4
3.
5–
45
.3
) 
 
44
.0
 
(4
3.
0–
44
.9
) 
 
43
.7
 
(4
2.
9–
44
.6
) 
 
44
.2
 
(4
3.
3–
45
.1
) 
 
43
.9
 
(4
3.
0–
44
.8
) 
 
42
.9
 
(4
2.
0–
43
.8
) 

 
 
N
on
-d
rin
ke
r 
29
.3
 
(2
8.
2–
30
.4
) 
 
28
.3
 
(2
7.
3–
29
.4
) 
 
29
.3
 
(2
8.
2–
30
.3
) 
 
29
.6
 
(2
8.
6–
30
.7
) 
 
29
.1
 
(2
8.
0–
30
.1
) 
 
31
.3
 
(3
0.
2–
32
.4
) 
 
31
.7
 
(3
0.
6–
32
.8
) 
 
31
.7
 
(3
0.
6–
32
.8
) 
 
33
.1
 
(3
2.
0–
34
.2
) 
 
33
.8
 
(3
2.
7–
34
.9
) 

 
 (c
on
tin
ue
d)
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a 
(c
on
tin
ue
d)
: P
at
ie
nt
 r
is
k 
fa
ct
or
s,
 2
00
5–
06
 to
 2
01
4–
15
 
 
P
er
 c
en
t (
95
%
 C
I) 

(a
)  
 
 
R
is
k 
fa
ct
or
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 
A
du
lt
s 
(a
ge
d 
18
 y
ea
rs
 a
nd
 o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
um
be
r 
of
 r
is
k 
fa
ct
or
s(
c)
 (n
) 
32
,0
76
 
 
29
,3
86
 
 
30
,0
02
 
 
32
,4
32
 
 
30
,7
95
 
 
30
,1
77
 
 
31
,4
01
 
 
30
,3
45
 
 
30
,2
50
 
 
31
,9
52
 
 
Ze
ro
 
27
.5
 
(2
6.
7–
28
.3
) 
 
26
.0
 
(2
5.
2–
26
.8
) 
 
26
.1
 
(2
5.
3–
26
.9
) 
 
25
.0
 
(2
4.
2–
25
.7
) 
 
25
.8
 
(2
5.
0–
26
.5
) 
 
25
.0
 
(2
4.
3–
25
.7
) 
 
25
.4
 
(2
4.
6–
26
.2
) 
 
25
.8
 
(2
5.
0–
26
.6
) 
 
25
.4
 
(2
4.
7–
26
.2
) 
 
25
.6
 
(2
4.
8–
26
.4
) 

 
O
ne
 
49
.2
 
(4
8.
5–
49
.9
) 
 
49
.8
 
(4
9.
1–
50
.6
) 
 
50
.1
 
(4
9.
4–
50
.8
) 
 
51
.8
 
(5
1.
1–
52
.5
) 
 
50
.3
 
(4
9.
6–
51
.0
) 
 
52
.2
 
(5
1.
5–
52
.9
) 
 
52
.1
 
(5
1.
4–
52
.8
) 
 
52
.0
 
(5
1.
3–
52
.7
) 
 
53
.0
 
(5
2.
3–
53
.7
) 
 
52
.2
 
(5
1.
5–
53
.0
) 

 
Tw
o 
19
.4
 
(1
8.
8–
20
.0
) 
 
20
.4
 
(1
9.
8–
21
.1
) 
 
19
.8
 
(1
9.
1–
20
.4
) 
 
19
.5
 
(1
8.
9–
20
.0
) 
 
20
.1
 
(1
9.
5–
20
.7
) 
 
19
.1
 
(1
8.
5–
19
.8
) 
 
18
.9
 
(1
8.
3–
19
.5
) 
 
18
.8
 
(1
8.
1–
19
.4
) 
 
18
.4
 
(1
7.
8–
19
.0
) 
 
19
.0
 
(1
8.
3–
19
.6
) 
—
 
Th
re
e 
3.
9 
(3
.6
–4
.1
) 
 
3.
7 
(3
.5
–4
.0
) 
 
4.
1 
(3
.8
–4
.4
) 
 
3.
8 
(3
.5
–4
.1
) 
 
3.
8 
(3
.6
–4
.1
) 
 
3.
7 
(3
.4
–4
.0
) 
 
3.
6 
(3
.3
–3
.9
) 
 
3.
4 
(3
.1
–3
.7
) 
 
3.
2 
(2
.9
–3
.4
) 
 
3.
2 
(3
.0
–3
.4
) 

 
C
hi
ld
re
n
 
(a
ge
d 
2–
17
 y
ea
rs
)(d
) (n
) 
3,
33
8 
 
3,
08
7 
 
3,
04
6 
 
2,
97
0 
 
3,
18
3 
 
3,
00
8 
 
3,
09
3 
 
3,
06
9 
 
2,
53
6 
 
3,
11
2 
 
O
be
se
 
10
.9
 
(9
.7
–1
2.
1)
 
 
10
.6
 
(9
.3
–1
1.
9)
 
 
11
.2
 
(1
0.
0–
12
.5
) 
 
10
.5
 
(9
.3
–1
1.
7)
 
 
9.
6 
(8
.4
–1
0.
8)
 
 
10
.6
 
(9
.3
–1
2.
0)
 
 
11
.1
 
(9
.8
–1
2.
5)
 
 
9.
0 
(7
.9
–1
0.
2)
 
 
9.
6 
(8
.3
–1
0.
8)
 
 
8.
6 
(7
.5
–9
.7
) 

 
O
ve
rw
ei
gh
t 
17
.9
 
(1
6.
5–
19
.2
) 
 
18
.6
 
(1
7.
2–
20
.0
) 
 
17
.1
 
(1
5.
7–
18
.5
) 
 
16
.7
 
(1
5.
3–
18
.2
) 
 
18
.0
 
(1
6.
7–
19
.4
) 
 
17
.7
 
(1
6.
2–
19
.1
) 
 
17
.6
 
(1
6.
2–
19
.0
) 
 
17
.3
 
(1
5.
9–
18
.7
) 
 
18
.7
 
(1
7.
1–
20
.4
) 
 
18
.4
 
(1
7.
0–
19
.9
) 
—
 
N
or
m
al
 
60
.7
 
(5
8.
9–
62
.5
) 
 
61
.2
 
(5
9.
3–
63
.0
) 
 
61
.7
 
(5
9.
7–
63
.6
) 
 
62
.9
 
(6
1.
0–
64
.8
) 
 
62
.3
 
(6
0.
4–
64
.1
) 
 
61
.8
 
(5
9.
9–
63
.8
) 
 
60
.3
 
(5
8.
4–
62
.3
) 
 
62
.5
 
(6
0.
6–
64
.5
) 
 
62
.1
 
(6
0.
1–
64
.2
) 
 
62
.1
 
(6
0.
3–
64
.0
) 
—
 
U
nd
er
w
ei
gh
t 
10
.5
 
(9
.3
–1
1.
7)
 
 
9.
7 
(8
.6
–1
0.
8)
 
 
10
.1
 
(8
.9
–1
1.
2)
 
 
9.
9 
(8
.8
–1
1.
1)
 
 
10
.1
 
(9
.0
–1
1.
3)
 
 
9.
9 
(8
.7
–1
1.
0)
 
 
11
.0
 
(9
.7
–1
2.
2)
 
 
11
.1
 
(9
.9
–1
2.
4)
 
 
9.
6 
(8
.3
–1
0.
8)
 
 
10
.8
 
(9
.6
–1
2.
0)
 
—
 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tra
lia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 ra
ng
e 
ba
se
d 
on
 a
ge
 a
nd
 s
ex
 w
er
e 
ex
cl
ud
ed
. 
(c
) 
B
ei
ng
 o
ve
rw
ei
gh
t o
r o
be
se
, a
 d
ai
ly
 s
m
ok
er
 o
r a
n 
at
-r
is
k 
dr
in
ke
r a
re
 th
e 
ris
k 
fa
ct
or
s 
an
 a
du
lt 
m
ay
 h
av
e.
  
(d
) 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
) w
ith
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tra
lia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
or
 C
en
tre
s 
fo
r D
is
ea
se
 C
on
tro
l h
ei
gh
t r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
.
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re
va
le
nc
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ie
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s 
am
on
g 
ad
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ts
 1
8+
 a
tt
en
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ng
 g
en
er
al
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ct
ic
e 
at
 le
as
t o
nc
e,
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00
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08
 to
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P
er
 c
en
t (
95
%
 C
I) 

(a
)  
 
 
R
is
k 
fa
ct
or
 
 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 
A
du
lt
s 
(a
ge
d 
18
 y
ea
rs
 a
nd
 o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
od
y 
m
as
s 
in
de
x 
cl
as
s(
b)
 (n
) 
 
 
31
,2
92
 
 
33
,5
16
 
 
31
,9
24
 
 
31
,3
17
 
 
32
,3
73
 
 
31
,4
49
 
 
31
,3
63
 
 
32
,9
56
 
 
 
O
be
se
 
 
 
23
.4
 
(2
2.
7–
24
.2
) 
 
24
.5
 
(2
3.
8–
25
.2
) 
 
25
.4
 
(2
4.
6–
26
.1
) 
 
26
.1
 
(2
5.
3–
26
.9
) 
 
26
.1
 
(2
5.
3–
26
.9
) 
 
26
.0
 
(2
5.
2–
26
.9
) 
 
26
.9
 
(2
6.
1–
27
.8
) 
 
27
.2
 
(2
6.
4–
28
.0
) 

 
 
O
ve
rw
ei
gh
t 
 
 
35
.3
 
(3
4.
6–
36
.0
) 
 
35
.4
 
(3
4.
7–
36
.0
) 
 
34
.4
 
(3
3.
8–
35
.1
) 
 
34
.6
 
(3
3.
9–
35
.3
) 
 
34
.9
 
(3
4.
2–
35
.5
) 
 
34
.4
 
(3
3.
7–
35
.1
) 
 
34
.6
 
(3
3.
9–
35
.2
) 
 
33
.9
 
(3
3.
3–
34
.6
) 

 
 
N
or
m
al
 
 
 
38
.9
 
(3
8.
0–
39
.9
) 
 
37
.7
 
(3
6.
8–
38
.6
) 
 
38
.0
 
(3
7.
1–
38
.9
) 
 
37
.0
 
(3
6.
2–
37
.9
) 
 
36
.9
 
(3
6.
0–
37
.8
) 
 
37
.0
 
(3
6.
1–
37
.9
) 
 
36
.3
 
(3
5.
4–
37
.2
) 
 
36
.6
 
(3
5.
7–
37
.5
) 

 
 
U
nd
er
w
ei
gh
t 
 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
2 
(2
.0
–2
.3
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
3 
(2
.1
–2
.5
) 
—
 
S
m
ok
in
g 
st
at
us
 (n
) 
 
 
31
,8
84
 
 
34
,1
89
 
 
32
,7
34
 
 
32
,1
61
 
 
33
,0
85
 
 
32
,4
97
 
 
32
,1
56
 
 
33
,6
85
 
 
 
D
ai
ly
 
 
 
19
.3
 
(1
8.
5–
20
.1
) 
 
18
.8
 
(1
8.
0–
19
.6
) 
 
17
.7
 
(1
6.
9–
18
.5
) 
 
17
.8
 
(1
7.
0–
18
.6
) 
 
17
.4
 
(1
6.
6–
18
.2
) 
 
17
.3
 
(1
6.
4–
18
.1
) 
 
16
.9
 
(1
5.
9–
17
.8
) 
 
16
.5
 
(1
5.
7–
17
.3
) 

 
 
O
cc
as
io
na
l 
 
 
3.
5 
(3
.2
–3
.9
) 
 
3.
5 
(3
.1
–3
.8
) 
 
3.
3 
(3
.0
–3
.6
) 
 
3.
5 
(3
.1
–3
.8
) 
 
3.
2 
(2
.9
–3
.5
) 
 
3.
3 
(2
.9
–3
.6
) 
 
3.
1 
(2
.7
–3
.4
) 
 
2.
8 
(2
.6
–3
.1
) 

 
 
P
re
vi
ou
s 
 
 
25
.7
 
(2
4.
9–
26
.5
) 
 
25
.3
 
(2
4.
6–
26
.1
) 
 
25
.9
 
(2
5.
1–
26
.6
) 
 
25
.4
 
(2
4.
7–
26
.2
) 
 
25
.7
 
(2
4.
9–
26
.4
) 
 
25
.7
 
(2
4.
7–
26
.2
) 
 
25
.6
 
(2
4.
8–
26
.3
) 
 
25
.1
 
(2
4.
3–
25
.9
) 
—
 
 
N
ev
er
 
 
 
51
.5
 
(5
0.
4–
52
.5
) 
 
52
.5
 
(5
1.
5–
53
.4
) 
 
53
.1
 
(5
2.
1–
54
.1
) 
 
53
.3
 
(5
2.
3–
54
.4
) 
 
53
.8
 
(5
2.
8–
54
.8
) 
 
54
.0
 
(5
3.
0–
55
.0
) 
 
54
.5
 
(5
3.
4–
55
.6
) 
 
55
.5
 
(5
4.
5–
56
.6
) 

 
A
lc
oh
ol
 c
on
su
m
pt
io
n 
(n
) 
 
 
30
,7
96
 
 
33
,3
47
 
 
31
,7
71
 
 
31
,1
90
 
 
33
,2
57
 
 
31
,6
40
 
 
31
,3
69
 
 
32
,8
35
 
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
 
 
29
.3
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8.
3–
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.3
) 
 
29
.2
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8.
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) 
 
29
.7
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.9
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6.
9–
28
.9
) 
 
27
.3
 
(2
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) 
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27
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
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r 
 
 
44
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) 
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) 
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) 
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) 
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45
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) 
 
44
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0–
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) 
 
43
.0
 
(4
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1–
43
.9
) 
—
 
 
N
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r 
 
 
26
.5
 
(2
5.
5–
27
.5
) 
 
26
.4
 
(2
5.
4–
27
.4
) 
 
26
.3
 
(2
5.
2–
27
.3
) 
 
28
.2
 
(2
7.
1–
29
.4
) 
 
28
.7
 
(2
7.
6–
29
.9
) 
 
28
.7
 
(2
7.
6–
29
.7
) 
 
29
.8
 
(2
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7–
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) 
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.8
 
(2
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31
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
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d 
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N
um
be
r 
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 r
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k 
fa
ct
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s(
c)
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) 
 
 
30
,0
02
 
 
32
,4
32
 
 
30
,7
95
 
 
30
,1
77
 
 
31
,4
01
 
 
30
,3
45
 
 
30
,2
50
 
 
31
,9
52
 
 
Ze
ro
 
 
 
24
.8
 
(2
3.
9–
25
.6
) 
 
24
.0
 
(2
3.
2–
24
.8
) 
 
24
.5
 
(2
3.
7–
25
.3
) 
 
24
.0
 
(2
3.
2–
24
.8
) 
 
24
.1
 
(2
3.
3–
24
.9
) 
 
24
.8
 
(2
3.
9–
25
.7
) 
 
24
.5
 
(2
3.
7–
25
.3
) 
 
24
.9
 
(2
4.
1–
25
.8
) 
—
 
O
ne
 
 
 
48
.2
 
(4
7.
5–
48
.9
) 
 
49
.1
 
(4
8.
4–
49
.8
) 
 
48
.6
 
(4
7.
8–
49
.3
) 
 
50
.0
 
(4
9.
2–
50
.7
) 
 
50
.2
 
(4
9.
5–
50
.9
) 
 
49
.9
 
(4
9.
2–
50
.7
) 
 
50
.6
 
(4
9.
8–
51
.3
) 
 
50
.1
 
(4
9.
4–
50
.9
) 

 
Tw
o 
 
 
21
.9
 
(2
1.
2–
22
.7
) 
 
21
.9
 
(2
1.
2–
22
.6
) 
 
22
.2
 
(2
1.
5–
22
.9
) 
 
21
.4
 
(2
0.
6–
22
.1
) 
 
21
.2
 
(2
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5–
21
.9
) 
 
20
.9
 
(2
0.
2–
21
.6
) 
 
20
.8
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21
.6
) 
 
21
.0
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21
.7
) 
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re
e 
 
 
5.
1 
(4
.7
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) 
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1 
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.7
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.4
) 
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8 
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–5
.1
) 
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7 
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–5
.0
) 
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) 
 
4.
4 
(4
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) 
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
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pa
tie
nt
s 
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 1
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rd
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gh
t o
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A
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n 
B
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of
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 ra
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 w
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. 
(c
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B
ei
ng
 o
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rw
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gh
t o
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se
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 d
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 s
m
ok
er
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r a
n 
at
-r
is
k 
dr
in
ke
r a
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 th
e 
ris
k 
fa
ct
or
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m
ay
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e.
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ot
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fid
en
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B
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y 
m
as
s 
in
de
x 
cl
as
s(
b)
 (n
) 
12
,8
82
 
 
12
,7
15
 
 
12
,1
26
 
 
13
,5
95
 
 
11
,9
45
 
 
12
,3
22
 
 
12
,5
31
 
 
12
,1
71
 
 
12
,0
22
 
 
12
,9
47
 
 
 
O
be
se
 
21
.6
 
(2
0.
7–
22
.5
) 
 
22
.4
 
(2
1.
6–
23
.3
) 
 
23
.1
 
(2
2.
1–
24
.1
) 
 
25
.0
 
(2
4.
1–
26
.0
) 
 
25
.5
 
(2
4.
6–
26
.5
) 
 
26
.1
 
(2
5.
2–
27
.1
) 
 
26
.4
 
(2
5.
4–
27
.4
) 
 
26
.7
 
(2
5.
7–
27
.7
))
 
 
27
.2
 
(2
6.
2–
28
.2
))
 
 
28
.1
 
(2
7.
1–
29
.0
) 

 
 
O
ve
rw
ei
gh
t 
42
.6
 
(4
1.
6–
43
.6
) 
 
42
.3
 
(4
1.
4–
43
.3
) 
 
43
.0
 
(4
2.
0–
44
.0
) 
 
43
.6
 
(4
2.
7–
44
.6
) 
 
42
.1
 
(4
1.
1–
43
.0
) 
 
42
.2
 
(4
1.
2–
43
.2
) 
 
42
.5
 
(4
1.
5–
43
.5
) 
 
42
.5
 
(4
1.
5–
43
.4
) 
 
42
.0
 
(4
1.
1–
43
.0
) 
 
41
.4
 
(4
0.
5–
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.4
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or
m
al
 
34
.3
 
(3
3.
3–
35
.4
) 
 
34
.0
 
(3
2.
9–
35
.1
) 
 
32
.7
 
(3
1.
6–
33
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3–
31
.4
) 
 
31
.6
 
(3
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2–
32
.3
) 
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(2
9.
5–
31
.6
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(2
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29
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(2
8.
7–
30
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) 
 
29
.6
 
(2
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6–
30
.6
) 
 
29
.6
 
(2
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30
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) 

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w
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t 
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5 
(1
.3
–1
.7
) 
 
1.
2 
(1
.0
–1
.4
) 
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(1
.0
–1
.4
) 
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) 
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,3
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,8
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,6
00
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,7
77
 
 
12
,5
18
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,2
94
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,1
80
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ai
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20
.7
 
(1
9.
7–
21
.8
) 
 
19
.4
 
(1
8.
3–
20
.5
) 
 
19
.8
 
(1
8.
8–
20
.8
) 
 
18
.1
 
(1
7.
2–
19
.0
) 
 
18
.1
 
(1
7.
1–
19
.1
) 
 
17
.8
 
(1
6.
9–
18
.7
) 
 
18
.0
 
(1
7.
1–
19
.0
) 
 
17
.6
 
(1
6.
6–
18
.6
) 
 
16
.7
 
(1
5.
7–
17
.8
) 
 
17
.4
 
(1
6.
5–
18
.4
) 

 
 
O
cc
as
io
na
l 
4.
1 
(3
.7
–4
.6
) 
 
3.
8 
(3
.4
–4
.2
) 
 
3.
3 
(2
.9
–3
.7
) 
 
3.
0 
(2
.6
–3
.4
) 
 
3.
1 
(2
.8
–3
.5
) 
 
3.
1 
(2
.7
–3
.5
) 
 
2.
9 
(2
.6
–3
.3
) 
 
3.
2 
(2
.8
–3
.6
) 
 
2.
9 
(2
.5
–3
.3
) 
 
2.
6 
(2
.3
–2
.9
) 

 
 
P
re
vi
ou
s 
35
.7
 
(3
4.
5–
36
.9
) 
 
37
.1
 
(3
5.
8–
38
.4
) 
 
36
.5
 
(3
5.
3–
37
.7
) 
 
37
.9
 
(3
6.
8–
39
.1
) 
 
36
.9
 
(3
5.
8–
38
.1
) 
 
36
.8
 
(3
5.
6–
38
.0
) 
 
36
.3
 
(3
5.
1–
37
.4
) 
 
36
.6
 
(3
5.
4–
37
.8
) 
 
37
.0
 
(3
5.
8–
38
.2
) 
 
36
.0
 
(3
4.
8–
37
.2
) 
—
 
 
N
ev
er
 
39
.5
 
(3
8.
2–
40
.7
) 
 
39
.7
 
(3
8.
5–
41
.0
) 
 
40
.4
 
(3
9.
2–
41
.6
) 
 
41
.0
 
(3
9.
8–
42
.2
) 
 
41
.8
 
(4
0.
6–
43
.0
) 
 
42
.3
 
(4
1.
1–
43
.5
) 
 
42
.8
 
(4
1.
6–
44
.0
) 
 
42
.6
 
(4
1.
4–
43
.8
) 
 
43
.4
 
(4
2.
1–
44
.7
) 
 
44
.0
 
(4
2.
8–
45
.2
) 

 
A
lc
oh
ol
 c
on
su
m
pt
io
n 
(n
) 
12
,7
92
 
 
12
,0
05
 
 
12
,0
71
 
 
13
,5
83
 
 
11
,9
74
 
 
12
,3
21
 
 
12
,5
72
 
 
12
,2
74
 
 
12
,0
79
 
 
12
,9
69
 
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
31
.6
 
(3
0.
3–
32
.8
) 
 
32
.5
 
(3
1.
2–
33
.8
) 
 
31
.7
 
(3
0.
5–
32
.9
) 
 
30
.1
 
(2
8.
9–
31
.2
) 
 
31
.6
 
(3
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4–
32
.8
) 
 
30
.0
 
(2
8.
8–
31
.2
) 
 
29
.3
 
(2
8.
1–
30
.5
) 
 
29
.3
 
(2
8.
2–
30
.5
) 
 
27
.6
 
(2
6.
5–
28
.8
) 
 
28
.2
 
(2
7.
1–
29
.4
) 

 
 
R
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ib
le
 d
rin
ke
r 
47
.9
 
(4
6.
7–
49
.1
) 
 
48
.0
 
(4
6.
7–
49
.2
) 
 
47
.6
 
(4
6.
4–
48
.8
) 
 
48
.9
 
(4
7.
8–
50
.1
) 
 
47
.6
 
(4
6.
4–
48
.8
) 
 
47
.7
 
(4
6.
5–
48
.9
) 
 
46
.7
 
(4
5.
5–
48
.0
) 
 
47
.6
 
(4
6.
4–
48
.8
) 
 
48
.8
 
(4
7.
6–
50
.0
) 
 
47
.0
 
(4
5.
9–
48
.2
) 
—
 
 
N
on
-d
rin
ke
r 
20
.5
 
(1
9.
4–
21
.6
) 
 
19
.5
 
(1
8.
5–
20
.6
) 
 
20
.7
 
(1
9.
6–
21
.8
) 
 
21
.0
 
(2
0.
0–
22
.0
) 
 
20
.8
 
(1
9.
7–
21
.9
) 
 
22
.3
 
(2
1.
2–
23
.5
) 
 
24
.0
 
(2
2.
8–
25
.2
) 
 
23
.1
 
(2
2.
0–
24
.2
) 
 
23
.6
 
(2
2.
4–
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.7
) 
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.7
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5–
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
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N
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be
r 
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 r
is
k 
fa
ct
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c)
 (n
) 
12
,5
72
 
 
11
,6
62
 
 
11
,7
84
 
 
13
,2
28
 
 
11
,6
13
 
 
11
,9
55
 
 
12
,2
52
 
 
11
,8
27
 
 
11
,6
87
 
 
12
,6
65
 
 
Ze
ro
 
21
.1
 
(2
0.
1–
22
.0
) 
 
20
.3
 
(1
9.
4–
21
.2
) 
 
20
.2
 
(1
9.
2–
21
.1
) 
 
19
.0
 
(1
8.
1–
19
.8
) 
 
19
.6
 
(1
8.
7–
20
.5
) 
 
19
.2
 
(1
8.
3–
20
.0
) 
 
18
.9
 
(1
8.
0–
19
8.
) 
 
18
.9
 
(1
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0–
19
.8
) 
 
19
.6
 
(1
8.
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20
.4
) 
 
19
.2
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20
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
 
O
ne
 
47
.3
 
(4
6.
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.3
) 
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.0
 
(4
7.
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.1
) 
 
48
.0
 
(4
7.
0–
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.0
) 
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.5
 
(4
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6–
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.5
) 
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.0
 
(4
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.0
) 
 
50
.9
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9.
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.9
) 
 
51
.5
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4–
52
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.3
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52
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) 
 
51
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) 
 
51
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52
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
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o 
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.7
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26
.7
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.2
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) 
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.9
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9–
26
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) 
 
25
.0
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) 
 
25
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26
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24
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25
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24
.3
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25
.2
) 
 
24
.5
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5–
25
.4
) 
 
23
.9
 
(2
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9–
24
.9
) 
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.1
 
(2
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26
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) 
—
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e 
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) 
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.0
) 
 
5.
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–6
.4
) 
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5 
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.9
) 
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6 
(5
.1
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.1
) 
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3 
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.9
–5
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) 
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.9
–5
.8
) 
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.9
–5
.8
) 
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.1
) 
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.3
–5
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n
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d 
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) 
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0 
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9 
 
1,
48
4 
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5 
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49
9 
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0 
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48
7 
 
1,
45
1 
 
1,
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6 
 
1,
49
5 
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11
.6
 
(9
.9
–1
3.
3)
 
 
11
.6
 
(9
.8
–1
3.
4)
 
 
11
.9
 
(1
0.
1–
13
.7
) 
 
10
.3
 
(8
.6
–1
1.
9)
 
 
10
.5
 
(8
.9
–1
2.
2)
 
 
11
.2
 
(9
.4
–1
2.
9)
 
 
11
.8
 
(1
0.
0–
13
.7
) 
 
10
.1
 
(8
.4
–1
1.
7)
 
 
10
.7
 
(8
.8
–1
2.
6)
 
 
9.
0 
(7
.5
–1
0.
5)
 
—
 
O
ve
rw
ei
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t 
17
.1
 
(1
5.
3–
19
.0
) 
 
19
.7
 
(1
7.
7–
21
.7
) 
 
17
.3
 
(1
5.
4–
19
.3
) 
 
18
.2
 
(1
6.
1–
20
.4
) 
 
17
.4
 
(1
5.
3–
19
.5
) 
 
17
.4
 
(1
5.
4–
19
.5
) 
 
17
.8
 
(1
5.
7–
19
.8
) 
 
17
.4
 
(1
5.
4–
19
.4
) 
 
17
.8
 
(1
5.
6–
20
.0
) 
 
17
.6
 
(1
5.
6–
19
.6
) 
—
 
N
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m
al
 
60
.3
 
(5
7.
8–
62
.8
) 
 
58
.8
 
(5
6.
2–
61
.4
) 
 
61
.1
 
(5
8.
5–
63
.5
) 
 
62
.0
 
(5
9.
3–
64
.7
) 
 
62
.2
 
(5
9.
6–
64
.9
) 
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.4
 
(5
9.
7–
65
.2
) 
 
60
.1
 
(5
7.
4–
62
.9
) 
 
61
.8
 
(5
9.
2–
64
.4
) 
 
62
.8
 
(5
9.
9–
65
.7
) 
 
63
.2
 
(6
0.
8–
65
.7
) 
—
 
U
nd
er
w
ei
gh
t 
11
.0
 
(9
.3
–1
2.
6)
 
 
9.
9 
(8
.4
–1
1.
5)
 
 
9.
6 
(8
.0
–1
1.
3)
 
 
9.
5 
(8
.0
–1
1.
1)
 
 
9.
8 
(8
.2
–1
1.
4)
 
 
9.
0 
(7
.4
–1
0.
6)
 
 
10
.3
 
(8
.6
–1
2.
0)
 
 
10
.7
 
(8
.9
–1
2.
4)
 
 
8.
7 
(7
.1
–1
0.
4)
 
 
10
.2
 
(8
.6
–1
1.
8)
 
—
 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tra
lia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 ra
ng
e 
ba
se
d 
on
 a
ge
 a
nd
 s
ex
 w
er
e 
ex
cl
ud
ed
. 
(c
) 
Th
e 
ris
k 
fa
ct
or
s 
fo
r a
n 
ad
ul
t i
nc
lu
de
d 
be
in
g:
 o
ve
rw
ei
gh
t o
r o
be
se
, a
 d
ai
ly
 s
m
ok
er
 o
r a
n 
at
-r
is
k 
dr
in
ke
r. 
 
(d
) 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
) w
ith
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tra
lia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
or
 C
en
tre
s 
fo
r D
is
ea
se
 C
on
tro
l h
ei
gh
t r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
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P
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
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)  
 
 
R
is
k 
fa
ct
or
 
 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 
A
du
lt
 m
al
es
 (a
ge
d 
18
 y
ea
rs
 a
nd
 o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
od
y 
m
as
s 
in
de
x 
cl
as
s(
b)
 (n
) 
 
 
12
,1
26
 
 
13
,5
95
 
 
11
,9
45
 
 
12
,3
22
 
 
12
,5
31
 
 
12
,1
71
 
 
12
,0
22
 
 
12
,9
47
 
 
 
O
be
se
 
 
 
22
.8
 
(2
1.
8–
23
.8
) 
 
24
.2
 
(2
3.
3–
25
.2
) 
 
25
.1
 
(2
4.
1–
26
.1
) 
 
25
.4
 
(2
4.
4–
26
.4
) 
 
25
.7
 
(2
4.
6–
26
.8
) 
 
26
.1
 
(2
5.
0–
27
.2
))
 
 
26
.2
 
(2
5.
1–
27
.4
) 
 
27
.1
 
(2
6.
0–
28
.1
) 

 
 
O
ve
rw
ei
gh
t 
 
 
42
.1
 
(4
1.
0–
43
.2
) 
 
42
.4
 
(4
1.
4–
43
.5
) 
 
40
.9
 
(3
9.
9–
41
.9
) 
 
41
.0
 
(3
9.
9–
42
.0
) 
 
41
.5
 
(4
0.
4–
42
.5
) 
 
41
.4
 
(4
0.
3–
42
.5
) 
 
41
.1
 
(4
0.
0–
42
.1
) 
 
40
.2
 
(3
9.
2–
41
.3
) 
—
 
 
N
or
m
al
 
 
 
34
.0
 
(3
2.
7–
35
.2
) 
 
32
.3
 
(3
1.
1–
33
.5
) 
 
32
.9
 
(3
1.
7–
34
.0
) 
 
32
.5
 
(3
1.
3–
33
.6
) 
 
31
.5
 
(3
0.
4–
32
.7
) 
 
31
.4
 
(3
0.
2–
32
.5
) 
 
31
.4
 
(3
0.
2–
32
.6
) 
 
31
.7
 
(3
0.
5–
32
.9
) 
—
 
 
U
nd
er
w
ei
gh
t 
 
 
1.
1 
(0
.9
–1
.4
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
1 
(0
.9
–1
.4
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
3 
(1
.1
–1
.5
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
3 
(1
.0
–1
.5
) 
 
1.
0 
(0
.8
–1
.2
) 
—
 
S
m
ok
in
g 
st
at
us
 (n
) 
 
 
12
,3
35
 
 
13
,8
41
 
 
12
,2
60
 
 
12
,6
00
 
 
12
,7
77
 
 
12
,5
18
 
 
12
,2
94
 
 
13
,1
80
 
 
 
D
ai
ly
 
 
 
23
.4
 
(2
2.
2–
24
.5
) 
 
22
.8
 
(2
1.
7–
24
.0
) 
 
21
.4
 
(2
0.
2–
22
.6
) 
 
21
.6
 
(2
0.
6–
22
.7
) 
 
21
.4
 
(2
0.
3–
22
.5
) 
 
21
.3
 
(2
0.
1–
22
.4
) 
 
20
.9
 
(1
9.
6–
22
.2
) 
 
20
.5
 
(1
9.
4–
21
.7
) 

 
 
O
cc
as
io
na
l 
 
 
4.
1 
(3
.6
–4
.6
) 
 
4.
1 
(3
.5
–4
.6
) 
 
3.
9 
(3
.4
–4
.3
) 
 
4.
1 
(3
.5
–4
.6
) 
 
3.
8 
(3
.3
–4
.2
) 
 
4.
2 
(3
.6
–4
.7
) 
 
3.
9 
(3
.3
–4
.4
) 
 
3.
5 
(3
.1
–3
.9
) 
—
 
 
P
re
vi
ou
s 
 
 
30
.5
 
(2
9.
4–
31
.6
) 
 
29
.9
 
(2
8.
8–
31
.0
) 
 
30
.6
 
(2
9.
5–
31
.7
) 
 
30
.0
 
(2
8.
9–
31
.1
) 
 
30
.4
 
(2
9.
3–
31
.5
) 
 
30
.5
 
(2
9.
4–
31
.6
) 
 
29
.8
 
(2
8.
7–
30
.9
) 
 
29
.5
 
(2
8.
3–
30
.6
) 
—
 
 
N
ev
er
 
 
 
42
.0
 
(4
0.
7–
43
.3
) 
 
43
.2
 
(4
1.
9–
44
.5
) 
 
44
.1
 
(4
2.
8–
45
.4
) 
 
44
.3
 
(4
3.
0–
45
.7
) 
 
44
.4
 
(4
3.
2–
45
.7
) 
 
44
.1
 
(4
2.
8–
45
.4
) 
 
45
.4
 
(4
4.
0–
46
.9
) 
 
46
.5
 
(4
5.
2–
47
.8
) 

 
A
lc
oh
ol
 c
on
su
m
pt
io
n 
(n
) 
 
 
12
,0
71
 
 
13
,5
83
 
 
11
,9
74
 
 
12
,3
21
 
 
12
,5
72
 
 
12
,2
74
 
 
12
,0
79
 
 
12
,9
69
 
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
 
 
35
.7
 
(3
4.
3–
37
.1
) 
 
35
.7
 
(3
4.
4–
37
.0
) 
 
35
.2
 
(3
3.
9–
36
.6
) 
 
34
.5
 
(3
3.
1–
35
.9
) 
 
33
.3
 
(3
2.
0–
34
.7
) 
 
33
.1
 
(3
1.
8–
34
.4
) 
 
31
.6
 
(3
0.
2–
32
.9
) 
 
31
.7
 
(3
0.
3–
33
.0
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
 
 
45
.0
 
(4
3.
8–
46
.3
) 
 
45
.1
 
(4
3.
9–
46
.4
) 
 
45
.3
 
(4
4.
0–
46
.6
) 
 
44
.7
 
(4
3.
4–
45
.9
) 
 
44
.3
 
(4
3.
1–
45
.6
) 
 
45
.3
 
(4
4.
0–
46
.5
) 
 
46
.5
 
(4
5.
2–
47
.8
) 
 
45
.3
 
(4
4.
2–
46
.5
) 
—
 
 
N
on
-d
rin
ke
r 
 
 
19
.3
 
(1
8.
2–
20
.4
) 
 
19
.2
 
(1
8.
1–
20
.3
) 
 
19
.5
 
(1
8.
3–
20
.7
) 
 
20
.9
 
(1
9.
6–
22
.1
) 
 
22
.3
 
(2
1.
1–
32
.6
) 
 
21
.7
 
(2
0.
5–
22
.8
) 
 
22
.0
 
(2
0.
7–
23
.2
) 
 
23
.0
 
(2
1.
8–
24
.2
) 

 
 (c
on
tin
ue
d)
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)  
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or
 
 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 
A
du
lt
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al
es
 (a
ge
d 
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ea
rs
 a
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r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
um
be
r 
of
 r
is
k 
fa
ct
or
s(
c)
 (n
) 
 
 
11
,7
84
 
 
13
,2
28
 
 
11
,6
13
 
 
11
,9
54
 
 
12
,2
52
 
 
11
,8
27
 
 
11
,6
87
 
 
12
,6
65
 
 
Ze
ro
 
 
 
18
.8
 
(1
7.
8–
19
.8
) 
 
17
.5
 
(1
6.
6–
18
.4
) 
 
18
.7
 
(1
7.
7–
19
.7
) 
 
18
.2
 
(1
7.
2–
19
.1
) 
 
17
.9
 
(1
7.
0–
18
.9
) 
 
18
.0
 
(1
7.
0–
19
.0
) 
 
18
.4
 
(1
7.
5–
19
.4
) 
 
18
.8
 
(1
7.
8–
19
.8
) 
—
 
O
ne
 
 
 
45
.8
 
(4
4.
7–
46
.9
) 
 
47
.0
 
(4
6.
0–
48
.1
) 
 
46
.8
 
(4
5.
7–
47
.8
) 
 
47
.9
 
(4
6.
8–
49
.1
) 
 
48
.8
 
(4
7.
7–
49
.9
) 
 
48
.8
 
(4
7.
7–
50
.0
) 
 
49
.1
 
(4
8.
0–
50
.3
) 
 
48
.1
 
(4
7.
0–
49
.3
) 

 
Tw
o 
 
 
28
.2
 
(2
7.
1–
29
.3
) 
 
28
.2
 
(2
7.
1–
29
.2
) 
 
27
.8
 
(2
6.
8–
28
.9
) 
 
27
.3
 
(2
6.
2–
28
.4
) 
 
26
.7
 
(2
5.
7–
27
.8
) 
 
26
.7
 
(2
5.
6–
27
.7
) 
 
26
.6
 
(2
5.
5–
27
.7
) 
 
27
.4
 
(2
6.
4–
28
.5
) 
—
 
Th
re
e 
 
 
7.
2 
(6
.6
–7
.8
) 
 
7.
3 
(6
.7
–7
.9
) 
 
6.
7 
(6
.1
–7
.3
) 
 
6.
6 
(6
.0
–7
.2
) 
 
6.
5 
(5
.9
–7
.1
) 
 
6.
5 
(5
.9
–7
.1
) 
 
5.
8 
(5
.3
–6
.4
) 
 
5.
6 
(5
.1
–6
.1
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
7–
08
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
7–
08
; a
nd
 —
 
in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
7–
08
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tra
lia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 ra
ng
e 
ba
se
d 
on
 a
ge
 a
nd
 s
ex
 w
er
e 
ex
cl
ud
ed
. 
(c
) 
Th
e 
ris
k 
fa
ct
or
s 
fo
r a
n 
ad
ul
t i
nc
lu
de
d 
be
in
g:
 o
ve
rw
ei
gh
t o
r o
be
se
, a
 d
ai
ly
 s
m
ok
er
 o
r a
n 
at
-r
is
k 
dr
in
ke
r. 
 
N
ot
e:
 C
I –
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on
fid
en
ce
 in
te
rv
al
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,4
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35
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se
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1.
7–
23
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.2
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3–
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) 
 
24
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.2
) 
 
25
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8–
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.4
) 
 
26
.2
 
(2
5.
3–
27
.0
) 
 
27
.2
 
(2
6.
3–
28
.1
) 
 
26
.7
 
(2
5.
8–
27
.5
) 
 
26
.6
 
(2
5.
7–
27
.5
) 
 
28
.1
 
(2
7.
2–
29
.0
) 
 
27
.9
 
(2
7.
0–
28
.8
) 

 
 
O
ve
rw
ei
gh
t 
29
.3
 
(2
8.
6–
30
.0
) 
 
30
.1
 
(2
9.
4–
30
.9
) 
 
30
.4
 
(2
9.
7–
31
.2
) 
 
30
.9
 
(3
0.
2–
31
.6
) 
 
29
.6
 
(2
8.
9–
30
.3
) 
 
30
.3
 
(2
9.
6–
31
.0
) 
 
30
.2
 
(2
9.
5–
30
.9
) 
 
29
.5
 
(2
8.
8–
30
.2
) 
 
30
.4
 
(2
9.
7–
31
.2
) 
 
29
.3
 
(2
8.
6–
30
.1
) 
—
 
 
N
or
m
al
 
44
.6
 
(4
3.
6–
45
.6
) 
 
42
.2
 
(4
1.
2–
43
.2
) 
 
41
.9
 
(4
0.
9–
43
.0
) 
 
40
.0
 
(3
9.
1–
41
.0
) 
 
41
.1
 
(4
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1–
42
.0
) 
 
39
.3
 
(3
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3–
40
.3
) 
 
40
.2
 
(3
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41
.2
) 
 
40
.4
 
(3
9.
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41
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) 
 
38
.5
 
(3
7.
5–
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.5
) 
 
39
.5
 
(3
8.
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40
.5
) 

 
 
U
nd
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w
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t 
3.
5 
(3
.2
–3
.8
) 
 
3.
5 
(3
.2
–3
.8
) 
 
3.
3 
(3
.0
–3
.6
) 
 
3.
4 
(3
.2
–3
.7
) 
 
3.
2 
(2
.9
–3
.5
) 
 
3.
2 
(2
.9
–3
.5
) 
 
2.
9 
(2
.6
–3
.1
) 
 
3.
5 
(3
.2
–3
.8
) 
 
2.
9 
(2
.7
–3
.2
) 
 
3.
3 
(3
.0
–3
.6
) 
—
 
S
m
ok
in
g 
st
at
us
 (n
) 
20
,2
88
 
 
18
,7
18
 
 
19
,0
81
 
 
20
,0
79
 
 
20
,2
24
 
 
19
,3
01
 
 
20
,0
60
 
 
19
,7
58
 
 
19
,6
25
 
 
20
,2
52
 
 
 
D
ai
ly
 
14
.7
 
(1
4.
0–
15
.4
) 
 
14
.0
 
(1
3.
3–
14
.8
) 
 
14
.4
 
(1
3.
7–
15
.2
) 
 
13
.3
 
(1
2.
6–
14
.0
) 
 
13
.3
 
(1
2.
6–
14
.0
) 
 
12
.9
 
(1
2.
2–
13
.6
) 
 
12
.6
 
(1
1.
8–
13
.3
) 
 
12
.4
 
(1
1.
7–
13
.0
) 
 
11
.6
 
(1
0.
9–
12
.3
) 
 
11
.9
 
(1
1.
3–
12
.6
) 

 
 
O
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l 
3.
3 
(3
.0
–3
.6
) 
 
2.
7 
(2
.5
–3
.0
) 
 
2.
6 
(2
.4
–2
.9
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
1 
(1
.9
–2
.4
) 
 
1.
9 
(1
.7
–2
.2
) 
 
2.
0 
(1
.7
–2
.2
) 

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s 
21
.5
 
(2
0.
7–
22
.3
) 
 
23
.3
 
(2
2.
5–
24
.2
) 
 
22
.3
 
(2
1.
4–
23
.1
) 
 
22
.5
 
(2
1.
7–
23
.3
) 
 
22
.8
 
(2
2.
0–
23
.7
) 
 
22
.7
 
(2
1.
8–
23
.5
) 
 
22
.6
 
(2
1.
8–
23
.5
) 
 
22
.1
 
(2
1.
3–
22
.9
) 
 
23
.3
 
(2
2.
4–
24
.1
) 
 
22
.4
 
(2
1.
6–
23
.3
) 
—
 
 
N
ev
er
 
60
.5
 
(5
9.
5–
61
.6
) 
 
59
.9
 
(5
8.
8–
61
.0
) 
 
60
.7
 
(5
9.
6–
61
.7
) 
 
61
.7
 
(6
0.
7–
62
.7
) 
 
61
.5
 
(6
0.
4–
62
.5
) 
 
62
.1
 
(6
1.
0–
63
.1
) 
 
62
.6
 
(6
1.
6–
63
.7
) 
 
63
.4
 
(6
2.
4–
64
.5
) 
 
63
.2
 
(6
2.
2–
64
.2
) 
 
63
.7
 
(6
2.
6–
64
.8
) 

 
A
lc
oh
ol
 c
on
su
m
pt
io
n 
(n
) 
19
,9
61
 
 
18
,3
42
 
 
18
,7
15
 
 
19
,7
64
 
 
19
,9
79
 
 
18
,8
69
 
 
19
,6
85
 
 
19
,3
66
 
 
19
,2
90
 
 
19
,8
66
 
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
22
.2
 
(2
1.
3–
23
.2
) 
 
23
.5
 
(2
2.
5–
24
.5
) 
 
22
.6
 
(2
1.
6–
23
.6
) 
 
21
.8
 
(2
0.
8–
22
.7
) 
 
23
.4
 
(2
2.
5–
24
.4
) 
 
21
.4
 
(2
0.
5–
22
.3
) 
 
21
.5
 
(2
0.
6–
22
.5
) 
 
20
.8
 
(1
9.
9–
21
.7
) 
 
20
.1
 
(1
9.
2–
20
.9
) 
 
20
.1
 
(1
9.
2–
21
.0
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
42
.8
 
(4
1.
8–
43
.9
) 
 
42
.4
 
(4
1.
3–
43
.5
) 
 
42
.6
 
(4
1.
6–
43
.7
) 
 
42
.6
 
(4
1.
6–
43
.7
) 
 
42
.5
 
(4
1.
5–
43
.6
) 
 
41
.5
 
(4
0.
4–
42
.6
) 
 
41
.8
 
(4
0.
8–
42
.8
) 
 
42
.1
 
(4
1.
0–
43
.1
) 
 
40
.8
 
(3
9.
8–
41
.9
) 
 
40
.2
 
(3
9.
2–
41
.3
) 

 
 
N
on
-d
rin
ke
r 
35
.0
 
(3
3.
6–
36
.3
) 
 
34
.1
 
(3
2.
8–
35
.4
) 
 
34
.8
 
(3
3.
5–
36
.1
) 
 
35
.6
 
(3
4.
3–
36
.9
) 
 
34
.0
 
(3
2.
8–
35
.3
) 
 
37
.1
 
(3
5.
7–
38
.5
) 
 
36
.7
 
(3
5.
3–
38
.0
) 
 
37
.2
 
(3
5.
9–
38
.5
) 
 
39
.1
 
(3
7.
8–
40
.4
) 
 
39
.7
 
(3
8.
3–
41
.0
) 

 
(c
on
tin
ue
d)
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P
er
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t (
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
(a
)  
 
 
R
is
k 
fa
ct
or
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 
A
du
lt
 fe
m
al
es
 (
ag
ed
 1
8 
ye
ar
s 
an
d 
o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
um
be
r 
of
 r
is
k 
fa
ct
or
s(
c)
 (n
) 
19
,5
04
 
 
17
,7
24
 
 
18
,2
18
 
 
19
,2
04
 
 
19
,1
82
 
 
18
,2
22
 
 
19
,1
49
 
 
18
,5
18
 
 
18
,5
63
 
 
19
,2
87
 
 
Ze
ro
 
31
.7
 
(3
0.
7–
32
.7
) 
 
29
.8
 
(2
8.
8–
30
.7
) 
 
29
.9
 
(2
8.
9–
30
.8
) 
 
29
.1
 
(2
8.
1–
30
.0
) 
 
29
.5
 
(2
8.
6–
30
.4
) 
 
28
.8
 
(2
7.
9–
29
.7
) 
 
29
.5
 
(2
8.
6–
30
.5
) 
 
30
.2
 
(2
9.
3–
31
.2
) 
 
29
.1
 
(2
8.
2–
30
.1
) 
 
29
.8
 
(2
8.
8–
30
.8
) 
—
 
O
ne
 
50
.4
 
(4
9.
5–
51
.2
) 
 
51
.0
 
(5
0.
1–
51
.9
) 
 
51
.4
 
(5
0.
6–
52
.3
) 
 
52
.7
 
(5
1.
8–
53
.5
) 
 
51
.2
 
(5
0.
3–
52
.0
) 
 
53
.1
 
(5
2.
2–
53
.9
) 
 
52
.5
 
(5
1.
7–
53
.4
) 
 
52
.5
 
(5
1.
6–
53
.3
) 
 
53
.7
 
(5
2.
8–
54
.5
) 
 
53
.1
 
(5
2.
2–
53
.9
) 

 
Tw
o 
15
.4
 
(1
4.
7–
16
.0
) 
 
16
.6
 
(1
5.
9–
17
.3
) 
 
15
.8
 
(1
5.
2–
16
.5
) 
 
15
.6
 
(1
5.
0–
16
.3
) 
 
16
.6
 
(1
5.
9–
17
.2
) 
 
15
.5
 
(1
4.
8–
16
.2
) 
 
15
.5
 
(1
4.
8–
16
.1
) 
 
15
.1
 
(1
4.
5–
15
.8
) 
 
15
.0
 
(1
4.
3–
15
.6
) 
 
14
.9
 
(1
4.
3–
15
.6
) 
—
 
Th
re
e 
2.
6 
(2
.3
–2
.8
) 
 
2.
6 
(2
.3
–2
.9
) 
 
2.
9 
(2
.6
–3
.2
) 
 
2.
6 
(2
.4
–2
.9
) 
 
2.
8 
(2
.5
–3
.0
) 
 
2.
6 
(2
.3
–2
.9
) 
 
2.
5 
(2
.2
–2
.8
) 
 
2.
2 
(1
.9
–2
.4
) 
 
2.
2 
(2
.0
–2
.5
) 
 
2.
2 
(2
.0
–2
.4
) 
—
 
Fe
m
al
e 
ch
ild
re
n
 
(a
ge
d 
2–
17
 y
ea
rs
)(d
)  (
n
) 
1,
69
8 
 
1,
57
8 
 
1,
56
2 
 
1,
55
5 
 
1,
68
4 
 
1,
55
8 
 
1,
60
6 
 
1,
61
8 
 
1,
31
0 
 
1,
61
7 
 
O
be
se
 
10
.3
 
(8
.7
–1
1.
8)
 
 
9.
6 
(8
.1
–1
1.
2)
 
 
10
.6
 
(8
.9
–1
2.
2)
 
 
10
.7
 
(9
.1
–1
2.
3)
 
 
8.
7 
(7
.3
–1
0.
2)
 
 
10
.1
 
(8
.4
–1
1.
8)
 
 
10
.5
 
(8
.8
–1
2.
1)
 
 
8.
1 
(6
.7
–9
.5
) 
 
8.
5 
(7
.0
–1
0.
1)
 
 
8.
2 
(6
.9
–9
.6
) 
—
 
O
ve
rw
ei
gh
t 
18
.6
 
(1
6.
7–
20
.5
) 
 
17
.5
 
(1
5.
6–
19
.4
) 
 
16
.8
 
(1
4.
9–
18
.8
) 
 
15
.4
 
(1
3.
5–
17
.2
) 
 
18
.6
 
(1
6.
6–
20
.5
) 
 
17
.8
 
(1
5.
9–
19
.7
) 
 
17
.4
 
(1
5.
6–
19
.3
) 
 
17
.2
 
(1
5.
3–
19
.2
) 
 
19
.6
 
(1
7.
3–
21
.9
) 
 
19
.2
 
(1
7.
2–
21
.3
) 
—
 
N
or
m
al
 
61
.1
 
(5
8.
8–
63
.5
) 
 
63
.4
 
(6
0.
9–
66
.0
) 
 
62
.2
 
(5
9.
6–
64
.7
) 
 
63
.7
 
(6
1.
1–
66
.2
) 
 
62
.3
 
(5
9.
8–
64
.8
) 
 
61
.3
 
(5
8.
8–
63
.8
) 
 
60
.5
 
(5
8.
0–
63
.1
) 
 
63
.2
 
(6
0.
6–
65
.7
) 
 
61
.5
 
(5
8.
7–
64
.2
) 
 
61
.2
 
(5
8.
6–
63
.7
) 
—
 
U
nd
er
w
ei
gh
t 
10
.0
 
(8
.5
–1
1.
6)
 
 
9.
4 
(7
.9
–1
1.
0)
 
 
10
.4
 
(8
.8
–1
2.
1)
 
 
10
.3
 
(8
.7
–1
1.
9)
 
 
10
.4
 
(8
.7
–1
2.
0)
 
 
10
.7
 
(9
.1
–1
2.
3)
 
 
11
.6
 
(9
.9
–1
3.
3)
 
 
11
.5
 
(9
.9
–1
3.
1)
 
 
10
.4
 
(8
.6
–1
2.
1)
 
 
11
.4
 
(9
.7
–1
3.
1)
 
—
 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
4–
15
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; a
nd
 —
 
in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
4–
15
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tra
lia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 ra
ng
e 
ba
se
d 
on
 a
ge
 a
nd
 s
ex
 w
er
e 
ex
cl
ud
ed
. 
(c
) 
Th
e 
ris
k 
fa
ct
or
s 
fo
r a
n 
ad
ul
t i
nc
lu
de
d 
be
in
g:
 o
ve
rw
ei
gh
t o
r o
be
se
, a
 d
ai
ly
 s
m
ok
er
 o
r a
n 
at
-r
is
k 
dr
in
ke
r. 
(d
) 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
) w
ith
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
or
 C
en
tre
s 
fo
r D
is
ea
se
 C
on
tro
l h
ei
gh
t r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
.  
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
. 
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R
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fa
ct
or
 
 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
 
20
13
–1
4 
 
20
14
–1
5 
A
du
lt
 fe
m
al
es
 (
ag
ed
 1
8 
ye
ar
s 
an
d 
o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
od
y 
m
as
s 
in
de
x 
cl
as
s(
b)
 (n
) 
 
 
18
,7
03
 
 
19
,6
71
 
 
19
,7
35
 
 
18
,7
41
 
 
19
,6
05
 
 
19
,0
64
 
 
19
,1
12
 
 
19
,7
65
 
 
 
O
be
se
 
 
 
23
.9
 
(2
3.
0–
24
.8
) 
 
24
.8
 
(2
3.
9–
25
.6
) 
 
25
.6
 
(2
4.
7–
26
.5
) 
 
26
.7
 
(2
5.
8–
27
.7
) 
 
26
.4
 
(2
5.
5–
27
.3
) 
 
26
.0
 
(2
5.
1–
27
.0
) 
 
27
.5
 
(2
6.
6–
28
.5
) 
 
27
.4
 
(2
6.
4–
28
.3
) 

 
 
O
ve
rw
ei
gh
t 
 
 
29
.7
 
(2
8.
9–
30
.4
) 
 
29
.4
 
(2
8.
7–
30
.2
) 
 
28
.8
 
(2
8.
1–
29
.6
) 
 
29
.1
 
(2
8.
4–
29
.9
) 
 
29
.3
 
(2
8.
5–
30
.0
) 
 
28
.4
 
(2
7.
6–
29
.1
) 
 
29
.1
 
(2
8.
3–
29
.8
) 
 
28
.5
 
(2
7.
7–
29
.2
) 
—
 
 
N
or
m
al
 
 
 
43
.1
 
(4
2.
1–
44
.2
) 
 
42
.3
 
(4
1.
2–
43
.3
) 
 
42
.4
 
(4
1.
4–
43
.4
) 
 
40
.9
 
(3
9.
9–
42
.0
) 
 
41
.5
 
(4
0.
4–
42
.5
) 
 
41
.9
 
(4
0.
9–
43
.0
) 
 
40
.3
 
(3
9.
3–
41
.4
) 
 
40
.8
 
(3
9.
7–
41
.9
) 

 
 
U
nd
er
w
ei
gh
t 
 
 
3.
3 
(3
.0
–3
.6
) 
 
3.
6 
(3
.2
–3
.9
) 
 
3.
1 
(2
.8
–3
.5
) 
 
3.
2 
(2
.9
–3
.5
) 
 
2.
9 
(2
.6
–3
.2
) 
 
3.
6 
(3
.3
–4
.0
) 
 
3.
1 
(2
.7
–3
.4
) 
 
3.
4 
(3
.1
–3
.6
) 
—
 
S
m
ok
in
g 
st
at
us
 (n
) 
 
 
19
,0
81
 
 
20
,0
79
 
 
20
,2
24
 
 
19
,3
01
 
 
20
,0
60
 
 
19
,7
58
 
 
19
,6
25
 
 
20
,2
52
 
 
 
D
ai
ly
 
 
 
15
.9
 
(1
3.
1–
16
.7
) 
 
15
.4
 
(1
4.
6–
16
.2
) 
 
14
.6
 
(1
3.
9–
15
.4
) 
 
14
.5
 
(1
3.
7–
15
.3
) 
 
14
.1
 
(1
3.
3–
14
.9
) 
 
13
.8
 
(1
3.
1–
14
.6
) 
 
13
.4
 
(1
2.
6–
14
.2
) 
 
13
.1
 
(1
2.
4–
13
.8
) 
—
 
 
O
cc
as
io
na
l 
 
 
3.
0 
(2
.7
–3
.3
) 
 
3.
0 
(2
.6
–3
.3
) 
 
2.
8 
(2
.5
–3
.1
) 
 
2.
9 
(2
.6
–3
.3
) 
 
2.
6 
(2
.3
–2
.9
) 
 
2.
5 
(2
.2
–2
.8
) 
 
2.
4 
(2
.1
–2
.7
) 
 
2.
3 
(2
.0
–2
.6
) 

 
 
P
re
vi
ou
s 
 
 
21
.7
 
(2
0.
8–
22
.5
) 
 
21
.4
 
(2
0.
6–
22
.2
) 
 
21
.9
 
(2
1.
1–
22
.7
) 
 
21
.5
 
(2
0.
7–
22
.4
) 
 
21
.7
 
(2
0.
8–
22
.5
) 
 
21
.2
 
(2
0.
4–
21
.9
) 
 
21
.9
 
(2
1.
1–
22
.7
) 
 
21
.3
 
(2
0.
5–
22
.1
) 
—
 
 
N
ev
er
 
 
 
59
.4
 
(5
8.
3–
60
.5
) 
 
60
.3
 
(5
9.
2–
61
.3
) 
 
60
.7
 
(5
9.
6–
61
.7
) 
 
61
.0
 
(6
0.
0–
62
.1
) 
 
61
.7
 
(6
0.
6–
62
.8
) 
 
62
.5
 
(6
1.
4–
63
.6
) 
 
62
.3
 
(6
1.
2–
63
.4
) 
 
63
.3
 
(6
2.
2–
64
.5
) 

 
A
lc
oh
ol
 c
on
su
m
pt
io
n 
(n
) 
 
 
18
,7
25
 
 
19
,7
64
 
 
19
,7
97
 
 
18
,8
69
 
 
19
,6
85
 
 
19
,3
66
 
 
19
,2
90
 
 
19
,8
66
 
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
 
 
24
.0
 
(2
3.
0–
25
.0
) 
 
23
.8
 
(2
2.
7–
24
.8
) 
 
24
.9
 
(2
3.
9–
25
.9
) 
 
23
.1
 
(2
2.
1–
24
.1
) 
 
23
.2
 
(2
2.
2–
24
.2
) 
 
22
.3
 
(2
1.
3–
23
.2
) 
 
21
.6
 
(2
0.
7–
22
.5
) 
 
21
.3
 
(2
0.
3–
22
.3
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
 
 
43
.4
 
(4
2.
4–
44
.5
) 
 
43
.7
 
(4
2.
7–
44
.8
) 
 
43
.0
 
(4
2.
0–
44
.1
) 
 
42
.4
 
(4
1.
2–
43
.5
) 
 
42
.6
 
(4
1.
5–
43
.6
) 
 
43
.0
 
(4
1.
9–
44
.1
) 
 
41
.9
 
(4
0.
7–
43
.0
) 
 
41
.0
 
(4
0.
0–
42
.1
) 

 
 
N
on
-d
rin
ke
r 
 
 
32
.6
 
(3
1.
3–
33
.9
) 
 
32
.5
 
(3
1.
2–
33
.8
) 
 
32
.0
 
(3
0.
8–
33
.3
) 
 
34
.5
 
(3
3.
1–
35
.9
) 
 
34
.2
 
(3
2.
9–
35
.6
) 
 
34
.7
 
(3
3.
4–
36
.0
) 
 
36
.5
 
(3
5.
1–
37
.9
) 
 
37
.6
 
(3
6.
3–
39
.0
) 

 
 (c
on
tin
ue
d)
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20
07
–0
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20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
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2 
 
20
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–1
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4 
 
20
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5 
A
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es
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ed
 1
8 
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s 
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d 
o
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r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
um
be
r 
of
 r
is
k 
fa
ct
or
s(
c)
 (n
) 
 
 
18
,2
18
 
 
19
,2
04
 
 
19
,1
82
 
 
18
,2
22
 
 
19
,1
49
 
 
18
,5
18
 
 
18
,5
63
 
 
19
,2
87
 
 
Ze
ro
 
 
 
29
.8
 
(2
8.
8–
30
.8
) 
 
29
.4
 
(2
8.
4–
30
.4
) 
 
29
.5
 
(2
8.
5–
30
.5
) 
 
28
.9
 
(2
8.
0–
29
.9
) 
 
29
.3
 
(2
8.
3–
30
.3
) 
 
30
.6
 
(2
9.
6–
31
.7
) 
 
29
.6
 
(2
8.
6–
30
.6
) 
 
30
.1
 
(2
9.
1–
31
.2
) 
—
 
O
ne
 
 
 
50
.2
 
(4
9.
4–
51
.1
) 
 
50
.8
 
(4
9.
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 Abbreviations 
ACE angiotensin-converting enzyme 
ACRRM Australian College of Rural and Remote Medicine 
AHW Aboriginal health worker 
AIHW Australian Institute of Health and Welfare 
ASGC Australian Standard Geographical Classification 
ATC Anatomical Therapeutic Chemical (classification) 
BEACH Bettering the Evaluation and Care of Health 
BMI body mass index 
CAPS Coding Atlas for Pharmaceutical Substances 
CI confidence interval (in this report 95% CI is used) 
CT computerised tomography 
DoH Australian Government Department of Health 
DoHA Australian Government Department of Health and Ageing 
DVA Australian Government Department of Veterans’ Affairs 
FACRRM Fellow of the Australian College of Rural and Remote Medicine 
FMRC Family Medicine Research Centre 
FRACGP Fellow of the Royal Australian College of General Practitioners 
FTE full-time equivalent 
GP general practitioner 
HbA1c haemoglobin, type A1c 
ICPC-2 International Classification of Primary Care – Version 2 
ICPC-2 PLUS a terminology classified according to ICPC-2 
INR international normalised ratio 
LCL lower confidence limit 
MBS Medicare Benefits Schedule 
OTC over-the-counter (medications advised for over-the-counter purchase) 
PBS Pharmaceutical Benefits Scheme 
PN practice nurse 
RACGP Royal Australian College of General Practitioners 
RFE reason for encounter 
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SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
UCL upper confidence limit 
URTI upper respiratory tract infection  
WHO World Health Organization 
Wonca World Organization of Family Doctors 
 Symbols 
. . intentionally left blank 
< less than 
> more than 
n number 
N/A not applicable 
NAv not available 
2 chi-square 
 indicates a statistically significant increase in 2014–15 when compared with the 
first year of data reported 
 indicates a statistically significant decrease in 2014–15 when compared with the 
first year of data reported 
 indicates a marginally significant increase in 2014–15 when compared with the 
first year of data reported 
 indicates a marginally significant decrease in 2014–15 when compared with the 
first year of data reported 
§ indicates a noteworthy change during the decade 
— indicates no significant change in 2014–15 when compared with the first year of 
data reported 
Ŧ rate is less than 0.05 per 100 encounters 
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 Glossary 
A1 Medicare items: See MBS/DVA items: A1 Medicare items. 
Aboriginal: The patient identifies himself or herself as an Aboriginal person. 
Activity level: The number of general practice A1 Medicare items claimed during the previous 3 
months by a participating GP. 
Allied health services: Clinical and other specialised health services provided in the management of 
patients by allied and other health professionals including physiotherapists, occupational therapists, 
dietitians, dentists and pharmacists. 
Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily representing 
the body systems. 
Chronic problem: See Diagnosis/problem: Chronic problem. 
Commonwealth concession card: An entitlement card provided by the Australian Government, which 
entitles the holder to reduced-cost medicines under the Pharmaceutical Benefits Scheme and some 
other concessions from state and local government authorities. 
Complaint: A symptom or disorder expressed by the patient when seeking care. 
Component (ICPC-2): In ICPC-2 there are seven components that act as a second axis across all 
chapters. 
Co-located health service: a health service (for example, physiotherapist, psychologist etc) located in 
the practice building or within 50 metres of the practice building, available on a daily or regular basis. 
Co-operative after-hours arrangements: the normal after-hours arrangements for patient care 
provision is undertaken in co-operation with another practice(s). 
Consultation: See Encounter. 
Diagnosis/problem: A statement of the provider’s understanding of a health problem presented by a 
patient, family or community. GPs are instructed to record at the most specific level possible from the 
information available at the time. It may be limited to the level of symptoms. 
• New problem: The first presentation of a problem, including the first presentation of a recurrence 
of a previously resolved problem, but excluding the presentation of a problem first assessed by 
another provider. 
• Old problem: A previously assessed problem that requires ongoing care, including follow-up for a 
problem or an initial presentation of a problem previously assessed by another provider. 
• Chronic problem: A medical condition characterised by a combination of the following 
characteristics: duration that has lasted, or is expected to last, 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that impact on an 
individual’s quality of life. (Source: O’Halloran J, Miller GC, Britt H 2004. Defining chronic 
conditions for primary care with ICPC-2. Fam Pract 21(4):381–6).  
• Work-related problem: Irrespective of the source of payment for the encounter, it is likely in the 
GP’s view that the problem has resulted from work-related activity or workplace exposure, or that 
a pre-existing condition has been significantly exacerbated by work activity or workplace 
exposure. 
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Encounter (enc): Any professional interchange between a patient and a GP. 
Indirect: Encounter where there is no face-to-face meeting between the patient and the GP but a 
service is provided (for example, prescription, referral). 
Direct: Encounter where there is a face-to-face meeting of the patient and the GP. Direct encounters 
can be further divided into: 
– MBS/DVA-claimable: Encounters for which GPs have recorded at least one MBS item number 
as claimable, where the conditions of use of the item require that the patient be present at the 
encounter.  
– Workers compensation: Encounters paid by workers compensation insurance. 
– Other paid: Encounters paid from another source (for example, state). 
Full-time equivalent (FTE): A GP working 35–45 hours per week. 
General practitioner (GP): A medical practitioner who provides primary comprehensive and continuing 
care to patients and their families within the community (Source: Royal Australian College of General 
Practitioners). 
Generic medication: See Medication: Generic 
GP consultation service items: See MBS/DVA items: GP consultation service items.  
MBS/DVA items: MBS item numbers recorded as claimable for activities undertaken by GPs and staff 
under the supervision of GPs. In BEACH, an MBS item number may be funded by Medicare or by the 
Department of Veterans’ Affairs (DVA). 
• A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 
40, 43, 44, 47, 48, 50, 51, 601, 602. 
• GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, A19, A20, 
A22, A23, A27, A30 and selected items provided by GPs classified in A11 and A15. 
• MBS/DVA item categories: (Note: item numbers recorded in BEACH in earlier years which are no 
longer valid are mapped to the current MBS groups). 
– Surgery consultations: Identified by any of the following item numbers: short 3, 52, 5000, 5200; 
standard 23, 53, 5020, 5203; long 36, 54, 2143, 5040; prolonged 44, 57, 2195, 5060, 5208. 
– Residential aged care facility: Identified by any of the following item numbers: 20, 35, 43, 51, 
92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267. 
– Home or institution visits (excluding residential aged care facilities): Identified by any of the 
following item numbers: 4, 19, 24, 33, 37, 40, 47, 50, 58, 59, 60, 65, 87, 89, 90, 91, 503, 507, 
5003, 5023, 5043, 5063, 5220, 5223, 5227, 5228. 
– GP mental health care: Identified by any of the following item numbers: 2700, 2701, 2702, 
2704, 2705, 2710, 2712, 2713, 2715, 2717, 2721, 2723, 2725. 
– Chronic disease management items: Identified by any of the following item numbers: 720, 721, 
722, 723, 724, 725, 726, 727, 729, 730, 731, 732. 
– Health assessments: Identified by any of the following item numbers: 700, 702, 703, 704, 705, 
706, 707, 708, 709, 710, 712, 713, 714, 715, 717, 718, 719. 
– Case conferences: Identified by any of the following item numbers: 139, 734, 735, 736, 738, 
739, 740, 742, 743, 744, 747, 750, 762, 765, 771, 773, 775, 778. 
– Attendances associated with Practice Incentives Program payments: Identified by any of the 
following item numbers: 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 2521, 2522, 
2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2598, 2600, 2603, 2606, 
2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2668, 2673, 2675, 2677, 
2704, 2705. 
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– Practice nurse/Aboriginal health worker/allied health worker services: Identified by any of the 
following item numbers: 711, 10950, 10951, 10960, 10966, 10970, 10986, 10987, 10988, 
10989, 10993, 10994, 10995, 10996, 10997, 10998, 10999, 16400, 82210. 
– Acupuncture: Identified by any of the following item numbers: 173, 193, 195, 197, 199. 
– Diagnostic procedures and investigations: Identified by item numbers: 11000–12533. 
– Therapeutic procedures: Identified by item numbers: 13206–23042 (excluding 16400). 
– Surgical operations: Identified by item numbers: 30001–52036. 
– Diagnostic imaging services: Identified by item numbers: 55037–63000. 
– Pathology services: Identified by item numbers: 65120–74991. 
Medication:  
• Generic: The generic name of a medication is its non-proprietary name, which describes the 
pharmaceutical substance(s) or active pharmaceutical ingredient(s). 
• GP-supplied: The medication is provided directly to the patient by the GP at the encounter. 
• Over-the-counter (OTC): Medication that the GP advises the patient to purchase OTC (a 
prescription is not required for the patient to obtain an OTC medication). 
• Prescribed: Medications that are prescribed by the GP (that is, does not include medications that 
were GP-supplied or advised for over-the-counter purchase). 
Medication status: 
• New: The medication prescribed/provided at the encounter/advised is being used for the 
management of the problem for the first time. 
• Continued: The medication prescribed/provided at the encounter/advised is a continuation or 
repeat of previous therapy for this problem. 
• Old: See Continued. 
Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. In this sense, 
sickness, illness and morbid conditions are synonymous. 
Non-English speaking background: The patient reported that the primary language spoken at home is 
not English. 
Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Patient seen previously: The patient has attended the practice before. 
Problem managed: See Diagnosis/problem. 
Provider: A person to whom a patient has access when contacting the healthcare system. 
Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or contacting 
the general practitioner. These can be expressed in terms of symptoms, diagnoses or the need for a 
service. 
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Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General Practitioners who 
participates in, and meets the requirements for, quality assurance and continuing medical 
education as defined in the Royal Australian College of General Practitioners (RACGP) Quality 
Assurance and Continuing Medical Education Program, or 
• undertaking an approved placement in general practice as part of a training program for general 
practice leading to the award of the Fellowship of the Royal Australian College of General 
Practitioners, or undertaking an approved placement in general practice as part of some other 
training program recognised by the RACGP as being of equivalent standard. (Source: 
Commonwealth Department of Health and Aged Care (DHAC) 2001. Medicare Benefits Schedule 
book. Canberra: DHAC).  
Referral: The process by which the responsibility for part, or all, of the care of a patient is temporarily 
transferred to another health care provider. Only new referrals to specialists and allied health services, 
and for hospital and residential aged care facility admissions arising at a recorded encounter are 
included. Continuation referrals are not included. Multiple referrals can be recorded at any one 
encounter. 
Repatriation Health Card: An entitlement card provided by the Department of Veterans’ Affairs that 
entitles the holder to access a range of repatriation health care benefits, including access to 
prescription and other medications under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant result. Statistical significance is 
measured at the 95% confidence level in this report.  
Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander person. 
Work-related problem: See Diagnosis/problem.  
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 Appendices 
Appendix 1: Example of a 2014–15 recording form
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Appendix 2: GP characteristics questionnaire, 
2014–15  
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Appendix 3: Patient information card, 2014–15 
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Appendix 4: Code groups from ICPC-2 and 
ICPC-2 PLUS 
Available at: <hdl.handle.net/2123/13765>. 
Table A4.1:  Code groups from ICPC-2 and ICPC-2 PLUS – reasons for encounter  
and problems managed 
Table A4.2: Code groups from ICPC-2 and ICPC-2 PLUS – chronic problems 
Table A4.3: Code groups from ICPC-2 and ICPC-2 PLUS – problems managed by  
practice nurses 
Table A4.4: Code groups from ICPC-2 and ICPC-2 PLUS – clinical treatments 
Table A4.5: Code groups from ICPC-2 and ICPC-2 PLUS – procedures 
Table A4.6: Code groups from ICPC-2 and ICPC-2 PLUS – clinical measurements 
Table A4.7: Code groups from ICPC-2 and ICPC-2 PLUS – referrals 
Table A4.8:  Code groups from ICPC-2 and ICPC-2 PLUS – pathology test orders  
(MBS groups) 
Table A4.9:  Code groups from ICPC-2 and ICPC-2 PLUS – imaging test orders  
(MBS groups) 
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